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The structure of this thesis 
Figure 1 graphically displays the structure of this thesis. Part A is meant as the main 
text of this thesis. It should be regarded as an introduction to the structural 
principles and problems of clinical decision making in oncology. Part В gives some 
extensions and applications from the field of diagnosis and treatment of patients 
with cancer of the head and neck. Part С gives the appendices to parts A and B. 
Since we were primarily concerned with the cure and care of patients already 
diagnosed with cancer, this thesis is focused on optimizing choices concerning 
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medical treatment in individual patients The evaluation of diagnostic tests is not 
discussed in this thesis 
A 1 
A 2 
A 3 
B 6 B 7 
A 4 
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Figure 1 · Structure of this thesis 
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1. Introduction: Clinical decision making and oncology 
Uncertainty is intrinsic to clinical practise In choosing and prescribing a certain 
treatment from several alternatives a physician is uncertain about the outcome in a 
patient, how the outcome is qualified by the patient or whether or not an alternative 
treatment might yield a better outcome [Sox et al , 1988] 
Clinical decision making is a rational approach to reduce uncertainties in 
choosing the best among several strategies in clinical practise and in health care 
planning It may thus provide more certainty about uncertainties Clinical decision 
making unifies the common sense of clinical practise with the probabilistic 
approach of clinical epidemiology, psychological measurement techniques and 
management sciences Although the origin of rational decision making at the 
patients' bedside goes back to the early Hippocratic days of medicine a more 
formal approach comes from the field of philosophy, management science, 
operations research and gamble theory [Bayes, 1763, Castles et a l , 1971, Krischer 
1980, Luce and Raiffa, 1957, Raiffa, 1968, Scott, 1967, Von Neumann and 
Morgenstern, 1953 Weinstein and Fineberg, 1980] 
Cancer is the collective noun for a group of diseases characterized by growth and 
spread of tissue beyond the normal anatomic boundaries which, untreated leads to 
physical, mental and social deterioration or death The goals of clinical care of 
patients with cancer can be summarized by the classical commitments of the 
medical profession Sometimes to cure frequently to relieve and always to comfort 
patients with cancer [Pare, 1510-1590] Since the commitments can be conflicting, 
both physician and patient have to consider the risks and outcomes of several 
treatments Clinical decision analysis can be useful in structuring and evaluating 
such difficult choices 
Clinical decision analysis in oncology may be limited for three impediments 
concerning 
(1) The validity of risk estimates, or probabilities, for particular events, which can be 
imprecise or even unknown, especially considering the conditionahty or 
multifactorial determination of certain events For instance The mortality rate of 
an individual patient with cancer of the vocal cords is not merely determined by 
the extent of the tumour and by the treatment received, but also by age, sex, 
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recurrence rates, the chance to be salvaged following recurrence, the risk of 
developing new malignancies and by a multitude of more or less defined other 
factors 
(2) The validity of value judgements The outcomes or 'health states' resulting from 
a medical treatment and hence the treatment itself, can only be judged by its 
subjective value, measuring the patient's value judgement of an outcome is 
called utility assessment Methods for utility assessment are still in an early 
phase of development and have not yet been applied to clinical decision 
making 
(3) Time Both risk estimates and value judgements are strongly dependent on 
time Tumour recurrence rates and subsequently mortality rates from cancer 
generally decrease in time but death from other causes (accidents, heart 
disease, new cancers etc ) increases in time Similarly, value judgements 
about the length of life and the quality of life may shift over time, as the data of 
this thesis suggest, one will generally attach more value to close life years than 
to distant life years Consequently, the value (or utility) attached to a worse 
health state compared to the best possible health state, is inversely related to 
life expectancy Treatment decisions in oncology have therefore to be 
evaluated considering the chronical aspects of the course of disease and the 
time-dependency of utilities 
Although these three factors are not specific for oncologic practise, they are 
characteristic for the problems encountered in decision making for individual 
patients with cancer and for health care planning in oncology This thesis will 
therefore focus on these three issues Chapters 2 and 3 are primarily focused on 
structuring and evaluating decision problems using fixed outcomes and static 
probabilities, chapter 4 gives the Markov model structuring decisions in a dynamic 
way to enable analysis with time varying probabilities and utilities, chapter 5 
describes methods for utility assessment 
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2. The structure of decisions: The decision tree1 
2.1 The elements of a decision tree 
The decision tree forms the main tool in structuring and evaluating the essentials of 
clinical decision making under uncertainty. The structural elements of clinical 
decision making and decision tree analysis are: 
(1) Define the decision problem 
What is the clinical problem faced by the doctor and patient ? For instance: 
What is at this moment the best treatment for this specific patient with this 
specific type of cancer ? 
(2) Identify the decision alternatives 
What treatments can be given to this patient, e.g. surgery, radiotherapy, 
chemotherapy or combination therapy ? 
(3) Structure the decision problem in time 
What may happen following treatment: Operative death, cure, tumour 
recurrence, cancer death? In what order do these events occur during the 
course of the disease: Operative death is an event directly following surgery; 
cure can be obtained either directly following treatment or following treatment of 
a tumour recurrence. 
(4) Define the outcomes 
What are the final outcomes of each treatment and in what terms are they 
expressed? What is the decision criterion? Quantitatively: Survival rate, cure 
rate, life-expectancy. Qualitatively: Grade of mutilation, physical impairment and 
other more subjective aspects of the quality of life. 
(5) Assign probabilities 
What are the chances of the above events and outcomes expressed in 
probabilities or rates, e.g. death rate, recurrence rate, cure rate following 
recurrence? 
(6) Assign utilities 
What value judgement or utility should be attached to the respective outcomes, 
compared to the best and worst outcomes? For instance: What is the utility of 
'cure with mutilation' and 'immediate death' compared to complete health? 
L.J.A. Stalpers, W.A.J, van Daal. Presented at the NVR-Dutch Society for Radiotherapy. 
Amsterdam, February 18th, 1989. 
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Given the estimates of probabilities and utilities the decision tree is used to 
calculate the expected effectiveness of each treatment The expected effectiveness 
is expressed by one of several quantitative decision criteria Frequently used 
criteria by which cancer treatments are compared are life-expectancy and survival 
rate Life-expectancy is the average future lifetime of a patient at a specified age 
Survival rate at a certain time t is the fraction of patients surviving to time t If the 
quality-of-life is considered in a comparison of treatments, utility theory can be used 
to weigh the life-expectancy following each treatment by the utilities of the 
respective outcomes The treatment yielding the most quahty-of-hfe adjusted life 
years (shortly QALYs), is commonly chosen as the preferred or 'best' treatment 
[Weinstein & Stasson, 1977, Williams, 1985] Considering costs with utilities is 
denoted as cost-utility analysis [Drummond, 1977, Smith, 1987] 
Since both the estimates of probabilities and utilities and the subsequent 
decisions harbour uncertainty due to insecurity of the values, a so-called sensitivity 
analysis is performed to check for the stability of a decision under varying 
estimates of observed or reasonably permitted values 
2 2 An example: A patient with cancer of the vocal cords 
Problem definition 
A 60-year old man with T3N0M0 glottic carcinoma is admitted for treatment Should 
this patient be advised surgery or radiotherapy7 
Structuring the decision problem 
Figure 2 1 gives the decision tree structuring the choice between radiotherapy and 
surgery for this patient, including the recurrence rate following primary treatment 
and the salvage rate following recurrence In patients with T3N0M0 glottic 
carcinoma, surgery usually consists of total laryngectomy Laryngectomy can be 
performed both as primary treatment and as salvage treatment following failure to 
primary radiotherapy Salvage treatment following failure to primary surgery 
generally consists of re-surgery with or without radiotherapy 
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Figure 2.1 · Decision tree for the choice between radiotherapy and surgery 
in a 60-year old man with a T3N0M0 glottic carcinoma 
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Following successful radiotherapy, a patient is able to speak with a natural speech 
Following laryngectomy, a patient has to learn some form of artificial speech 
(oesophageal speech, speech by an electronical device or by a so-called 
Groninger button) and some 5% of patients will never recover their speech 
A decision node, denoted by a box, dissects the decision tree into the 
alternative treatments RADIOTHERAPY in the upper branch and SURGERY in the 
lower The outcomes are given at the extreme right in boxes, being ALIVE, 
NATURAL SPEECH following cure by radiotherapy, ALIVE, ARTIFICIAL SPEECH 
following recurrence and salvage and DEATH FROM CANCER following treatment 
failure of a recurrence The chance nodes denoted by a circle, divide the course of 
disease into events to which the respective probabilities are attached The 
recurrence rates and salvage rates following radiotherapy and surgery for T3N0M0 
glottic carcinoma are mean estimates based on a literature study described in 
chapter В 1 The stream of events following surgery is similar to the events following 
radiotherapy but for two important exceptions 
(a) Following surgery, both recurrence rates and salvage rates are lower than 
following radiotherapy 
(b) All surgically treated patients have to learn an artificial speech, whereas 
successfully cured patients following radiotherapy are able to speak naturally 
As an index of comparison of both treatments, figure 2 1 gives both the life-
expectancy (LE) expressed in years and the expected utility (EU) expressed m 
quality adjusted life years (QALYs) 
Evaluating outcomes Life-Expectancy 
For a succesfully treated 60-year old male patient with glottic carcinoma, we 
presume a life-expectancy similar to the age-specific life-expectancy in the male 
Dutch population, being 17 9 years, both following successful primary treatment 
and following successful salvage surgery [CBS, 1985] Following unsuccessful 
treatment of a tumour recurrence, death from laryngeal cancer generally occurs 
within several months However, since it might have taken some years before 
recurrence, patients with a fatal recurrence will have lived some years, say 2 0 
years The respective life-expectancies are attached as leaves to the branches of 
the decision tree 
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Based on the probabilities leading to each outcome and the life-expectancy of each 
outcome, the contribution of each branch to the average life-expectancy following 
radiotherapy and surgery can be calculated. For instance: The branch ALIVE, 
NATURAL SPEECH contributes 0.58 χ 17.9 years = 10.38 years to the average life-
expectancy following radiotherapy. The branches ALIVE, ARTIFICIAL SPEECH and 
DEATH FROM CANCER contribute 0.42 χ 0.37 χ 17.9 years = 2.78 years and 0.42 χ 
0.63 χ 2 years = 0.53 years respectively, resulting in an average life-expectancy of 
13.69 years following radiotherapy. 
Following surgery, the decision tree yields an average life-expectancy of 
14.73 years. Based on the best life-expectancy alone, surgery will be preferred over 
radiotherapy in a 60-year old male patient with T3N0M0 glottic carcinoma. 
Evaluating outcomes: Quality Adjusted Life Years 
In the previous analysis, the quality of life is not considered in the choice between 
radiotherapy and surgery. 
Since the quality of speech constitutes a major criterion of treatment success 
in glottic cancer, it is natural to consider it as a decision criterion in a decision tree 
analysis. 
The quality of speech can be expressed by a numerical value or utility. There 
are several methods to measure utilities for decision analytic purposes. Some of 
these methods will be discussed in chapter 5. For illustrative purposes only, we will 
here use the time tradeoff technique to measure utilities [Torrance, 1972]. For the 
time tradeoff technique one presumes that the utility of a certain outcome, e.g. an 
artificial speech, lies somewhere on a utility scale ranging from 0.0 for the worst 
outcome, i.e. immediate death, to 1.0 for the best outcome, i.e. natural speech. The 
utility of an artificial speech is measured by assesment of the maximum number of 
life years with an artificial speech a patient is willing to tradeoff to live with a natural 
speech. The utility of an artificial speech is the ratio resulting from dividing the 
number of years with a normal speech by the number of life years with an artificial 
speech. For instance, if a patient is willing to sacrifice 4 years of 20 years with an 
artificial speech to live (16 years) with normal speech (utility=1.0), then the utility of 
an artificial speech is said to be proportional to the respective life years, i.e. 16 
years/20 years = 0.8. This utility can be used to adjust the life-expectancies 
following radiotherapy and surgery. For instance, following SURGERY, figure 2.1 
gives a cure rate of 0.73 resulting in ALIVE, ARTIFICIAL SPEECH with 17,9 life 
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years The contribution to the life-expectancy is 0 73 χ 17 9 years = 13.07 years with 
an ARTIFICIAL SPEECH. Multiplication of these life years by the utility of an 
ARTIFICIAL SPEECH yields the contribution to the expected utility (EU) of surgery 
expressed in QALYs: 0.8 χ 13 07 years = 10 45 QALYs 
Analogously, we can weigh the number of life years for each outcome by its 
utility 'Cure' following RADIOTHERAPY results in life with a NATURAL SPEECH 
contributing 0 58 χ 17 9 years χ 1 0 = 10.38 QALYs to the expected utility of 
radiotherapy. 'Salvage' laryngectomy following a 'recurrence' after RADIO­
THERAPY results in an ARTIFICIAL SPEECH (utility = 0 8) contributing 0.42 χ 0.37 
χ 17 9 years χ 0 8 = 2.22 QALYs to the expected utility of radiotherapy For a patient 
who dies from cancer after a recurrence with 'no salvage', we presume that he will 
have lived 2 years with a normal speech, hence resulting in a contribution of 0 42 χ 
0 63 χ 2 years χ 1 0 = 0 53 QALYs to the expected utility of radiotherapy. 
The expected utilities (EU) following radiotherapy and surgery are 13.13 and 
11 78 QALYs respectively. Under the mam principle of utility theory, namely utility 
maximization, the treatment with the highest expected utility should be preferred 
[Von Neuman and Morgenstern, 1953] So, going by QALYs, in the example in 
figure 2.1 radiotherapy should be preferred to surgery. 
Sensitivity Analysis· The stability of conclusions 
The calculations of both life-expectancies and expected utilities are only valid 
under the given or 'baseline' probabilities and utilities. For instance. (1) What would 
happen if the utility of an artificial speech was not 0 8 but much higher (i.e. what if a 
patient was willing to sacrifice less than 20% of his life-expectancy to live a life with 
natural speech instead of with an artificial speech)? And (2) what if the recurrence 
rate following radiotherapy was higher, i.e. 0.50 instead of 0.42 ? 
(1) Figure 2.2 gives the results of the sensitivity analysis on the expected utilities 
of radiotherapy and surgery for varying utilities of life with an artificial speech 
Figure 2.2 demonstrates that, for a utility of artificial speech ranging from 0.5 to 1.0, 
the expected utilities of both radiotherapy and surgery increase. However, as 
appears from a steeper curve for surgery than for radiotherapy, the expected utility 
of surgery is more sensitive to variation of the utility of artificial speech than that of 
radiotherapy. The curves have a break-even point for which the expected utilities of 
radiotherapy and surgery are equal. The utility corresponding with the break-even 
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point (utility = 0.91) is called the threshold utility: Based on the expected utility, a 
patient who attaches less than the threshold utility of 0.91 to life with an artificial 
speech will be advised radiotherapy, a patient with higher utility values will be 
advised surgery. 
OS 0 9 10 
Utility of Artificial Speech 
Figure 2.2 · Expected utility of radiotherapy and surgery expressed in quality 
adjusted life years (QAL Ys) after radiotherapy and after surgery for a patient with a 
T3N0M0 glottic carcinoma for varying utilities attached to the quality of voice after 
laryngectomy (artificial speech). The utility of an artificial speech is expressed on a 
utility scale ranging from 0.0 for death to 1.0 for natural speech. 
(2) Figure 2.3 gives the results of a sensitivity analysis on the threshold utility of 
an artificial speech for varying recurrence rates following radiotherapy. For a 
recurrence rate ranging from 0.3 to 0.7, the threshold utility of an artificial speech 
will decrease from 1.0 to 0.65. For pairs (utility, recurrence rate) below the threshold 
curve, the expected utility of radiotherapy is higher than that of surgery. From this 
figure we can read that for the baseline recurrence rate of 0.42 following 
radiotherapy, surgery is to be preferred if the utility attached to an artificial speech is 
higher than 0.91. However, if we presume a much higher recurrence rate of 0.50 
following radiotherapy, we can read from figure 2.3 that a lower utility can be 
1 4 The structure of decisions 
accepted to have surgery preferred, i.e. utility > 0.84. However, if the utility of an 
artificial speech is 0.80, -as we earlier presumed-, radiotherapy will still be 
preferred, even for such a high recurrence rate. In the latter case, figure 2.3 shows 
that surgery is only to be preferred if the recurrence rate following radiotherapy 
ranges above 0.54. Here we always presume, of course, that the other probabilities 
(the salvage rate both following radiotherapy and surgery and the recurrence rate 
following surgery) remain stable. 
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Recurrence Rate following Radiotherapy 
Figure 2.3 · Threshold utilities for the quality of speech following laryngectomy 
(artificial speech) on varying recurrence rates for T3N0M0 glottic carcinoma. 
What if both the recurrence rates following radiotherapy and surgery are higher 
than the baseline values assumed? 
Figure 2.4 gives a two-way threshold analysis on the recurrence rates 
following radiotherapy and surgery for the respective utilities of artificial speech 
0.7, 0.8, 0.9 and 1.0. It should be recognized that the analysis using a utility of 
artificial speech of 1.0, -which by definition is equal to the utility of natural speech-, 
is in fact a two-way sensitivity analysis on life-expectancy. For instance, if the 
recurrence rate following radiotherapy is 0.50 and the recurrence rate following 
surgery is 0.40, then radiotherapy will only be preferred if the utility of artificial 
speech is only slightly less than the maximum utility of 1.0. 
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Figure 2.4 · Sensitivity analysis of the threshold utility by varying the recurrence rate 
following radiotherapy, and/or the recurrence rate following surgery and for 
stepwise variations of the utility of an artificial speech from 0.7 to 1.0. 
Based on the utility theory, a decision tree analysis offers a simple tool to structure 
and formally evaluate decision problems. It may be clear that considering the 
uncertainty of the probabilities and utilities, a decision tree analysis will not 
generate a clear cut advice for a specific treatment. The goal of decision tree 
analysis is to indicate within what range of values the decision problem is at stake 
and when it is relevant to consider other decision criteria rather than life-expectancy 
alone, for instance the quality of speech, and to what extent the assessment may be 
pivotal in the decision at stake. The ultimate choice of a treatment predominantly 
depends on the credentials the doctor and patient give to the most uncertain factors 
of the analysis, namely the validity of both probabilities and utilities. 
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2.3 Probability Assessment 
Several sources can be used to assess probabilities for decision tree analysis. 
Most commonly used sources are expert opinions, published data and data bases. 
Expert opinions 
Expert opinions and other sources that draw on personal experiences belong to the 
most hazardous forms of probability assessment. Many studies have shown the 
pitfalls in probability assessment due to several biases, amongst which selective 
memory and wishful thinking [Kahneman et al., 1982; Spetzler & Stael von 
Holstein, 1975; Tversky & Kahneman, 1974]. It is therefore advised to use 
probabilities assigned by experts only as an ultimum refugium in assigning risks 
and rates, or as indicators for maximal or minimal tolerable risks. 
Published data 
Data published in medical journals and books, -shortly denoted by 'the literature'-, 
may provide reasonably reliable estimates of probabilities. There are three 
limitations to the use of published data for utility estimates: 
The first drawback is concisiveness. Since most journals prefer short and 
concise papers to extensive and detailed ones, only the most general rates will be 
published such as survival and recurrence rates in their most concise form. In a 
literature study of the results of radiotherapy and surgery in glottic carcinoma 
described in chapter B.1, detailed rates such as the salvage rate following tumour 
recurrence were only scarcely and imprecisely described. 
Secondly, for the same reason of concision, survival rates and recurrence 
rates are more often than not represented by only one endpoint such as the five-
years rate, without considering the temporal characteristics of the course of 
disease. Such one-point measurements are valid only for events which occur only 
once at a specific time, such as operation mortality. As described earlier the course 
of disease in cancer is generally better characterized by a sequence of risky events, 
for which the probabilities change with time. A description of rates with preservation 
of the time-dependent characteristics may give a more accurate insight in the 
course of the disease. For instance, in the literature it is said that patients with oral 
cancer have an enhanced risk of developing lung cancer warranting regular 
screening for lung cancer [De Vries, 1987]. From our own study, described in 
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chapter В 3, the incidence of lung cancer following oral carcinoma was both 
calculated as a crude rate, being 22/213 = 0 103 and as an actuarial incidence rate, 
taking into account the time of clinical follow-up The latter description yielded a 
two-years cumulative incidence of 0 13 and showed no further rise after these two 
years Since no new lung cancer was detected after two years, it seems as if there 
is no more enhanced risk for lung cancer and that intensive screening for lung 
cancer becomes superfluous after two years follow-up 
A third hazard of published papers is the inclination of medical journals to 
publish positive results and to publish negative or less favourable results only in a 
later phase Sackett gives an example of the evolution of the value of the carcmo-
embryomc antigen (CEA) in the early detection of colon cancer [Sackett, 1982] The 
CEA test was originally introduced in 1969 as a test with a high diagnostic 
sensitivity being 97% (the percentage of colon cancer patients who had a positive 
CEA test result) However, in subsequent studies performed in less selected 
populations the sensitivity dropped to 90% in 1970, 87% in 1971, 82% in early 
1972 and 72% later in 1972 A similar decline was seen for the diagnostic 
specificity (the percentage of patients without colon cancer who had negative CEA 
test results) 
Broad and Wade [1982 &. 1985] have described several cases of malpractice 
to publishing faked results, some scientists yield to temptation to commit fraud, 
forced by the preference of journals to publish positive results, in combination with 
the need of research grants that are awarded based on number of publications 
Data bases 
Data bases, such as the classical medical files and more recently the hospital 
computer systems, are among the most reliable sources to assess probabilities, 
although they store a relatively small number of relevant data for specific (hospital) 
populations The usefulness of data bases is highest for prospective studies, ι e m 
which the questions which have to be solved and the relevant variables are 
structured in advance For retrospective studies (in which the questions of the study 
are posed following the collection of data), relevant information is frequently 
missing or inaccurately recorded in the medical files Compared with expert 
opinions and the concise data from the literature, data bases allow us to provide 
more accurate answers on more specific and more complex questions It is our 
conviction that, wherever possible, a prospective clinical trial should be preceded 
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by a retrospective study of own data to simulate and analyse the trial with the most 
appropriate data. Based on a retrospective study in patients with laryngeal cancer 
described in chapter B.4, chapter B.5 shows how these data were structured and 
analysed to give accurate estimates of the effect of bronchoscopy for the early 
detection of secondary lung cancer, providing some indications in the design of a 
randomized controlled trial. 
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3. Evaluating outcomes: DEALE-ing with Life Expectancy and 
Mortality R a t e s 1 
3.1 Introduction 
In 1982, BECK et al. presented a simple method known as the "DEALE" method, to 
approximate the life expectancy for an individual patient using information from 
various sources, such as disease specific survival rates and age- and sex-specific 
life expectancies from a table of vital statistics [Beck et al., 1982a]. In a subsequent 
paper, the use of the DEALE method in quantitative decision making is 
demonstrated [Beck et al., 1982b]. The DEALE is convenient to estimate life 
expectancy for a patient with particular disease characteristics. However, as we 
demonstrate in this report, the annual mortality force used in the DEALE formula is 
not similar to the annual mortality rate, despite the similar unity "per year". 
Therefore, the DEALE method is not appropriate and can actually be rather 
confusing in dealing with patients' questions about the average risk of dying next 
year or the chance of survival the next five years. In a decision analytical context, 
these questions are of particular importance for the assessment of both the 
probabilities used in a simple decision tree analysis and the transition probabilities 
used in a Markov model [Beck and Pauker, 1983; Beck, 1988]. In this short 
communication, we propose a slightly adjusted version of the DEALE appropriate to 
estimate both life expectancy and the instantaneous mortality rate. 
3.2 The DEALE 
The DEALE, which stands for 'decreasing exponential approximation of [ife 
expectancy' is based on the assumption that the survival curve S(t) follows a simple 
declining exponential function of time, assuming an annual mortality force μ that is 
constant for all following times t: 
S(t) = e^1 {1a] 
Lukas J.A. Stalpers, M.D., Hans J.M. van Gasteren, Ph.D. and Willem A.J. van Daal, M.D., Ph.D. 
Published in Medical Decision Making, 1989; 9: 150-152 
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The annual mortality force μ can be inferred by a logarithmic transformation of S(t) 
InS(t) ,_ . 
μ = - — j — per year {2a} 
The life expectancy LE is the inverse of the mortality force μ: 
t 
InS(t) L E " _ = -|^öm Уе а г tèal 
By combining information from different sources, the DEALE can be used to 
estimate the life expectancy of an individual patient, based on patient-specific 
characteristics such as age, sex, stage of disease and concomitant diseases Using 
mortality forces μι,μ2...μι<ϊθΓ к prognostic factors, DEALE approximates survival 
rate, mortality force and life expectancy as follows: 
S(t) = e {lb} 
μ = μι + μ2+... μ/c per year {2b} 
LE = years {3b} 
(μΐ + μ2 +. μ id 
For example: The life expectancy of a 60-year old male patient with a T2N0 glottic 
carcinoma treated by radiotherapy can be calculated from (1) the disease-specific 
survival of all patients with T2N0 glottic carcinoma treated by radiotherapy, and (2) 
the age-specific life expectancy of a 60-year old male. 
( 1 ) A recent review of 26 articles on results of treatment of glottic cancer gives an 
average five-year disease-specific survival rate of 70% for patients with T2N0 glottic 
carcinoma [Stalpers et al., 1987]. The DEALE yields a disease specific mortality 
force PQ: 
InO 7 „ „ , „ μ 0 = - g— = 0.071 per year 
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(2) A table of vital statistics gives a life expectancy of 17 9 years for males aged 
60 [CBS, 1987]. The DEALE yields an average age- and sex-specific mortality force 
for the period beyond 60 years MAS. 
PAS = ^ 7 9 = 0.056 per year 
The overall or 'compound' mortality force μ for this specific patient is μο + μ AS = 
0 071 + 0 056 = 0 127 and hence the life expectancy LE = 1/0.127 = 7 87 years. 
3.3 The 'adjusted" DEALE 
The mortality force μ does not represent some readily interpretable rate or 
probability estimate We therefore propose an adjusted version of the DEALE, 
based on the instantaneous mortality rate β, to predict survival rates, the 
instantaneous mortality rate per time-interval and life expectancy. The adjusted 
DEALE is based on the assumption that survival follows an exponential function on 
the complement of the instantaneous mortality rate β: 
S(t) = (1-ß)t {4a} 
with the instantaneous or annual mortality rate β: 
InS(t) 
β = 1 - e * per year {5a} 
and the life expectancy LE: 
LE =
 -|ra) yearS {6a} 
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Although the mortality force μ bears the unity "per year , μ is obviously not an 
instantaneous or annual mortality rate, but a transformation of the instantaneous 
mortality rate β 
μ = -ln(l-ß) {7a} 
β = 1 -
β
· μ per year {7b} 
= 1 - e 1/I-E per year {7c} 
For instance· The mortality force μ = 0.127 for the patient with glottic carcinoma 
does not mean that the mortality rate in the next years averages 0 127 per year but 
β = ι .
θ
-οΐ27 = ο 119, or 11 9% per year 
For к prognostic factors, the adjusted DEALE gives 
S(t) = [(1-βι)(1-β2)..(1-β*)]* Hb} 
β = 1 - [(1-ßi)(1-ß2) ..(1-ßA) ] per year {5b} 
LE
 - -¡4>• Щшішійа]years i6b} 
For example For a male aged 60 with T2N0M0 glottic carcinoma, the adjusted 
DEALE may generate both the predicted survival rate, an instantaneous mortality 
rate per year and a life expectancy in years: 
(1) Based on a five-year disease free survival of 0 7, equation {5a} yields an 
instantaneous mortality rate: 
InS(t) 
ßo = 1 - e ι = 1 - 0.931 = 0 069, or 6 9% per year 
(2) Based on an age- and sex-specific life expectancy of 17 9 years, equation {7c} 
yields an instantaneous mortality rate: 
PAS = 1-е 1 / L E = 0.054, or 5.4% per year 
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(3) Equation {5b} yields the compound mortality rate per year· 
ß = 1 - [ ( I -PD)(1 -PAS)] = 1-(0 931 )(0 946) = 0 119, or 11.9% per year 
(4) Equations {4a} and {6a} yield the expected five year survival rate. 
S(5) = (1 -0.119)5 = 0.53, or 53% 
and a life expectancy: 
LE =
 -|nÍ(t) = 7 8 7 y e a r s 
3.4 Conclusion 
The original DEALE is convenient to estimate life expectancies using a compound 
of several prognostic factors, but it is less appropriate to calculate a compound 
mortality rate. The adjusted DEALE yields both a life expectancy and a more readily 
interpretable average mortality rate for a certain time interval, which may be used 
as an estimation of a probability in a decision tree or a transition probability in a 
Markov model. 
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4. Evaluating outcomes: The Markov model1 
4 1 Introduction 
A simple decision tree and the DEALE-method are both used to describe the 
distribution of outcomes of a certain medical strategy for a fixed endpomt in time, 
e g to estimate a five-year survival rate or a life expectancy The simple decision 
tree approach is most useful in clinical situations where events occur only once in a 
lifetime, mostly at the beginning of the course of a disease Clinical events with 
such a unique and early occurrence are for example the risk of operative death and 
other acute complications of disease and treatment The DEALE-method is most 
appropriate under the assumption that mortality rates are constant for all years 
following treatment However, many clinical events in oncology are characterized 
by a chronic occurrence Tumour recurrence, tumour metastasis, complications of 
treatment or cancer and subsequent death can occur at any time following 
treatment The corresponding event rates will vary in time, in general, cancer 
related event rates decrease with time 
Another important time-dependent feature in generally older patients with 
cancer, is the steadily increasing age-specific mortality rate from other diseases 
Chronic events may lead to a changing distribution of outcomes or health states 
over time and to variable durations spent in the subsequent health states 
Events that repeatedly occur in the course of a disease can be structured in a 
decision tree However, if we want to model the course of a disease for about 20 
years follow-up in a decision tree, defining a new decision tree for each year of the 
follow-up, the tree will rapidly grow into an inextricable brushwood with 
innumerable branches For example The simple decision tree described in chapter 
В 7, using three outcomes, namely NORMAL speech, ARTIFICIAL speech and 
DEAD-, will have more than 1000 branches following 20 years after primary 
treatment of glottic cancer Analogously, the slightly more complex tree described in 
chapters В 10 and В 12 will have over one billion branches if modelled in a static 
decision tree 
Dynamic probabilistic systems can be used to structure repeatedly occurring 
chance events to generate more accurate estimates of the distribution of health 
states at any time and of the time spent in the respective states [Elashoff, 1984, 
1 A A Markov, 1856-1922 Russian mathematician [Ondar, 1981] 
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Sonnenberg, 1984, Mau & Steinke, 1986, Myers et al , 1980] Merely for its relative 
simplicity, the Markov model can be used as a convenient method for decision 
analytic purposes [Beck & Pauker, 1983] Paragraphs 4 2 and 4 3 discuss some 
specific problems in applying the Markov model to oncology Some elaborate 
examples of the Markov model are described in chapters В 10 and В 12 
4 2 Principles and problems of Markov models 
In a Markov model the course of a disease is modelled in terms of probabilistic 
transitions from one state to another state in discrete time steps or 'Markov cycles' 
The Markov process of prognosis is a finite probabilistic system [Kemeny & Snell, 
1976] 
In a Markov chain, the transition probability from one state to another is equal 
for every cycle [Jam, 1986, Silverstem et a l , 1988] Only a few examples of Markov 
chains in oncology have been described [Elashoff, 1984, Sonnenberg, 1984, 
Roach, 1988] Indeed, it is very unlikely that relevant risks, -such as recurrence rate 
and mortality rate-, remain stable over time In general, disease-related risks 
gradually decrease following treatment whereas age-related mortality risks 
increase over time 
In a Markov process, -using time-dependent probabilities-, the transition 
probability depends on the time passed since initiation of the process [see e g 
Myers et a l , 1980, Mau &. Steinke, 1986] The Markov process is based on a major 
assumption, referred to as the Markov property [Kemeny &. Snell, 1976] The 
Markov property assumes that the probability distribution of health states after л 
time steps (Sn) only depends on the former distribution of health states (Sn-i) The 
associated transition probability P[SnlSn-i] neglects information about previous 
states For this reason the Markov process is said to have 'a lack of memory' in 
determining the transition probability at each time step η 
In chapter В 10, a three-state Markov process (WELL, LUNG CANCER and 
DEAD) is used to model the incidence and mortality from lung cancer in patients 
with laryngeal cancer with respect to the overall mortality A possible course of 
disease is that of a patient who gets lung cancer at time = ι and dies in one of the 
subsequent times, denote by time = j 
The Markov model 27 
Time 0 ι I 
WELL -> LUNG CANCER - DEAD 
The Markov property assumes that the transition probability from WELL to LUNG 
CANCER at time Τ = ι only depends on the previous health state at Τ = ι-1, and 
does not depend on the sequence of the preceding states A possible violation of 
the Markov property is bypassed by presuming (1) unidirectional transition and (2) 
no other states in between than WELL For unidirectional transitions, a hierarchical 
structure of transition states is presumed Transitions 'down' from WELL to LUNG 
CANCER are allowed, but transitions 'up' from LUNG CANCER to WELL are not 
allowed Since WELL is the initial state at time Τ = 0, the transition probability P, 
from WELL to LUNG CANCER only depends on Τ = ι-1 Since the DEAD state is the 
'lowest' Markov state, and all patients die eventually, the DEAD state is called the 
absorbing state and the Markov model becomes a finite probabilistic system 
The Markov property further assumes that the transition Markov probability Pj 
from LUNG CANCER to DEAD is independent from the time spent in the state 
LUNG CANCER This is unlikely for patients with lung cancer In general the lung 
cancer survival curve strongly descends in the first 2-3 years following diagnosis 
and becomes constant after this period 
The modelling problem can be bypassed by several solutions 
The first and most simple solution would be to presume a Markov chain, using a 
mean approximation of the mortality rate inferred from one or several points in the 
survival curve, e g from the five-years survival rate The adjusted DEALE is a 
convenient method to infer such an average mortality rate In the case of patients 
with lung cancer, this solution could falsely lead to an underestimation of the 
mortality rate in the near years and to an overestimation of the mortality rate for 
distant years 
A second solution would be to presume unidirectional transitions from LUNG 
CANCER to DEAD and to model a second Markov tree dependent on the time lung 
cancer occurred However, such a second or higher degree in the Markov process 
is very cumbersome, with respect to modelling and evaluating 
A third solution is a quasi second degree Markov chain, introducing intermediate 
Markov states [Kemeny & Snell, 1976] In chapter В 10, four intermediate LUNG 
CANCER states were defined, indicated by LUNG CANCER_2nd to LUNG 
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CANCER_5th denoting the lung cancer states m year 2 to 5 following the 
occurrence of lung cancer Presuming unidirectional transitions the mortality 
probability Pj (and its complementary survival probability Qj = 1-P|) from lung cancer 
can then be modelled in a time-dependent fashion for the first five years following 
lung cancer As the mortality rate from lung cancer has virtually become zero after 
five years, the number of intermediate states can be limited to five After the last 
LUNG CANCER state, the process is reverted to the initial state WELL 
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Scheme 4 1 · All possible year-by-year courses of disease in patients with normal 
speech (N) after radiotherapy, followed by a laryngectomy after tumour recurrence, 
resulting in oesophageal speech (O) in the third, second or first year, and finally 
death (D) in the fourth year. 
Example- In chapter В 12 a six-state Markov process is described to model the 
follow-up of patients with radiotherapy for glottic carcinoma Scheme 4 1 shows all 
possible courses of disease in a hypothetical patient with a normal speech (N) after 
radiotherapy, followed by a laryngectomy after tumour recurrence, resulting in 
oesophageal speech (O) in the third, second or first year, and finally death (D) in 
the fourth year The transition probabilities denoted by pNN, pNO, pOO and pOD (a 
fifth transition probability, namely pNO, is not used in scheme 4 1 ) If the transition 
probabilities are equal for all years, the Markov model is called a Markov chain, if 
the transition probabilities vary with each year, the Markov model is called a Markov 
process 
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The Markov property assumes that the risk of dying with oesophageal speech in the 
fourth year following radiotherapy is equal for all laryngectomized patients, 
irrespective of whether a patient was laryngectomized for tumour recurrence in the 
first, second or third year following radiotherapy. This is unlikely as the mortality rate 
in the first year following laryngectomy is higher than in the subsequent years. In 
structuring the Markov model, this violation of the Markov property has been 
partially bypassed by presuming that the mortality from tumour following a 
recurrence is only increased in the year of recurrence and that the mortality from 
tumour in subsequent years is equal to the recurrence rate. 
We do not agree with Beck that the Markov model is not fit for oncology 
'..while cancer clearly does not...obey the Markov property. In malignancies, the 
prognosis depends on which specific remission or relapse is being experienced' 
[Beck, 1988]. On the contrary, as demonstrated in chapters B.10 and B.12, the 
Markov process can be considered as a simple and powerful tool to model the 
course of a disease of a patient with cancer and to make accurate predictions about 
the prognosis of an individual patient and to estimate the survival in a group of 
similar patients. 
4.3 Modelling time-dependent probabilities 
Necessarily, actuarial incidence and mortality rates are only probabilistic estimates. 
Both for practical convenience and for a systematic analysis, combining and 
comparison of these rates, some mathematical model has to be assumed to frame 
the actuarial data. The choice of a mathematical model depends on three, -not 
necessarily exclusive or conflicting-, criteria: 
1. Biological soundness: Model according to what you think is reasonable 
considering the theoretical concepts or assumed biological principles. 
2. Experimental faithfulness: Model according to your data (i.e. according to some 
'best fit' criterion). 
3. Simplicity: Model what is practically most convenient. 
For instance, figure 4.1 gives three mathematical approximations of the same 
actuarial estimates of the tumour recurrence-rate from a follow-up study in 556 
patients treated for laryngeal cancer [B.9, B.10]. In order to describe a biological 
process like tumour recurrence, we may wish to model the data as a continuous 
function of time, in accord with one of three above mentioned criteria: 
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1. Biological soundness: A widely accepted theory assumes that tumour 
recurrence is highest just after treatment and gradually decreases during the 
following years, but that the threat of a recurrence will never completely cease 
[Dippel & Segaar, personal comment]. A mathematical approximation which 
meets this theory is an exponentially decreasing function of time t with 
incidence accelerator λ: 
Incidence-rate = β"λ* {1} 
as drawn in figure 1 a. 
2. Experimental faithfulness: Figure 1b gives a complex mathematical function 
according to a 'best fit' approach, which (almost exactly) describes the 
experimental data. 
3. Simplicity: According to the third approach, figure 1c gives a simple linearly 
decreasing function with the best data-fit. 
The major drawback of the biologically sound approach is that it may result in 
wishful and conservative thinking. From a idealistic point of view, an over-reliance 
on theoretical concepts and an underestimation of the experimental data, may stray 
from new insights or new hypothesis about the 'real' structure of life. 
The opposite can be said of relying too much upon the experimental data, 
since the data may be insecure due to statistical variation or observation biases, 
and may be (and probably are) determined by the interaction between several 
simultaneously acting biological processes which can only be fit by a complex 
mathematical model. 
The drawback of the third approach is over-simplicity, hence violating both 
the most basic biological concepts about real life (e.g. a recurrence-rate cannot be 
less than zero, as suggested by figure 1c) or that it may poorly fit into the 
experimental data. 
Although the most complete or ideal deterministic model may eventually be the 
mathematical model that optimally describes and predicts our data [Hawking, 
1988], it is important to realize that in modelling for practical purposes, -such as in 
clinical decision analysis-, we have to be content with a compromise between the 
wishful, the experienced and the feasible. 
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5. Utility Assessment1 
5 1 Cancer Treatment, Quality of Life and Decision Making 
Survival rates, cure rates and life-expectancy are major outcomes of treatment of 
patients with cancer In recent years some powerful and sophisticated methods 
such as the Markov model for medical prognosis have been developed to generate 
accurate estimates of such quantitative outcomes, especially useful to medical 
decision making in oncology 
Aware of the fact that the preservation of the quality of life constitutes an 
important goal of cancer patient treatment, few physicians with experience in 
oncology will cling to survival and cure rates as the only criteria in choosing 
between alternative cancer treatments However, since the quality of life seems to 
be a too weakly defined 'soft' and subjective matter, many physicians will hold to 
survival and cure rates as the mam criteria of treatment success A further reason 
for the scarse use of the concept of quality of life in medical practice and clinical 
decision making, can be attributed to the inexperience with and lack of convenient 
methods to measure the quality of life or relevant and decisive aspects of the quality 
of life 
The semantic and ethical issues of quality of life in medical practice have 
been extensively discussed by others [Mulder, 1983, Musschenga, 1987, Verkes, 
1987, De Haes, 1988]. The present study deals with the practical problems of 
quality of life measurement for medical decision making in oncology 
In 1948 Karnofsky et al. introduced a bedside scaling method to give a quick and 
quantitative description of the general health-state of a patient with cancer 
[Karnofsky et al , 1948, Karnofsky and Burchenal, 1949] The Karnofsky 
Performance Status Scale has become a popular tool to register the quality of life in 
cancer patients, especially for the evaluation of cancer clinical trials [Mor et a l , 
1984] 
Many adaptations and variations have been developed based on the 
Karnofsky scale, ranging from simple bedside tools to elaborate questionnaires in 
order to obtain an impression of a patient's general health-state or quality of life 
Presented at the Second Conference of the European Society for Medical Decision Making, 
Copenhagen, June 1st 19ΘΘ [Stalpers et a l , 1988] 
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[Van Dam et al , 1984] De Haes and Van Knippenberg give a detailed 
methodological review of the current methods to assess the general quality of life in 
patients with cancer [De Haes and Van Knippenberg, 1985] Most of these methods 
generate a more or less accurate general description of a patients well-being 
Such merely descriptive methods can be very convenient to monitor qualitative 
changes in the course of a disease in cancer clinical trials However, such 
predominantly qualitative descriptions do not, by themselves, provide any norms 
that may guide medical decision making Norms for quality of life are highly 
desirable to weigh against other attributes such as survival-rate, cure-rate and/or 
life-expectancy The quantitative weighing of various qualitative properties on a 
common scale is called utility assessment. The utility of a certain attribute, -for 
instance the quality of life-, is a value judgement (by patent and/or doctor) of the 
quality of life, and this is to be balanced against the utility of another attribute, for 
instance life-expectancy, generally assessed by a patient or a physician The utility 
approach to medical decision making is based on the expected utility theory as 
described by Von Neuman and Morgenstern (1953) The expected utility theory 
states that individuals should assign (or act as if they assign) a utility to each 
possible outcome and faced with a set of alternatives, choose the one that yields 
the highest mathematical expectation of utility [Hershey and Baron, 1987] The 
expected utility theory works in either direction (1) Utilities can be inferred from 
choices in simple cases or assessed in a simple test and (2) these utilities can be 
used in the analysis of complex clinical cases Utility assessment is based on two 
mam principles 
1 Compensation A qualitative loss on one aspect of life can be compensated by 
a qualitative gam on another attribute 
2 Quantification Losses and gams can be expressed quantitatively 
Some fifteen years ago, utility assessment made its first cautious steps into medical 
decision making Important work has been done by Torrance et al in the 
development of simple utility assessment tests for clinical use, especially in the 
development of the basic reference gamble and the time tradeoff test [Torrance, 
1987] Practical and conceptual shortcomings of these methods actuate the search 
for alternative measurement techniques In this chapter we will describe the 
principles of and some experiences with these two methods and introduce additive 
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conjoint measurement as an alternative method that can meet at least some of the 
shortcomings of the former methods. 
5.2 The Life Standard Gamble (LSG) 
5.2.1. Principles of the Life Standard Gamble (LSG) 
The 'basic reference gamble' or 'life standard gamble' (LSG) is directly based on 
the utility theory as originally described by Von Neuman and Morgenstern. Adapted 
to the medical field, the Von Neuman-Morgenstern principle states that the utility of 
a certain health-state is equal to the expected utility of a gamble between a worse 
and a better health-state. 
A first application of the LSG in oncology has been described by McNeil et al. 
[1978]. A LSG was used to assess risk attitudes in 14 patients operated upon for 
lung cancer. They were retrospectively asked to choose between surgery and 
radiotherapy, considering that in the case of surgery they would have a better 
longevity than following radiotherapy, but with a higher short-term operative 
mortality. 
Figure 5.1 schematically gives an example of the LSG in which a patient was 
asked to assess the amount of years, -the certainty equivalent-, that s/he 
considered equally desirable as a 50/50 gamble between a longevity of 25 years 
and immediate death. The mathematically expected number of life-years of the 
gamble equals 12.5 years. 
Figure 5.1 · Schematic 
representation of a life standard 
gamble for the choice between 
a 50/50 gamble of a longevity of 
25 years (utility = 1.0) о r 
immediate death (utility = 0.0) 
and the individually assessed 
certainty equivalent CE in years 
with a utility equal to the 
expected utility EU of the 
gamble (EU = 0.5) (see text). 
Expected Utility - 0.5 
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If the certainty equivalent is similar to the mathematical expected life-expectancy, a 
subject is said to have a risk-neutral attitude on life years Risk-aversity on near life-
years states that subjects are more reluctant to take a gamble with life when faced 
with a short life-expectancy than with life-years somewhere in a distant future This 
interpretation was used by several authors to adjust utilities for the quality of life, 
assessed by a time tradeoff test (see §5 3) By varying the basic values in the 
gamble, a utility curve for the risk-attitude on life-years can be constructed such as 
illustrated by figure 5 2 
Step I Assessment of the certainty equivalent to a utility of 0 5 
By attaching a utility to the respective outcomes on a utility scale ranging from 0 0 
for immediate death to 1 0 for a longevity of 25 years, the average or 'expected 
utility' (EU) of the gamble represented in figure 5 1 is 0 5 If a patient considers 12 5 
certain life-years equal to the gamble, s/he is said to behave 'risk neutrally' If s/he 
is already satified with less than 12 5 years, say seven certain life-years to avoid the 
gamble, s/he is said to behave 'nsk-aversively' 
Step II Assessment of the certainty equivalent to a utility of 0 25 
The certainty equivalent to a utility of 0 25 is calculated by replacing the longevity of 
25 years in the 50/50 gamble by the certainty equivalent to a utility of 0 5 For 
instance The nsk-aversive patient mentioned above, is asked for the certainty 
equivalent to the 50/50 gamble between 'immediate death' and 'seven years' If the 
certainty equivalent is less than the mathematically expected 3 5 years, say three 
years, the patient is still said to be 'nsk-aversive' 
0 75· 
0 5 0 -
025 
ODO· 
/ 
• 
Rek А вгм 
Risk Neutral 
/ 
Figure 5 2 · Utility curves on life-
years U(l) The solid line gives 
the linear utility on the life-years 
curve for a subject with a risk-
neutral attitude The broken line 
gives a non-linear utility function 
on life-years denoting nsk-
aversity 
Life y«iri 
Additive Conjoint Measurement 37 
Step III: Assessment of the certainty equivalent to a utility of 0.75 
The certainty equivalent to a utility of 0.75 is calculated by assessing the certainty 
equivalent to a 50/50 gamble between a longevity of 25 years (utility = 1.0) and the 
certainty equivalent to a utility of 0.5 (as assessed in step I). For instance: The risk-
aversive patient in steps I and II is asked for the certainty equivalent to the 50/50 
gamble between 'seven years' and 'twenty-five years', being for instance fourteen 
certain life-years. 
We did a pilot-study with 15 volunteers to reproduce the results of McNeil 
and to investigate the feasibility of the LSG for practical medical decision making. 
5.2.2. Population and methods 
Fifteen volunteers aged 18-64 (mean = 28 years), most of them academically 
educated, were personally interviewed and asked to imagine having lung cancer 
with a choice between surgery and radiotherapy, of which surgery offered a longer 
life-expectancy but a higher short term mortality. The test used is given in appendix 
C.1. 
5.2.3. Results and discussion 
Five out of fifteen were not able to finish the interview completely. Twelve out of 
fifteen were not able to approach life as a simple gamble or did not understand the 
rules of the game. 
Almost all of them stated that they grasped the rules of the gamble but there 
was an equivocal reluctance to deal with life as a gamble and they therefore 
disapproved of the LSG. This gives rise to severe doubt about the validity of the 
LSG. Repeated disappointing results in a group of 12 general physicians and in a 
group of 20 medical students (not presented) and the negative results of other 
researchers forced us to renounce further research on the LSG [Llewellyn-Thomas 
et al., 1982; McNeil et al., 1982; Tversky and Kahneman, 1981]. 
5.3 The Time Tradeoff Test (TTT) 
5.3.1. Principles of the Time Tradeoff Test (TTT) 
The time tradeoff test (TTT) is used for the assessment of utilities for the quality of 
life by tradeoffs between quality of life and life-expectancy. One of the few 
applications in oncology described in the literature was presented by McNeil et al. 
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in 1981. This study deals with volunteers assessing the preference between 
radiotherapy and surgery in T3 laryngeal cancer, with radiotherapy offering better 
quality of speech but a shorter life-expectancy than surgery. 
The time tradeoff test is based on the major assumption that the utility of a 
certain health-state A is proportional to the minimal amount of years a patient is 
willing to accept to live in the better health-state В compared with the (larger) 
number of life years in the worse state A. 
For example: In chapter B.11, a subject is faced with the choice between 
radiotherapy and surgery for cancer of the vocal cords. Successful radiotherapy will 
lead to NATURAL speech and surgery implies an artificial speech with a longer life-
expectancy than following radiotherapy. If a subject faced with a life-expectancy of 
25 years with ARTIFICIAL speech is willing to tradeoff 5 years (i.e. leaving 20 years) 
to have a life with NATURAL speech, the utility of life with an ARTIFICIAL speech is 
said to be 1 - 5/25 = 0.8 of the utility of NATURAL speech. 
The assumption of proportional tradeoffs requires that the utility of an 
ARTIFICIAL speech holds for all given life-years. For instance: If a subject faced 
with 25 years ARTIFICIAL speech is assumed to be prepared to sacrifice 5 years for 
a life with NATURAL speech, then this same subject is willing to sacrifice the same 
proportion (=20%) of 5 years ARTIFICIAL speech, i.e. 1 year. The present study was 
designed to test this condition of proportional tradeoffs in 65 medical professionals. 
5.3.2. Population and methods 
Fifty-six health-science students and nine general physicians were asked to answer 
a written interview. The interview began with a description of the goals and the 
hazards of both radiotherapy and surgery for cancer of the vocal cords. The 
subjects were asked to imagine they had cancer of the vocal cords and a choice 
between radiotherapy and surgery. It was suggested that the test was designed to 
help patients with cancer of the vocal cords to facilitate a treatment choice. 
The time tradeoff test consisted of six items. In each item the subject had to 
assess the maximum number of life-years s/he was willing to sacrifice from a given 
life-expectancy with an artificial speech, in order to live with natural speech. The 
given life-expectancy in the six consecutive items was 25, 20, 15, 10, 5 and 2 years. 
It was explicitly stated that, if desired, it was possible to tradeoff parts of a year or to 
express the tradeoff in months. 
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The test was concluded with a short questionnaire on some personal 
characteristics (sex, age, marital state, education) and two multiple-choice 
questions investigating the ability to imagine having cancer and the ability to deal 
with quality of life in a quantitative way. 
Linear regression statistics were used to test the condition of proportional 
tradeoffs: Letting L denote the length of life and U(a) the utility of artificial speech, 
the condition of proportional tradeoffs holds if in the regression equation U(a) = с + 
ßL the coefficient β = zero so that U(a) equals the constant с 
5.3.3. Results 
On a utility scale ranging from 0.0 for death to 1.0 for life with natural speech, figure 
5.3 shows the utility of artificial speech as a function of life-expectancy. The broken 
horizontal line gives the expected graph for strict proportional tradeoffs for all life-
expectancies. The solid line interpolates the mean utility, showing a decreasing 
utility attached to artificial speech for increasing life years (β = -0.003). The graph 
shows a significant deviation from the condition of proportional tradeoffs (P < 0.01). 
Neither sex, age, marital state, family circumstances nor smoking behaviour 
showed any particular association with these outcomes. 
Almost all (95.4%) subjects stated that they had at least some difficulty to 
imagine they had cancer of the vocal cords and two-third (66.2%) had great 
problems or were unable to imagine having cancer of the vocal cords. 
With respect to dealing with the quality of life quantitatively, 97% had at least 
some problems and 73.8% had severe problems or found it practically impossible. 
Figure 5.3 · The utility of artificial 
speech U(a) according to the 
number of years to live as expected 
if the condition of proportional trade­
offs would hold (broken line) and as 
observed in 65 medical profes­
sionals (solid line) (see text). 
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5.3.4. Discussion 
This study confirms the findings of a pilot study with volunteers (not presented) that 
the time tradeoff test reflects a subject's actual attitude against quality of speech 
and survival; the non-patient population, -although educated in clinical thinking and 
accustomed to medical problems-, encountered the greatest problems imagining 
having cancer of the vocal cords. 
A major observation is that the TTT did not meet the required condition of 
proportional tradeoffs. This fact poses great questions to the usefulness in decision 
analysis: In individual cases, the eventual choice between radiotherapy and 
surgery may strongly depend on whether a subject is offered 25 years or 5 years for 
tradeoff and may less depend on the 'real' utility attached to the quality of speech. 
Violation of the condition of proportional tradeoffs between the quality of life 
and life-years can be explained by two phenomena: 
(1 ). Mutual dependence of attributes. The tradeoffs are proportional but the utility 
of artificial speech is determined by the utility of life-years, i.e. the shorter the length 
of life, the higher the utility of artificial speech. Without knowledge about the 
property, -i.e. the mathematical relation-, of the dependence between quality of 
speech and quantity of life, it is not possible to correct for possible violations of 
proportionality. One can imagine some kind of dependence for extreme short 
lengths of life: When faced with only days or hours to live, one might at least wish to 
have a natural speech to be able to make final arrangements. In that case, the utility 
of artificial speech must be very low. In less extreme situations it is hard to explain 
disproportionality by mutual dependence of attributes. In general, independence 
between attributes is considered an axiom in utility assessment. 
(2). Non-constant utility function of life-years U(l), i.e. not all years have an equal 
value. In general, life-years in the nearby future will be valued higher than distant 
life-years. Such a utility function much resembles the non-linear utility function on 
life-years due to risk-aversity U(l)as depicted in figure 5.2 (dotted line). Then, the 
ordinate in figure 5.3 does not represent the utility of artificial speech, but a hybrid 
utility of two different (mutual independent) utility functions: One for the quality of 
speech U(q)and one for life-years U(l). 
As discussed by Von Winterfeldt and Edwards [1986, p. 221 ff.], some utility 
theorists make a distinction between utility functions and value functions. Utility 
functions are assessed in gambles, such as the LSG, and value functions are 
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assessed in direct scaling methods in a 'riskless' context2, such as the TTT We 
agree with Von Wmterfeldt and Edwards that the distinction between utility functions 
and value functions is spurious and that these functions can be treated similarily in 
decision analysis We further state that it is potentially harmful to correct quality of 
life utilities assessed in a TTT with utilities for life-years assessed m a LSG, as was 
suggested by McNeil et al [1981] Although there is a semantic difference between 
trading and gambling with life-years [McNeil et al , 1978, Pliskin et al , 1980], we 
have doubts whether this difference holds in actual utility assessment 
A utility function of life-years with relatively higher utilities for life-years in the 
nearby future than for distant life-years, can be expressed by some kind of discount 
utility curve For instance A yearly discount of 10% states that the utility of a certain 
year ι is 10% less than that of the preceding year i-1 Such discount values were 
used by Glasziou and Simes [1988] in a quality-adjusted survival analysis in 
patients with breast cancer Discount values for the utility of life-years are more 
based on assumptions than on empirical evidence 
5 4. Additive Conjoint Measurement (ACM) 
5 4.1 Principles of ACM 
The practical difficulties of subjects to deal with risks in the life standard gamble and 
the conceptual shortcomings of the time tradeoff test, require a search for 
alternative measurement techniques to assess separate utility functions for (a) the 
quality of life and (b) the value of life-years Conjoint measurement models may 
meet the shortcomings of the previous methods by assessing these two utility 
functions simultaneously in a riskless context [Luce & Tukey, 1964]. Conjoint 
measurement models presume the existence of (a) separate utility functions for the 
quality of life (UQ) and life-years (UL) and (b) a conjunction of both attributes 
resulting in a conjoint utility function UQ
 L that can be described as a simple 
mathematical function based on the separate utility functions The most simple 
mathematical model presumes a simple additive utility function 
U Q , L = U Q + UL {5 3} 
Riskless in the sense that, -in the test-, there are no explicitly mentioned absolute risk expressions 
or probability statements However, risk attitude or risk related behaviour may implicitly be 
considered in a subject's preference assessment 
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Under certain conditions, the utility function UQ |_ and the separate utility functions 
UQ and и|_сап be inferred from a preference ranking on pairs of life-expectancy L 
and the quality of life Q. These pairs Q,L are denoted as 'dyads' The model 
conditions are' 
(1) Independence of attributes The utility of one attribute is not determined by the 
utility of the co-attribute For instance. Let q, r, s . denote the levels on attribute 
Q and let I, m, п.. denote the levels on attribute L. If you prefer the dyad (q,l) to 
dyad (r,l), you prefer q to r for any other level on L Similarly, if you prefer (q,l) to 
(q,m) then you prefer I to m for any level on Q. 
(2) Transitivity of preferences: If for any dyads A,B and C, you prefer dyad A to B, 
and В to C, then you prefer A to С The opposite (or violation) of transitivity is 
called circularity For instance If you prefer dyad A to В, В to С and С to A, there 
is a cycle in the preference ranking on the three elements А,В and С In a 
preference ranking on the dyads A,B,C ..Z, both the number of cycles and the 
number of dyads in each cycle contribute to the severity of mtransitivity 
[Bezembinder, 1981]. 
(3) Double cancellation of preferences: 
If: and if: then: 
L 
Q 
mute 
oesoph. 
normal 
(years) 
3 6 
m,3 m,6 
o,3 o,6 
n,3 n,6 
9 
m,9 
0,9 
n,9 
3 
m,3 
o,3 
n,3 
6 
m,6 
\ 
n,6 
9 
m,9 
o,9 
n,9 
3 
т.з 
o,3 
n,3 
6 9 
m,6 m,9 
^ 
o,6 o,9 
n,6 n,9 
Figure 5.4 · Double cancellation demonstrated by a 3x3 matrix for the dyads of Q 
(mute, oesophageal speech and normal speech) and L (3, 6 and 9 years) (see text) 
Let mute, oesophageal and normal denote three levels on quality of speech Q, 
and let 3, 6 and 9 years denote three levels on life-expectancy L. Figure 5 4 
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gives the dyads of (Q,L) ordered in a 3x3 matrix If you prefer the dyad (n 6) to 
(o,3) (left panel) and the dyad (o,9) to (m,6) (middle panel) then you prefer the 
dyad (n,9) to (m,3) (right panel) If the condition of double cancellation is 
violated, there is no solution that yields additive utility functions from the 
preference ranking With q>3 and l>3 the number of levels in Q and L, 
respectively, the condition of double cancellation goes for any 3x3 submatnx 
resulting from the original qxl matrix by picking three levels on Q and three 
levels on L 
5 4 2 Determining a Preference Ranking 
Based on ACM, a test was designed to assess an individual preference ranking on 
a set of dyads of quality of speech and life-expectancy in patients with cancer of the 
vocal cords 
In our experiments, we chose five (n and m) levels on each attribute On life-
expectancy 3, 6, 9, 12 and 15 years On quality of speech Mute (M), electronic 
larynx (E), oesophageal speech (O), hoarseness (H) and normal speech (N) The 
five levels for the quality of speech might need some clarification By surgery for 
cancer of the vocal cord the voice box of a patient is sacrificed These patients have 
to learn an artificial speech About 70% of these patients manage to learn a so-
called oesophageal speech by belching swallowed air This method requires 
patience, intelligence and long practice and not all patients are successful The 
latter patients (25%) may be helped by a so-called electronic larynx This 
electronical device produces a vibration that is amplified and modelled by the oral 
cavity The result is a somewhat metallic and monotonous speech About 5% of 
patients will never learn any form of artificial speech and stay mute for the rest of 
their life Following successful radiotherapy, the quality of speech may range from 
near normal speech to hoarseness From five life-expectancies and five qualities, 
25 dyads can be formed ranging from worst, being 3 years mute, to best, being 15 
years normal speech The ranking of the other 23 dyads has to be assessed by 
individual testing Figure 5 5 gives an example of a preference ranking of the 25 
dyads in a 5x5 matrix (η χ m data matrix) 
Each cell contains the rank number for each dyad of Q and L Having these 
25 dyads directly put into a preference ranking results into a transitive ranking but 
this task mostly appears very difficult if not virtually impossible for most subjects 
Also, the result will generally not be very stable It is much easier for a subject to 
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make a choice between two simple alternatives. Therefore we made pairs of dyads, 
-so-called paired comparisons-, and we asked the subject to assess his or her 
preference in each paired comparison. 
L. 3y 6y 9y 12y 15y 
Q 
Mute 
Electronic larynx 
Oesophageal 
Hoarseness 
Normal 
0 
1 
2 
3 
5 
4 
6 
7 
9 
10 
8 
11 
12 
14 
18 
13 
16 
17 
19 
22 
15 
20 
21 
23 
24 
Figure 5.5 · Arrangement of a preference ranking on 25 dyads of quality of speech 
and life-expectancy in a 5x5 matrix (nxm data matrix). 
For example-
What do you prefer ? 
A. Living 9 years with a normal speech 
or 
B. Living 12 years mute 
From 25 dyads, 252 = 625 paired comparisons can be constructed. Figure 5.6 gives 
all 625 paired comparisons arranged in a 25x25 matrix (nm χ nm matrix). The entry 
in each matrix cell is 0 or 1, indicating that either the column dyad (1) or the row 
dyad (0) is preferred. Under certain constraints, preferences need not be assessed 
on all 625 paired comparisons: 
1. If we presume the following natural preference order on the attributes, i.e 
for life-expectancy: 15>- 1 2 > - 9 ^ 6 > - 3 years 
and for the quality of speech: N>-H>-0>-E>-M, 
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then only those comparisons are non-trivial in which the dyads show opposite 
directions of this natural order of the attributes. The >- sign denotes strict 
preference in the observed data. 
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Figure 5.6 · Arrangement of 625 paired comparisons in a 25x25 matrix. This matrix 
gives an empirical example: One ('1') denotes preference of a row-dyad to the 
corresponding column-dyad. L· denotes the column sum-score, 2> denotes the row 
sum-score. Non-trivial paired comparisons have been represented in bold 
characters (see text). (To enhance readibility, zero's in trivial paired comparisons 
have been replaced by '-') 
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For instance in the paired comparison: 
A. Living 9 years with a normal speech 
or 
B. Living 12 years mute 
the order of attributes is opposite, since 9 years -< 12 years and normal speech 
>- mute. In each non-trivial paired comparison a patient thus chooses either the 
better quality of speech or the better life-expectancy. In the 625 paired 
comparisons, 200 are non-trivial. 
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Figure 5.7 · Detail from the binary matrix in figure 5.6 sorted by increasing row sum-
scores and by decreasing column sum-scores. The paired comparisons in italics 
correspond with the dyads involved in a cycle (see text). 
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2 The 200 non-tnvial paired comparisons may easily be reduced to 100 For 
instance the paired comparison 
A Living 9 years with a normal speech 
or 
В Living 12 years mute 
is equivalent to the paired comparison 
A Living 12 years mute 
or 
В Living 9 years with a normal speech 
So, 100 paired comparisons suffice for representing all non-tnvial (hard) choices3 
Appendix С 3 gives the 100 paired comparisons used in the ACM test On each 
paired comparison, a subject was asked to indicate a preference either for a better 
quality of speech (dyad A) or for a longer life (dyad B) 
Appendix С 4 gives the FORTRAN programme to generate all paired 
comparisons from a matrix with η levels on Q and m levels on L and to check the 
nm χ nm matrix for (violation of) transitivity Figure 5 7 gives a detail from the binary 
matrix of figure 5 6 sorted by increasing row sum-scores and by decreasing column 
sum-scores The sorted matrix graphically displays an asymmetric structure around 
the blank diagonal line The asymmetry is due to circularity in four dyads 3N, 6M, 
6E, 60 
Based on this binary matrix, Bezembinder designed a mathematical method 
to identify the cycles in a preference ranking [Bezembinder, 1981] It can be shown 
that in a transitive binary nm χ nm matrix, sorted by increasing row sum-score, the 
cumulative row sum-score S(k) for dyad к equals k(k-1 )/2 for к = {1,2 .nm} 
Further, it can be proven that a dyad for which S(k) > k(k-1)/2 is involved in a 
cycle In a preference ranking on dyads, all consecutive dyads with S(|
<
) > k(k-1)/2 
and the next dyad with S(|
<
) = k(k-1)/2 belong to one cycle For instance, the next 
preference ranking on dyads shows that dyads 3N, 6M, 6E and 60 all belong to 
one and the same cycle 
3 For a matrix with η levels on Q and m levels on Ц the number of dyads is τ 
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Dyad 
к 
Row sum (ΣΓ) 
s (k) 
k(k-1)/2 
3M 
1 
0 
0 
0 
3E 
2 
1 
1 
1 
30 
3 
2 
3 
3 
3H 
4 
3 
6 
6 
3N 
5 
5 
11 
10 
6M 
6 
5 
16 
15 
6E 
7 
6 
22 
21 
60 
8 
6 
28 
28 
6H 
9 
8 
36 
36 
In a single test, circularity may occur accidentally because a subject may simply 
have made a mistake by putting one of the test-cards on the wrong stack Therefore, 
the ACM-test is performed three times with one week intervals If for a specific 
dilemma Q is preferred at least twice, Q is said to be preferred for this dilemma 
Otherwise it is said that L is preferred Then, the results of all three replications can 
be processed as if it were one single test 
Circularity after three replications of the test is likely to be explained by 
violation of transitivity in the preference ranking Both the number of cycles in a 
preference ranking and the number of dyads in each cycle contribute to the severity 
of violation of transitivity in a preference ranking [Bezembinder, 1981] 
A simple method to restore transitivity is by switching or 'reversing 
appropriate choices, the well-known solution is the one that can be obtained by the 
smallest number of switches However, this method does not yield a unique 
solution [Bezembinder, 1981] 
Since we want to obtain a patient's 'real' preferences, we suggest the 
practical solution to confront a subject with his/her circularity and have him/her 
correct his/her preferences by ordering the dyads involved in a cycle For instance 
Figure 5 7 shows a cycle for the dyads 3N, 6M, 6E and 60 In a discussion between 
the interviewer and the subject, the subject is asked to rearrange the four dyads in a 
transitive order 
For practical reasons, these corrections are only made for limited violations of 
transitivity, involving only few and small cycles Of course, this procedure may also 
lead to the conclusion that the patient is unable to reach a transitive order In that 
case, this procedure does not result into an advice as to what treatment is to be 
preferred 
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5 4 3 Obtaining an Additive Preference Ranking 
In the former paragraph, we described how to obtain a transitive preference ranking 
on dyads of Q and L Next we have to determine whether there is an additive 
solution for this preference ranking, ι e whether we can infer two independent utility 
functions UQ and UL as well as the additive conjoint utility function UQ I L = UQ + U L 
Further, if the preference ranking meets the conditions of 'independence of 
attributes' and 'double cancellation of preferences, there generally will be an 
additive solution 
Since in the ACM-test strict order was presumed on both attributes Q and L, 
independence requires that an nxm data matrix, such as figure 5 5, shows 
increasing cell entries in each column 1,2 η for each row, and increasing cell 
entries in each row 1,2 mfor each column In this case, a check on independence 
can readily be seen by a visual inspection of the data matrix 
Figure 5 4 shows the check on double cancellations in a 3x3 data matrix In 
an nxm data matrix, each 3x3 submatnx should be tested for double cancellation in 
each of its (3')2 = 36 possible permutations Any nxm matrix has (ni/3(n-3)i)(mi/3(m-
3)1) possible 3x3 submatnces, a 5x5 matrix has 100 possible 3x3 submatnces 
Double cancellation has to be checked for any permutation of rows and colums of 
the 3x3 matrix, yielding (З'НЗ1) = 36 permutations Then, a 5x5 matrix requires 3600 
checks on double cancellation If each of η rows and and each of m colums are 
fixed such as in figure 5 4 and figure 5 5, 36 checks are required for each 3x3 
submatnx 
Analogously to the correction of the violation of transitivity, one can suggest 
to correct violations of independence and of double cancellation in a discussion 
with the subject However, the limited experience with the ACM-test almost always 
showed at least some mtransitivities Correcting these mtransitivities always turned 
out to be sufficient for establishing both independence and double cancellation 
5 4 4 Inferring Utility Function UQL, UQ and U^ 
Two methods are available to infer utility functions UQ
 L, UQ and U L 
The most straightforward method is to find a solution by trial and error Such 
an iterative process is performed by the FORTRAN-program UNICON 
[Bendermacher &. Thissen, 1987] UNICON is based on an algorithm which looks 
for a solution by minimizing the error or 'stress function' For an additive preference 
ranking on dyads, a solution can be found without any stress In that case, namely 
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when additivity is completely met, there generally is more than one unique solution. 
Following an iterative search process, UNICON gives only one, quite arbitrary 
solution, namely the first solution with stress = 0. 
Since there are many solutions to an additive preference ranking, it is 
essential to define the boundaries (or extreme solutions) of the solution space and 
to find a representative solution within this space. ORDMET3 is a FORTRAN 
program by Roskam which finds the extreme solutions by describing and solving 
the preference ranking as a set of linear inequalities [Roskam, 1987]. A set of linear 
inequalities is a consistent set of linear comparisons (-< or >-) with unknown 
elements which can be solved by linear programming presuming an additive 
model. For instance: The 3x3 matrix in figure 5.8 yields 36 linear inequalities: 
a b c Figure 5.8 · The 3x3 matrix for Q (q,r,s) 
q 1 2 4 and L (a.b.c) above, yields the 36 linear 
r 3 5 7 inequalities below. 
s 6 8 9 
q+a -< q+b 
q+b -<cf+c 
q+c>- r+a 
r+a -< r+b 
r+b -< r+c 
r+c >- s+a 
s+a -< s+b 
s+b -<s+c 
q+a -< q+c 
q+a -< s+b 
q+b -< r+a 
q+b ·< s+c 
q+c -< r+b 
r+a -< r+c 
r+b -< s+a 
r+c -< s+b 
s+a -< s+c 
q+a -< r+a 
q+a -< s+c 
q+b -< r+b 
q+c-< r+c 
r+a -< s+a 
r+b •< s+b 
r+c-« s+c 
q+a -< r+b 
q+b -< r+c 
q+c -< s+a 
r+a •< s+b 
r+b •< s+c 
q+a ·< r+c 
q+b -: s+a 
q+c -< s+b 
r+a -< s+c 
q+a •< s+a 
q+b ·< s+b 
q+c -< s+c 
If the 3x3 matrix meets additivity (transitivity, independence and double 
cancellation), the eight linear inequalities in the first column are sufficient to 
determine the solution space, i.e. to determine all sets of utility values q, r, s, a, b, 
and с The eight linear inequalities are the comparisons between each cell-entry 
and its immediate successor in the strict simple order given by the 3x3 matrix. 
By fixing one utility value on either attribute, -generally the worst Q and the least L-, 
the solution space can be described as a convex polyhedral cone within a space 
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with (n-1)(m-1) dimensions or degrees of freedom. The extreme solutions can then 
be imagined as edge-vectors of the convex polyhedron space (see figure 5.9). 
ORDMET3 allows one to follow one's own predilection and to choose any solution 
within this space as a representative solution. Three methods, each yielding only 
one 'unique' solution within the solution space are mentioned here: 
1. The maximin solution, representing the vector which correlates best with any of 
the extreme solutions (the smallest angle with any of the extreme vectors) 
[Roskam, 1987]; 
2. The least squares solution representing the solution with the smallest distance 
to any extreme solution [Tversky &. Zivian, 1966]. 
3. The centroid solution representing the average of the extreme solutions. 
Chapter B.12 describes how the centroid utility function UQ and UL can be used 
in a decision tree analysis. 
Figure 5.9 * A convex poly-
hedral cone bound by four 
edge vectors. 
5 4.5. Limitauons of ACM; Further research 
Table 5.1 summarizes some characteristics of additive conjoint measurement 
compared with the life standard gamble and the time tradeoff test. 
Independence of attributes is prerequisite for all measurement models here 
considered. Transitivity is presumed both for the TTT and the LSG without 
considering whether or not transitivity is met; the ACM-model provides both a tool to 
check for transitivity, to correct for (limited) violations of transitivity and to infer 
/ 
f, ç> 
/ 
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independent utility functions for the quality of life and for life-expectancy from a 
transitive preference ranking on dyads of quality and quantity of life 
Proportionality of tradeoffs between the quality and quantity of life are both 
required in the TTT test and in the LSG, but not in the ACM test In The LSG test, the 
tradeoffs and the resulting utilities are further disturbed by a subject's attitude 
towards risks and probabilities, hence, the LSG is generally not used for the 
assessment of tradeoffs between the quality and quantity of life but merely for the 
assessment of risk attitude upon life-years [see Pliskin et a l , 1980, McNeil et a l , 
1978, 1981] Neither in the TTT test nor in the ACM test are risk properties explicitly 
mentioned in the assessment of tradeoffs However, such risk properties may 
implicitly be considered by a subject during his/her utility assessment Adjustment 
of utilities for the quality of life, as assessed in a TTT test by risk attitude upon life-
years assessed m a LSG, as proposed by Pliskin et al and by McNeil et al , may 
falsely lead to overadjusted utilities for the quality of life 
Table 5 1* Summary of some characteristics of additive conjoint measurement 
(ACM), the life standard gamble (LSG) and the time tradeoff test (TTT) 
ACM LSG 
Independence presumed 
Transitivity 
Proportional tradeoffs 
Risk attitude 
Practical ease 
Mathematical ease 
Yes 
Required 
No 
Neutral 
Good 
Complex 
Yes 
Presumed 
Yes 
Averse or 
Seeking 
Poor 
Bedside 
Yes 
Presumed 
Yes 
Neutral 
Poor 
Bedside 
A major difficulty of the LSG, and to a minor extent of the TTT test, is that subjects 
encounter great difficulties to grasp the quintessence of the gamble or to deal with 
the quality of life in a quantitative way The simplicity of simple two-by-two choices 
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in the ACM test may facilitate to establish quantitative tradeoffs of subjective values 
of quality of life and life-expectancy 
The calculation of utilities are quite simple for both the TTT test and the LSG, 
these methods have therefore been promoted as simple bedside methods to 
assess utilities. The ACM test requires more effort: The test itself takes only 15 to 20 
minutes, but has to be replicated three times and generally requires a fourth time to 
correct for violations of the model assumptions. Both the identification of violations 
of the model assumptions, the inference of additive utility functions UQ and UL and 
the decision tree analysis using time dependent utilities, have been facilitated by 
specific computer programmes. 
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6. Results of radiotherapy and surgery for glottic carcinoma1 
6.1 Introduction 
Cancer of the larynx accounts for 2% of malignancies diagnosed in the United 
States It is a predominantly male disease The estimated incidence for 1983 was 
9,100 in men and 1,800 in women with an estimated death rate of 3,100 in men 
and 600 in women [5,50] 
About 60% of the patients are older than 50 with a median age of 60 [52] 
Smoking is strongly associated with laryngeal cancer, with increased risks up to 25 
times found for war-veterans smoking more than 40 cigarettes daily compared with 
non-smokers [27,5] 
Laryngeal cancer originates in the glottic (55%), supraglottic (40%) and 
subglottic regions (5%) Patients with glottic carcinomas are curable both by 
radiotherapy and by surgery The good prognosis can be attributed to 
(1) Early detection of the tumour because of early symptoms, especially 
hoarseness, 
(2) Late metastatic tumour spread because of the sparse lymphatic and vascular 
supply of the vocal cords, 
(3) Relatively easy technical approach of the tumour by surgery or radiotherapy 
Although the survival rates are favourable, the disease itself as well as its treatment 
can severely affect glottic anatomy and functioning, resulting in impaired voice 
qualities ranging from simple hoarseness to total loss of speech Surgery, even so-
called conservation surgery, gives more voice-debilitating results than radiotherapy 
[33,7,20] 
Currently, radiotherapy is accepted as the first mode of treatment for glottic 
carcinoma confined to the vocal cord (TINQMO) Most therapeutic centres favour 
radiotherapy in the case of tumour extension to either the supraglottic or subglottic 
regions without fixation of the vocal cords (T2N0M0) [10,58,38,37,8,34,49,11 7,43, 
15,23,39] Others advocate surgery as first treatment, especially if conservation 
surgery is possible or if the mobility of the vocal cords is impaired [3,4,29,32,35,44] 
Radiotherapy may also be the primary mode of treatment for patients with more 
L J A Stalpers, MD A L M Verbeek ALM, MD, PhD and W A J Van Daal MD, PhD Published m 
Cancer Treatment Reviews, 19Θ7, 14 131-141 
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extensive tumours (T3 and T4), especially since the understanding of 
radiotherapeutic failures has improved and irradiation techniques have been 
optimized [9,14,16,18,19,43,45,56]. 
In a 1970 literature review on the role of radiotherapy for cancer of the larynx 
Vermund stated: 'It is only by constant comparison and review of the various modes 
of treatment that we can hope to achieve better results'. Especially when treatment 
modalities are controversial, treatment results as presented in scientific papers, 
have to be carefully reviewed and compared. 
The aim of this study was to see whether, by reviewing the literature, we 
could find factors and arguments that would favour radiotherapy or surgery for 
glottic cancer. This is essential when more extensive tumours are concerned for 
which the optimal choice of treatment is still controversial. 
6.2 Data and methods 
The laryngologic and oncologic literature of the period 1973-1986 has been 
reviewed for factors and arguments which play a decisive role in the choice 
between primary radiotherapy and primary surgery, as well as for treatment results 
of glottic carcinoma. 
Only articles using the TNM system for tumour classification were studied 
[1,25]. Because the degree of mobility in T2 carcinomas is assumed to have 
prognostic significance, a distinction was made between Тга and Тгь- This literature 
study only deals with treatment results of tumours that had not metastasized to 
regional lymph nodes or distant organs at the time of primary diagnosis. 
We described treatment results in terms of 5-year survival rates, 5-year 
disease-free survival rates, recurrence rates and salvage rates. The 5-year period 
was chosen because it is used in most articles and because the few authors 
describing longer periods of investigation, state that their survival results do not 
essentially differ from 5-year results [22,43,51,53]. Shorter periods ( e.g. 3 years) 
were not evaluated for survival and disease-free survival because data were 
scarce. In all, 26 articles were reviewed describing 5-year survival and 5-year 
disease-free survival; for the study of recurrence and salvage after recurrence 28 
articles were evaluated. 
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According to the UICC TNM general rules, survival results can be presented in two 
ways [24]: 
1. The crude survival rate calculated by the direct method, is the number of 
persons known to be alive at the end of the period considered, divided by the total 
number who were alive at the beginning of this period: 
alive 
bcrude - alive+dead+lost 
The alternative or life table method of computing survival rates uses all the 
information accumulated over the whole period of observation and provides a 
description of the survival pattern [2,6,28]. In describing five-year survival, an 
actuarial method gives a weighted correction for patients who left the study alive at 
the end of the study-period and had no five-year follow-up. For these patients the 
term withdrawal is used. 
2. The corrected or adjusted survival rate. There are different methods of 
correcting the crude rate for death from intercurrent diseases and for those patients 
lost to follow-up. In an actuarial method these types of corrections can be made by 
regarding those patients as withdrawals. This methodic analogy of correction may 
lead to the erroneous assumption that an actuarial method always gives a 
correction for death from intercurrent diseases and for patients lost to follow up. This 
explains why many authors seem to compare an 'actuarial' method with a 'crude' 
method, while in fact they are comparing a 'corrected actuarial' method with an 
'uncorrected actuarial' method in the sense described above. In this study 
'corrected' rates are rates from studies where correction was made for death from 
intercurrent disease and for patients lost to follow-up. If it was not clear from the 
study whether any or what correction was made, a 'crude' rate was assumed. 
Salvage rates and disease-free survival rates are given in ranges and 
means. These means are proportionally weighted for the number of patients in 
every study: 
n/= number of eligible patients in study i 
Pi= survival rate in study i £ (л/ χ ρ,) 
mean = — 
ι
η<-
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In describing recurrence rates and salvage rates cumulative means are given 
/·/= number of recurred (or salvaged) patients in 
study ι 
n, = number of patients at risk in study ι 
Salvage was defined as curation after recurrence, generally by surgery Using this 
definition two kinds of salvage-rates are described in the literature The first salvage 
rate is the rate of successful salvages among all patients who had tumour 
recurrence The second is the rate of successful salvages among all patients who 
had undergone a salvage procedure The second rate disregards patients who had 
tumour recurrence but, for whatever reason, did not undergo a salvage procedure 
If possible, salvage rates of both types will be presented 
6.3 Results 
Radiotherapeutic schedules and techniques differ within time and within the varying 
treatment centres Table 1 summarizes irradiation dose, overall treatment time, 
dose-fractionating schedules, techniques and some indicative survival-figures as 
described by the different authors Articles in which no technical specification for 
radiotherapy were mentioned are not tabulated in Table 1 [32,37,47] 
Survival and disease-free survival (Tables 2 and 3) 
5-year survival results for non-metastasized glottic carcinoma are summarized in 
Table 2 For TINQMO tumours crude and corrected data are quite different A similar 
difference between crude and corrected figures can be found in the review of 
T2N0M0 carcinomas, although surgical results are scarce, as are survival results for 
T3 and T4 tumours The broad ranges in survival for T4 tumours can be ascribed to 
the small populations, both for radiotherapy and for surgery Table 3 summarizes 
data on 5-year disease-free survival Unlike radiotherapeutic results, only few 
surgical results have been published 
JJW 
cumulative mean = ' — 
Table 6.1 · Radiotherapy for поп-metastasized glottic carcinoma 
Reference + Author 
(year of publication) 
Class. Dose Time Fractionation 
(Gy) (weeks) (no/week,dose) 
Technique + field size 
(cm χ cm) 
5-year Survival 
Qude 
Τι T2 Тз T4 
CorTECted 
T4 
4 Brandenburg(1977) 
7 Dickens (1983) 
8 Ennuyer (1975) 
11 Goffi net (1973) 
12,15 Harwood (1979) 
13 Harwood (1979) 
16,18 Harwood (1980, 1981) T3.4 
22 Hmtz (1983) T, 
23,49 Hunter (1980); T 1 4 
Stewart (1975) 
T M 
Ti-? 
T1-4 
Ты 
Tl-? 
Tl 
Т3-4 
60-70 
56-60 
60-75 
50-70 
55 
50-70 
55 
6-7 
5-7 
4-6.5 
5-7 
5 
5.5-6.5 
4-5 
-
-; 1.73-2.50 Gy 
-
4-5/week;2.0 Gy 
24-26 fx 
5/week; 20 fx 
5/week; 2 5 Gy 
ca 55 3 16 fx 
Co; >T1 cervival nodes=50 Gy 
Co; lateral fields + wedge 
Co; individual dose by response 
4MeV; lateral wedged fields 4x4 or 4x5 
Co; compression technique 5x5 or 6x6 
Co; 4x4 or 5x5 
Co; angled down + wedges + cast 
Co; 4MeV, lateral angled wedged fields 
4MeV, antero-lateral wedged 
or parallel opposed fields 
29,30 Kaplan (1983, 1984) T ) ^ 60-65 6-6.5 
31 Kim (1978) 
35 Lippi (19Θ4) 
37.55 Miller (1975); 
Wang (1974) 
39 Mills (1979) 
40 Mmja (1984) 
41 
43 
51 
53 
Nass (1976) 
Notter (1984) 
Sung (1979) 
T1-2 
Тз 
Tl.2 
Tl-4 
T1-2 
Тз 
Tl 
Т ы 
Т ы 
Tl-2 
-; parallel opposed fields 5x5 to 6x6 
or anterior oblique wedged fields 
5/week; 2 25 or 2.5 Gy Co; parallel opposed 
5/week; 2.0 Gy fields 6x6 
5/week; 1 8-2 0 Gy 
5/week; 2 0 Gy 
5/week; 2.0 Gy 
5/week; 2.0 Gy 
Van den Bogaert(1980) T2 
50-70 -
65-70 -
>50 
65-70 6-7 
55 5.5 
70 7 
20+36 8 
or 40 
before 1966. 
30-65 -
since 1966: 
60-65 6-7 
60-70 6-7 
49-93 4-10.5 12-44 fx 
47-76 5-a S/week; 2.0 Gy 
40-70 4-7 5/week;2 0 Gy 
MeV, Co, 1 anterior electron 
or 2 opposed Co fields 
2MeV, Co, single or opposed 
lateral or wedged fields 
Co; parallel opposed + wedged fields 
Co; 2 weeks split after 2 weeks 
5/week, 1.4-2.0 Gy 250kV Orthovolt 
5/week; 2 0 Gy 
5/week; 2.0 Gy 
only 3-year survival results 
indeterminate results 
82% 
74% 
73% 
63% 54% 75% 
36% -
. 
-
-
59% 47% 33% 
95% 
90% 
95% 
87% 
92% 
94% 
-
80% 
80% 
-
_ 
85% 
75% 46% 
92% 62% 
Co; parallel opposed fields 6x8 
2MeV, Co, 6MeV; opposed wedged fields 85% 76% 
Co, 4-5MeV, antero-lateral wedged fields 8 1 % 72% 
T1-2 4x4 - 6x6, T3. booster, split, 6x6 - 8x8 
Orthovolt, Co, 6MeV, 22MeV,· 
parallel opposed fields: 5x6 
Co; parallel opposed fields - 46% 
74% 64% 
57% 
fx » fraction(s), Co =• Cobalt gamma; MeV - megavolt photons, Orthovolt = low energy photons, N E D = no evidence of 
88% 
96% 
87% 72% ( N E D ) 
98% -
82% (N.E D.) 
89% -
98% 9 1 % -
76% 66% (N E.D.) 
disease 
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Table 2 · Five-year survival of поп-metastasized glottic carcinoma 
(literature review 1973 - 1986) 
R a d ι о t h e 
crude 
73% - 86% 
mean » 79% 
r a p y 
corrected 
87% - 98% 
mean = 94% 
S u r g e r y 
crude 
7 6 % - 8 1 % 
mean = 80% 
corrected 
89% and 91% 
mean = 89% 
References 
T1 
46% - 78% 
mean = 68% 
80% - 91 % 
mean = 84% 
59% and 72% B8% 
mean = 66% 
T2a 54% and 82% 80% - 96% 
mean - 72% mean - 91 % 
Ν Ρ 
Тгь 40% and 58% 75% - 82% Ν Ρ 
mean = 5 1 % mean - 78% 
Тэ 36% - 67% 57% and 74% 79% 
mean = 48% mean = 68% 
89% 
80% 
59% 
T4 25% - 75% 64% 50% and 67% Ν Ρ 
mean = 45% mean = 54% 
RTcrude 8(71) 12(333),35(63), 
39(49),41,(38),43(95) 
47(52),49(168),55(183) 
RT corr 11(78),12(333),13(151), 
22(91),23(175),31(129), 
39(49),41 (38),43(168), 
49(168),55(183) 
SU crude B(16),35(217),47(17) 
SU corr 8(16),42(182) 
RT crude 8(26),23(32),35(22),41(21) 
,43(100),49(37),53(61) 
RT corr 11(21),15(154),23(32), 
29(31),43(100), 
SU crude 8(18),35(58),47(54) 
SU corr 29(24) 
RT crude 43(58),53(33) 
RT corr 15(95),29(25).43(58) 
SU corr 29(9) 
RT crude 43(42),53(2β) 
RT corr 15(54),29(6).43(42) 
SU corr 29(15) 
RT crude 8(26), 11 (33),39(15),49(67) 
RT corr 16(112),49(67) 
SU crude 4(48) 
SU corr 11(14) 
RT crude4(4)l8,8(4),49(3) 
RT corr 18(56) 
SU crude 8(9),26(32) 
θ 3-year survival ( no 5-year survival described ) 
Ν Ρ - not published 
Recurrence rate and salvage (Tables 4 and 5) 
Table 4 summarizes ranges and mean values for local and/or distant metastatic 
tumour recurrence. Few rates other than crude recurrence rates have been 
published. Correction for time under observation was mentioned in very few cases; 
actuarial correction for intercurrent diseases has never been described. 
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Table 3 · Five-year no-evidence of disease (NED.) after radiotherapy 
or surgery for поп-metastasized glottic carcinoma 
R a d i o t h e r a p y 
crude corrected 
S u r g e r y 
crude corrected 
References (patients at risk) 
Ti 72% and 73% 76% - 93% 95% 
mean - 72% mean - 84% 
Ν Ρ 
Tg 37%-72% 67%-75% 59% and 8 1 % 65% 
mean = 63% mean · 70% mean = 64% 
T2a Ν Ρ 
T2b N P 
тз 
77% - 80% 
mean » 78% 
51%-68% 
mean - 59% 
26% and 38% 5 1 0 
mean = 30% 
T4 25% and 33% 56% 
mean = 27% 
Ν Ρ 
Ν Ρ 
79% 
Ν Ρ 
Ν Ρ 
Ν Ρ 
50% and 67% Ν Ρ 
mean = 54% 
RT crude 8(71),41(38) 
RT corr 22(91),23(175),30(149), 
31(129),40(174),51(119) 
SU crude 30(15) 
RT crude 8(26),23(32),37(90). 
39(13).41(21),49(37) 
RT corr 15(154).39(29),43(100).51(22) 
SU crude 8(16),47(63) 
RT corr 15(93),29(25),43(58) 
RT corr 15(52),29(6),43(42) 
RT crude 8(26) 37(45) 
RTcorr 16(112) 
SU crude 8(26) 
RT crude B(4),49(3) 
RT corr 18(56) 
SU crude 8(9),26(32) 
Ν Ρ = not published 
Hence, no differentiation between crude or corrected rates could be made. This 
may explain the broad range of recurrence rates. A cumulative mean rate of all 
articles reviewed has been calculated. For all stages recurrence after radiotherapy 
proved higher than after surgery. As 5-year corrected survival for Ti and Ta tumours 
is almost equal for either treatment, the discrepancy between recurrence rates and 
survival rates must to some extent be counterbalanced by better salvage results for 
radiotherapeutic failures than for surgical failures. This can be seen in Table 5. 
Salvage rates of the first type are lower than those of the second type. The 
discrepancy can run up from 3% for recurrences of Ti tumours to 2 1 % for T3 
tumours. 
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Table 4 · 
R a d i 
range 
Recurrence rates for primary treated non-metastastzed 
glottic carcinoma (not corrected) 
o t h e r a p y S u r g e r y References (patients at risk) 
cumulative mean range cumulative mean 
Τι 5%-46% 335/2438 = 14% 
T2 16% - 60% 105/353 - 29% 
23(32) ,29(31 ) ,31 (17) ,35(22), 
T j a 8%-67% 17/82-20% 
Тгь 27%-50% 19/61=31% 
Тз 35% - 83% 108/260 - 42% 
T¿ 66% - 75% Ν Ρ 
0%-18% 59/515=11% RT 4(26),7(90),8(67),11(78), 
12(333),13(151) 22(91), 
23(176),31(129) .32(121), 
35(63),39(49),40(174),43(95), 
49(168),51(119) 55(183) 
SU 4(34),8(16),30(15),32(15), 
35(238),42(1 β2),42(182), 
43(31,55(12) 
1 1 % - 3 1 % 50/234 = 21% RT 4(5),7(49),8(27), 11(21), 
39(22),49(37)155(90) 
SU 3(58),4(9),8(18),29(24), 
35(62),47(63) 
N P 1/9 = 11% RT 29(251,39(12),55(45) 
SU 29(9) 
N P 3/24=13% RT 29(6),39(10),55(45) 
SU 29(24) 
0% and 3 1 % 15/56 = 27% RT 4(12),8(26),11(47),37(45), 
39(18),49(67) 
SU 4(48),β(8) 
31%-50% N P RT 4(4),8(4),49(3) 
SU 4(13),8(9),26(32) 
Ν Ρ = not published 
6.4 Discussion 
Comparing treatment results of competing therapeutic modalities is necessary but 
difficult. The great variety of statistical methods that have been used in describing 5-
year survival of primary treated glottic carcinoma makes comparison of 
radiotherapy and surgery extremely difficult By making a division between crude 
and corrected survival rates, we could partly overcome such problems. As shown 
above, corrected rates are considerably more favourable than crude ones, which is 
not surprising since the disease manifests itself in older age when death from 
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cardiovascular and other diseases is substantial. Survival rates show almost equal 
results for primary radiotherapy of Τι and T2 tumours and primary surgery. The 
scarce data for T3 and T4 tumours suggest the same. Then, in T2, T3 and T4 
tumours opting for radiotherapy in preference to surgery may depend on the value 
that a patient attaches to the quality of voice [20,36,48]. 
Table 5 · Cumulative mean rates for salvage of recurrence añer primary 
radiotherapy or surgery of поп-metastasized glottic carcinoma 
Radiotherapy salvage rate Surgery salvage rate References 
1st type 2nd type 1st type 2nd type 
Τι 211/292-72% 222/295 = 75% 39/60 = 65% 7/10 = 70% HT' 4,7,8,11,12,13,21,22. 
23,31,32,35,37.39, 
40,43,46,49,51,55 
SU:4,32,35,42,43,55 
T2 4 5 / 8 8 - 5 1 % 78/107 = 73% 17/62 = 27% 11/23=47% RT-4,7,8,11,23,29,31, 
35,37,39,43,49 
SU-3,4,8,29,35,46,47 
Тз 40/108-37% 38/66-58% 5/19-26% N P . RT 4,8,11,37,39,49 
SU 4,8 
T4 8% N P. 0% 0% RT.18 
SU 4,8,26 
salvage rate 1st type - successfully salvaged / all recurred cases 
salvage rate 2nd type - successfully salvaged / operated for recurrence 
N.P. - not published 
Corrected and/or actuarial data for recurrence are seldom mentioned in the 
literature, nor have such data for salvage ever been described. This methodological 
shortcoming may partly be excused considering the small patient populations at 
risk. That also explains the broad range of recurrence rates and salvage rates ( the 
latter are not summarized in Table 5 ). Therefore cumulative mean rates of 
recurrence rate and salvage rate may be more representative. 
As could be expected, recurrence rates increase with increasing tumour size, 
both after primary radiotherapy and though to a lesser degree, after primary 
surgery. In general, recurrences after radiotherapy are more localized than after 
surgical failure. This may explain why salvage results are better after radiotherapy 
than after surgery. 
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Differences of up to 23% may occur depending on whether salvage is described as 
successful salvage among all recurred cases (1st type of salvage) or as successful 
salvage among all operated recurrences (2nd type of salvage). This difference can 
be ascribed to the number of patients with recurrent tumour who were not eligible 
for salvage. Reasons for non-eligibility can be numerous, but tend to increase with 
increased size of the original tumour, for both radiotherapeutic and surgical 
recurrences. 
Radiotherapeutic treatment schedules and -techniques, when mentioned, 
showed relatively few differences between the different treatment centres, as can 
be read in Table I. More importantly, within each centre, treatment techniques may 
well have undergone a great evolution. However a breakdown of treatment results 
for these technical changes is seldom mentioned. Therefore, a breakdown of 
treatment results of radiotherapy in terms of different techniques could not be made. 
In summary it can be said that the great diversity and incomplete description 
of statistical means and methods by which treatment results of glottic carcinoma are 
presented in the literature, make evaluation and comparison of surgical and 
radiotherapeutic treatments a difficult venture. These methodological shortcomings 
can partly be overcome if an author: 
1. Describes actuarial results, both crude and corrected for intercurrent 
disease and those lost to follow up, and mentions the method applied (e.g. Kaplan-
Meier, Berkson-Gage, Cutler-Ederer) [2,6,28]. 
2. Describes survival, disease-free survival (after primary treatment), 
recurrences, eligibility for salvage (and reasons for non-eligibility) and success of 
salvage (if possible of both types described above). 
Results based on a literature review for the period 1975-1985 show equal 
survival for Τι and T2 glottic carcinoma, both after radiotherapy and after surgery. 
Scarce results for more extended primary tumours suggest the same. In the final 
choice between primary radiotherapy and primary surgery for glottic carcinoma, 
one should also consider the quality of life. Quality of life can be expressed in terms 
of conservation of normal swallowing, normal breathing and acceptance of 
complications especially concerning the quality of speech. Decision analytic 
methods can be used to evaluate if and how a definite choice may change if 
treatment results vary and if voice quality were taken into account [48]. 
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7. Radiotherapy or surgery for T2N0M0 glottic carcinoma ? 
A decision-analytic approach1 
7.1 Abstract 
Decision analysis was used to evaluate the results of treatment of T2N0Mo glottic 
carcinoma as presented in the literature. Based on mean values for recurrence, 
salvage eligibility after recurrence and salvage success, the 5-year survival after 
radiotherapy and after surgery proved to be almost the same: 85% and 86% 
Varying the recurrence rates and salvage rates demonstrated a marginal 
advantage for surgery in small tumours (Тга) and a major advantage in more 
extended Пгь) tumours if only survival is considered. 
To take the quality of speech into account, a utility analysis was performed. A 
utility scale was defined ranging from 0.0 as the value for death to 1.0 for a 
successfully irradiated patient with preservation of normal speech. A utility value of 
0 99 or less for the laryngectomized patient would favour radiotherapy over surgery 
for all T2 tumours. In patients with Тгь tumours and in extreme circumstances, 
namely in institutions where failure rates of radiotherapy are extremely high and in 
those where recurrence rates after surgery are extremely low, an exact assessment 
of patient utilities may be pivotal Under normal circumstances radiotherapy is 
preferred for T2N0M0 glottic carcinoma if both survival and the quality of speech are 
taken into account. 
7.2 Introduction 
According to the TNM-system for tumour classification the non-metastasized 
carcinomas of the vocal cord confined to the larynx with extension either to the 
supra- or subglottic regions with normal or impaired mobility, are classified as 
ТгМоМо glottic carcinomas [AJC, 1978, UICC, 1982]. Patients with а ТгМоМо glottic 
carcinoma can be treated with curative intention by: 
(1). Primary surgery, either by conservative (partial) laryngectomy or by total 
laryngectomy. 
L J A. Stalpers, MD, A.L.M. Verbeek, MD, W A J. van Daal, PhD, MD. 
Radiotherapy and Oncology, 14. 209-217, 1989. 
70 Radiotherapy or surgery for 
(2). Primary radiotherapy with surgery if needed for loco-regional failure (so-
called 'salvage surgery') [Million and Cassisi, 1984]. 
After primary treatment most patients with ТгМоМо glottic carcinoma will be 
free of disease for the period under observation (e.g. 5 years disease-free survival). 
The major advantage of irradiation compared with laryngectomy or 
hemilaryngectomy is that the quality of voice is likely to be better and that a 
mutilating operation can be avoided [Lederman and Dalley, 1965]. 
Patients with tumour recurrence after primary treatment may undergo a 
salvage procedure. In general, salvage will consist of surgical removal of the 
recurrent process. Some patients with tumour recurrence after primary treatment 
are not eligible for salvage surgery for various reasons: A poor general condition, 
the presence of distant metastases, irresectability of the tumour or simply because 
patients refuse any further treatment. Spontaneous regression of recurrent tumours 
has never been described: These patients will die of the tumour. Patients eligible 
for salvage surgery may become free of disease again or the tumour will persist 
and they will die as a result. 
The choice between primary radiotherapy and primary surgery in fact 
depends on treatment results expressed as disease-free survival, disease-free 
survival-after-recurrence and overall survival. In this study we have examined how 
decision analytic methods can be used in interpreting 5-year treatment results of 
the T2N0Mo glottic carcinoma as presented in medical literature from 1974 - 1986. 
The questions are: 
(1) Can we make a rational choice between radiotherapy and surgery as 
treatments for the T2N0M0 glottic carcinoma ? 
(2) How does this choice between radiotherapy and surgery vary within the 
range of probabilities known from literature, e.g. recurrence rate, especially 
considering the different risks for patients with small (Taa) and extended (Тгь) 
tumours ? 
(3) How does this choice alter if we could attach a value to the quality of 
voice after radiotherapy and after surgery? Or rather: What is it worth to the patient 
to have his voice preserved? Then, to what extent will the patient accept an 
increased rate of tumour recurrence ? These more subjective aspects are difficult to 
quantify but can be of decisive importance in the choice patient and doctor have to 
make. Therefore, a choice merely based on survival, can shift by attaching a value 
to the quality of voice. 
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7 3 Literature Review 
In a review of literature on treatment results of radiotherapy and surgery for non-
metastasized glottic carcinoma, we looked for the treatment results expressed as 
disease-free survival and overall survival Furthermore we looked for indicators of 
treatment success such as the recurrence rate and the rate of salvage success 
[Stalpers et al , 1987] Based on a series of well known clinical studies, the 5-year 
results for T2NoM0 glottic carcinoma are summarized in table 7 1 
Table 7 1 · 5-year treatment results of T^QMQ glottic carcinoma [30] 
Primae 
Radiotherapy 
Primary 
Surgery 
References 
Survival rate crude 
adjusted 
Recurrence rate 
allT2 
T2a 
T2b 
46%-72% 
mean-68% 
80%-91% 
mean=86% 
16%-60% 
mean=30% 
80/o-67% 
mean=20% 
27%-50% 
mean-30% 
59%-72% [5,12,19,24,32,36,5,19,29] 
mean=66% 
88% 
1 1 % 
13% 
[7,9,12,14,25, 14] 
11%-31% [3,4,5,7 12,14,16,19,22, 
mean=20% 35,55, 2,3,5,14,19,29] 
[14,22,38 14] 
[14,22,38, 14] 
Salvage rate 50% 30% [3,4,5,7,12,14,16, 
19,22,25,32,2,3, 
5,14,19,28,29] 
Adjusted - for the follow-up adjusted 5-year survival 
The rates have been structured and visualized in a decision tree presented in figure 
7 1 With this figure 5-year survival was calculated (see Appendix) Based on mean 
values for recurrence rate and salvage success, figure 7 1 gives an 85 0% 
calculated 5-year survival for primary radiotherapy Compared with those articles 
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which mention a for follow-up adjusted 5-year survival ranging from 80%-91%, the 
calculated survival represents a fair mean of the survival results explicitly 
mentioned. Analogously, the survival after primary surgery was calculated, showing 
an 86.0% 5-year survival rate. To our knowledge only one study, by Kaplan and 
Johns [1984] presented a comparable rate: A 5-year life table survival rate of 
88.0%. The calculated survival for primary surgery (86.0%) is only slightly better 
than for primary radiotherapy (85.0%) and these values can be used as 
representative averages from the literature reviewed. 
UTILITIES 
RADIOTHERAPY 
85% 
AUVE. NATURAL SPEECH 
ALIVE, ARTIFICIAL SPEECH 
DEATH 
AUVE, ARTIFICIAL SPEECH 
SURGERY ALIVE. ARTIFICIAL SPEECH 
DEATH 
Figure 7.1 · Decision tree for the treatment of patients with 
T2N0M0 glottic carcinoma 
1 0 
00 
00 
After primary radiotherapy tumour recurrence is high (30%) but the chance of being 
cured by salvage surgery is also fairly high (50%), resulting in 15% being free of 
disease after tumour recurrence. Tumour recurrence after surgery is lower (20%), 
but the chance of being salvaged after recurrence is also lower (30%), resulting in 
6% free of disease following tumour recurrence. 
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Although the expected survival rates are almost equal for radiotherapy and 
surgery, we have to investigate the factors which may influence a decision. There 
are reasons why making a decision based on these figures could be hazardous. 
The conclusion of the decision tree analysis should be regarded with some reserve 
as our analysis is based on mean rates taken from the literature. For separate 
treatment centres and for particular populations different figures may be found 
which lead to different conclusions. 
7.4 Sensitivity Analysis 
In medical decision making analysis of the stability of a conclusion by varying rates 
in a decision tree is called a 'sensitivity analysis'. In the decision tree analysis we 
assumed all patients with T2 tumours to be equally curable. In fact patients with T2 
glottic cancer are not one homogeneous group of patients. Therefore, based on the 
mobility of the vocal cords, a distinction was made between prognostic favourable 
T2a tumours and prognostic unfavourable Тгь tumours. Although several reports 
have been published presenting radiotherapeutic results for Тга and Тгь 
carcinomas separately [Harwood & De Boer, 1980; Kaplan et al, 1983; Notter et al., 
1984; Van den Bogaert et al., 1983; Wang, 1974; Mills, 1979], we found only one 
paper describing comparable surgical results [Kaplan et al., 1983]. The recurrence 
rates and survival rates are summarized in table 7.1. Based on the decision tree 
approach, survival rates were calculated using the mean values for recurrence 
rates for patients with Тга and Тгь tumours. In this analysis we presumed the 
salvage rate to be constant at 50% following radiotherapeutic failure and 30% 
following surgical failure. So, the calculated survival for patients with Тга tumours is 
slightly higher after surgery than after radiotherapy, 92.3% and 90.0% respectively. 
The difference in the calculated survival is remarkably higher for Тгь tumours, being 
90.9% following surgery and 85.0% following radiotherapy. Based on these 
calculated survivals, surgery should be preferred as primary treatment both for Тга 
and particularly for Тгь tumours. However, the calculated survivals are only point 
estimates. If the recurrence rate after radiotherapy for Тга tumours would be lower, 
for example 8% as found by Kaplan et al. [1983] instead of the mean value 20%, 
the survival from radiotherapy would be 96% instead of 90%. Then, compared with 
the 92% survival rate after surgery, radiotherapy would be preferred as primary 
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treatment for Тга tumours Figure 7 2 shows the survival rates for varying recurrence 
rates after radiotherapy 
40 4 1 ' • I ' 1 
0 20 40 60 BO 100 
Recurrence following radiolherspy (%) 
Figure 7 2 · Calculated survival rates for T2N0M0 glottic carcinoma following 
radiotherapy (solid line) or surgery (broken lines) for varying recurrence rates 
following radiotherapy The results of Тга and Тдь tumours are based on only one 
study presenting relatively low recurrence rates, this explains for the lower 
calculated survival rates for all T2 tumours based on six studies (see text) 
The points where the solid radiotherapy line crosses the broken surgery lines are 
called the threshold-points At these specific threshold-levels for the recurrence 
rates following radiotherapy, -being 15 4% for Тга. 18 2% for Тгь and 28 0% for all 
T2 tumours- , the calculated survival rates are equal for radiotherapy and surgery 
For lower recurrence rates following radiotherapy, radiotherapy will be preferred 
over surgery 
In figure 7 2, the recurrence rates following surgery were kept constant for 
Тга. Тгь and all T2 tumours The recurrence rates after surgery for Тга and Тгь 
tumours were based on only one study [Kaplan et al, 1983] The surgical results of 
all T2 tumours, -based on six studies-, are generally worse than the one study by 
Kaplan et al This finding may suggest that the results of surgery for Тга and 
particularly Тгь tumours in most surgical clinics work out to be worse Then, if we 
presume higher recurrence rates after surgery, the calculated survival after surgery 
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will be lower and the threshold-levels for the recurrence rate after radiotherapy will 
be higher 
The numerical relation between varying recurrence rates after surgery, as well as 
varying recurrence rates after radiotherapy and the consequently varying survival 
rates following surgery and radiotherapy, is displayed by the threshold-survival line 
in figure 7 3a The threshold-survival line denotes the recurrence rates after surgery 
and the recurrence rate after radiotherapy for which the calculated survival rates 
are equal Based on survival alone, radiotherapy will be preferred for recurrence 
rates left-above the threshold line and surgery will be preferred for recurrence rates 
right-under the threshold-line For example Suppose we find a recurrence rate 
after radiotherapy for Тгь tumours being 27%, as found by Wang [1974], then from 
figure 7 3 it can be read that radiotherapy will be preferred as primary treatment if 
we expect the recurrence rate after surgery to be equal or higher than 19 3%, as 
was found by some authors for all T2 tumours [Lippi et al , 1984, Skolnik et al , 
1975] Always presuming, of course, that the salvage rate after radiotherapy is 50% 
and after surgery 30% Figure 7 3b and 3c give threshold-survival lines for some 
different salvage rates following radiotherapeutic failure (3b) and following surgical 
failure (3c) 
7.5 Utility Analysis: The Quality of Speech 
In medical decision making, utility analysis is based on the proposition that the 
preference for a treatment (or the utility of a treatment) depends on many aspects of 
the competing treatments, including life expectancy and quality of life Utility 
assessment assumes that a loss in life expectancy can be compensated by a gam 
in quality of life, and that loss and gam can be measured 
In this particular clinical situation it means that in the treatment of glottic 
carcinoma, survival should not be the only parameter for treatment success It 
seems obvious to consider the value the patient attaches to preservation of normal 
use of his/her voice in a choice between radiotherapy and surgery Although 
radiotherapy may impair the quality of voice to some extent, [Stoicheff, 1975, 
Stoicheff et al, 1983] there is a general agreement that loss of speech after surgery, 
even after conservation surgery, is greater and more of a handicap [Harwood and 
Rawlmson, 1983] 
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Several authors have recognized the problem of loss of laryngeal speech and the 
corresponding loss of quality of life [King et al, 1968, Minear and Lucente, 1979, 
Volin, 1980]. However, few attempts have been made to measure this loss 
[Harwood and Rawlinson, 1983, McNeil et al, 1981]. Such studies are essential 
since attaching a numerical value to quality of life could rationalize a decision to be 
taken. 
In this analysis such a numerical value will be attached to different outcomes 
after treatment of T2NoM0 glottic carcinoma by either surgery or radiotherapy. A 
utility scale is defined ranging from 0.0 as the value for death to 1.0 for a 
successfully irradiated patient with normal speech. Any qualitative loss by surgery, 
either as primary treatment or as salvage treatment, will be expressed as loss in 
quality of life compared with normal speech after succesfull radiotherapy. 
At the extreme right of the decision tree (figure 7.1) the utilities U for the 
quality of life have been attached to the various outcomes. In accordance with the 
calculation of survival, a weighted survival-value after both modalities of treatment 
can be calculated (see Appendix). Survival, adjusted for the utility of speech, is 
called expected utility [Weinstein and Fineberg, 1980]. Based on the data 
presented in figure 7.1, figure 7.4 gives expected utilities for an artificial speech 
following (partial) laryngectomy. 
From figure 7.1 we can read that after radiotherapy, 70% of patients would 
have normal speech and only 15% would eventually have an artificial speech. After 
surgery, all patients will have (partial) laryngectomy and artificial speech. This 
explains why in figure 7.4 the expected utility or the 'for speech quality corrected 
survival' shows a higher sensitivity for variation of the utility of an artificial speech 
after surgery than after radiotherapy. For instance, a decrease in utility for the 
laryngectomized (artificial speech) from 0.8 to 0.7, leads to a decrease in expected 
utility after surgery from 0.69 to 0.60, while the one after radiotherapy decreases 
only from 0.82 to 0.81. It is striking that for a utility of 0.986 after laryngectomy the 
corresponding expected utilities for radiotherapy and surgery are the same. Or in 
other words: If a patient with T2NoMo glottic carcinoma states that on a utility scale 
between 0.0 for death and 1.0 for life with a natural speech, the quality of life after 
(partial) laryngectomy is equal or less than 0.986 (or 98.6%), radiotherapy is 
preferred over surgery as primary treatment. Always presuming of course, that the 
mean values for all T2 tumours taken from the literature are representative. If, for 
instance, the recurrence rate after surgery was not 20% but 12%, as described by 
78 Radiotherapy or surgery for 
Kaplan et al., the calculated survival would be 92% (i.e. much higher than the 85% 
survival after radiotherapy). Then patients with a lower utility for loss of voice due to 
surgery, would prefer surgery to radiotherapy. 
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Figure 7.4 · Expected utilities after radiotherapy and after surgery for ΤΣΝ/^ΙΟ glottic 
cancer for varying utility values for the quality of voice after (partial) laryngectomy 
(=artificial speech). 
From the solid line in Figure 7.5a we can read that for a recurrence rate of 12% 
following surgery, the threshold-utility for artificial speech will be 0.92. Figure 7.5b 
gives a similar analysis on the variation of the recurrence rates after radiotherapy. It 
is questionable whether the quality of life value for the laryngectomized of 0.92 in 
situations with extremely high recurrence rates after radiotherapy or extraordinarily 
low recurrence rates after surgery for T2N0M0 glottic carcinoma are realistic. If so, 
radiotherapy is to be preferred as treatment for T2NoM0 glottic carcinoma. 
7.6 Discussion and Conclusion 
Rather simple decision analytic methods can be used as a tool in evaluating 
treatment results of the T2NoMo glottic carcinoma as presented in literature, even 
though some figures are incomplete or subjective. 
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A preliminary calculation of survival yielded survival rates which were similar to the 
average survival rates described in the literature But these survival rates were 
insufficient for us to make a founded choice between radiotherapy and surgery as a 
primary treatment for T2N0M0 glottic carcinoma as treatment results vary between 
different treatment centres and for different populations of patients 
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In a sensitivity analysis the influence of different recurrence rates and salvage rates 
was evaluated Salvage of recurrent tumours after irradiation, -unlike after surgery-, 
does substantially increase survival figures for primary radiotherapy This sensitivity 
analysis seems to support the following practical approach 
• If surgery is preferred as primary treatment for T2N0Mo glottic carcinoma, it 
is essential to keep recurrence rates low This might be accomplished by radical 
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surgery This may impair life qualities to an unacceptable level, thus outbalancing 
the reduction of recurrence rates Little extra survival will be gained by improving 
the salvage rate 
• If we prefer, or want to improve, radiotherapy as a primary treatment for 
T2N0M0 glottic carcinoma, we first of all have to try to keep recurrence rates as low 
as possible This might be accomplished by improved radiotherapeutic techniques 
e g optimal localization and treatment planning [Fletcher et al, 1975, Peters and 
Fletcher, 1983] Increasing the radiation dose does not seem to improve the results 
[Harwood and Tiene, 1979, Harwood and DeBoer, 1980, Harwood et al, 1981], but 
accelerated fractionation might [Withers et al, 1988] 
But, in contrast to primary surgery, improvement of the salvage success after 
radiotherapeutic failure could significantly contribute to better survival results This 
again stresses the importance of optimal tumour follow-up aiming at early detection 
and treatment of recurrences 
A utility analysis illustrated the effect on a decision by quantifying the quality 
of life of a laryngectomized patient compared to a succesfully irradiated patient 
Compared with death (utility = 0 0) and with radiotherapy (utility = 1 0), a minimal 
loss in the quality of life after (partial) laryngectomy compared with successful 
radiotherapy, will result in a preference for primary radiotherapy with surgical 
salvage in reserve for patients with T2N0Mo glottic carcinoma This, if a decision 
was based on mean values for treatment results taken from the literature 
It depends on the representativity of these calculated utilities whether this 
preference for radiotherapy holds in (1) patients with more extended T2 tumours 
and in (2) treatment institutes where radiotherapeutic failure rates are extremely 
high or surgical recurrence rates are extraordinary low In these cases it would be 
useful to measure the utilities exactly [Stalpers et a l , 1988] 
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7 7 Appendix 
Based on the recurrence rate (Prec) and the salvage rate after recurrence (Psai). 
formula {8 1} gives the calculated survival rate for the data used in the decision tree 
Psurvival = ( 1 0 - Prec) + Prec X Psal {1} 
For example, after surgery for T2N0M0 glottic carcinoma we found a recurrence rate 
of 20% and a salvage rate of 30%, resulting in a calculated five-year survival rate 
Psurvival = (1 0 - 0 20) + 0 20 X 0 30 = 0 86 or 86% 
The for quality of speech corrected survival or 'expected utility' after radiotherapy 
(EUrad) can be calculated with formula {8 2} 
EUrad = ( 1 0 - Prec) X Uad + Prec X Psal X USUr {2} 
where Urad = the utility after successful! radiotherapy with natural speech and Usur = 
the utility after surgery with artificial speech The expected utility after primary 
surgery, either conservative or total laryngectomy, can be calculated as 
EUsur = ( 1 0 - Prec) X Usur + Prec X Psal X U s u r {3} 
For example, for a recurrence rate after primary surgery of 20%, a salvage rate of 
30% and a utility after (partial) laryngectomy of 0 92, the expected utility is 0 79 (or 
79%) 
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8. The role of yearly chest radiography in the early detection 
of lung cancer following oral cancer1 
8.1 Summary 
In a study of 213 patients with oral cancer we investigated the incidence and 
prognosis of lung malignancies in patients offered a yearly chest radiography in the 
follow-up. Three conclusions can be drawn: 
(1) Metastatic or primary lung cancer was diagnosed in 22 (10.3%) patients. 
The 2 year actuarial incidence rate of lung cancer following cancer of the oral cavity 
is 13%. No new lung cancers were detected after 2 years follow-up. This suggests 
that after this period, yearly chest radiography may be superfluous for the early 
detection of lung cancer. 
(2) The survival rate of patients with a lung malignancy following cancer of 
the oral cavity is poor (1-year = 25%). The survival rate of patients detected by the 
yearly chest radiography without symptoms is higher than for patients detected after 
symptoms (p=0.006). It Is not clear to what extent this different survival rate is 
biased by lead-time and selection of patients with a favourable prognosis. A 
randomized study would be required to assess whether patients with oral cancer do 
benefit from the yearly chest radiography compared with no regular chest 
radiography. 
(3) From 22 patients with lung cancer, 13 (59%) were detected by chest 
radiography without symptoms. In the first year following oral cancer, 11 patients 
were diagnosed with lung cancer. Only 4 of these 11 patients (36%) were detected 
by chest radiography in an asymptomatic stage. The detection of patients with lung 
cancer in an asymptomatic stage may be increased by more frequent chest 
radiography examinations in the first year following oral cancer. 
8.2 Introduction 
In Western countries the annual incidence of squamous cell carcinoma of the oral 
cavity is 4:100.000 in men, and 1:100.000 in women. Cancer of the oral cavity is 
1
 L.J.A. Stalpers, P.B.J. Van Vierzen, J.J.A. Brouns, I. Bruaset, J.J. Mannl, A.LM. Verbeek, J.H.J. 
Ruys and W.A.J. Van Daal. Published in The International Journal of Oral and Maxillofacial Surgery 
1Θ: 99-103, 19Θ9. 
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predominantly a disease of the fifties [Waterhouse et al, 1982]. Smoking, abundant 
alcohol consumption, bad oral hygiene and a combination of these are the most 
important etiologic factors [Wynder et al. 1957; Vogler et al., 1962; Rothman and 
Keller, 1972; Stockwell and Lyman, 1986]. Both radiotherapy and surgical resection 
are successfully applied as primary treatment [Mendenhall et al., 1981; Million and 
Cassisi, 1984; Zagars and Norante, 1983]. However, the lifespan of patients will be 
limited by metastases and second primary malignancies. Increased risks for the 
development of second primary malignancies following another cancer have been 
described as early as 1932 by Warren and Gates. Table 8.1 gives an overview of 
the literature on incidences of second primary malignancies following oral cancer. 
Smoking and alcohol abuse are related to the development of second 
primary malignancies [Wynder et al, 1977; Batasakis, 1979]. The etiologic role of 
immunologic and genetic factors in the development of multiple primary 
malignancies is not clear [De Vries et al., 1986; De Vries et al., 1987]. Early 
detection and early treatment of these second primary malignancies and 
metastases may improve the survival of patients with oral cancer. This is the 
rationale of regular physical and radiological lung examination in the follow-up of 
patients with cancer of the oral cavity. 
In this study we looked for: (1) The incidence of pulmonary malignancies, 
both primary and metastatic, following oral carcinoma, and (2) the value of the 
yearly chest radiography in the early detection of these pulmonary malignancies. 
8.3 Patients and Methods 
Between January 1st 1979 and January 1st 1986, 238 patients with a squamous 
cell carcinoma of the oral cavity were admitted for treatment to the University 
Hospital St. Radboud in Nijmegen, The Netherlands. Eligible for this study were all 
patients admitted for primary treatment of carcinoma of the oral cavity. Excluded 
were 25 patients who came for a recurrency treatment. Included were eight patients 
cured from another malignancy before occurrence of the carcinoma of the oral 
cavity. Also included were four patients with synchronous oral cancer and lung 
cancer. Eventually the medical records of 213 patients were reviewed for this study. 
For the study of the lung cancer incidence rate, follow-up closed on January 
1st 1987. The median observation period is 49 months. In patients with lung cancer 
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following oral cancer, follow-up closed on July 1st 1988, ensuring at least 18 
months follow-up of lung cancer. 
Table 8.1· Literature review of incidence ratios of second primary 
malignancies following cancer of the oral cavity 
Reference Period Patients Second primary malignancies 
atnsk All sites Upper aerodig. Lung 
tract 
BERG e/a/, 1970 
COHN& 
PEPPARD, 1980 
'A9-'62 
70-79 
GLUCKMAN et al., 1980 
I. prospective 77-79 
II. retrospective 74-78 
III. oral cavity '50-79 
TEPPERMAN & 
FITZPATRICK, 1981 
floor of mouth '58-75 
3443 
264 
72 
158 
1551 
377 
248 (7.1%) 110(3.2%) 
44 (16.7%) 
9 (12.5%) 
28 (17.7%) 
187(12.0%) 
101(26.8%) 82(21.8%) 
HORDIJK & DE JONG, 
BLACK etaU 1983 
DE VRIES et al., 1986 
VELLI N efa/ , 1986 
Present study, 1988 
1983 
58-79 
'50-78 
•63-,84 
•43-'B3 
79-'87 
152 
1551 
210 
372 
213 
26 (17.1%) 
287(18.5%) 
38 (18.1%) 
29 (13.6%) 
22 (14.4%) 
135(8.7%) 
23(11.0%) 
23(10.8%) 
11 (3.0%) 
5 (2.3%) 
Table 8.2 presents the distribution of patients by the site of the primary tumour and 
the actuarial five-year survival rate. At diagnosis of the oral cavity cancer, the sex-
ratio was 151 men and 62 women = 2.4 ; the mean and median age was 62.5 years 
(range 27-91 years). All patients were classified and staged by the UICC-TNM 
norms for tumour classification [UICC, 1980]. Surgery was performed on operable 
patients. Radiotherapy was given (1) pre-operatively up to 40 Gy in T3 and T4 
carcinomas (before 1983), (2) post-operatively up to 60-64 Gy if surgery was not 
radical or if tumour-spill was likely or in the presence of extranodal spread and (3) 
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in inoperable patients. Chemotherapy was reserved for palliative care of incurable 
carcinomas. 
Table 8.2 · Tumour site and actuarial five-year survival of 
213 patients with cancer of the oral cavity 
Tumour site 
Tongue 
Floor of mouth 
Buccal mucosa 
Retromolar trigone 
Alveolar ridge 
Lip 
All sites 
Number 
66 
59 
27 
15 
34 
12 
213 
Five-year 
Survival 
49% 
60% 
43% 
70% 
52% 
76% 
52% 
Table 8.3 presents the follow-up protocol for patients treated for oral cancer. The 
follow-up includes a yearly chest radiography consisting of an antero-posterior view 
and a lateral view. 
Table 8.3 · Protocol for the follow-up of patients with oral 
cavity carcinoma (Nijmegen, The Netherlands) 
I. Policlinical examinations 
1st year bimonthly 
2nd year threemonthly 
3rd year fourmonthly 
4th year semiannual 
>4 years yearly 
II. Yearly X-chest examination 
- antero-posterior view 
- lateral view 
III. Blood- and/or urine-analysis 
on indication 
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The pre-operative chest radiogram used for the staging of oral cancer is defined as 
the first yearly chest radiogram. All chest radiograms were reviewed at least three 
times before a definite report was given: A first examination by a resident in 
diagnostic radiology, review by a radiologist and finally discussion in the weekly 
meeting between a diagnostic radiologist and a radiotherapist. If the chest 
radiography was suspect for a pulmonary malignancy, further examinations were 
performed, generally including pulmonary planigraphy. To plan the further 
diagnostic and therapeutic strategy, each patient was evaluated by the 
interdepartmental Workgroup for Lung Cancer. Further histologic diagnosis 
depended on the feasibility of invasive diagnostic techniques (bronchoscopy, 
cytologic punction or diagnostic thoracotomy) and on the curability of the patient. 
Surgery was performed on curable and operable lung cancer; radiotherapy and 
chemotherapy were reserved for palliative care. 
In 1932, Wareen and Gates defined three diagnostic criteria for second 
primary malignancies. We applied the three criteria as modified by Gluckman et al. 
in 1980 : 
(1) The neoplasms must be clearly malignant as determined by histologic 
evaluation. 
(2) Each neoplasm must be geographically separate and distinct. The 
lesions should be separated by normal-appearing mucosa. If a second neoplasm is 
contiguous to the initial primary tumour or is separated by mucosa with intra 
epithelial neoplastic change, the two should be considered as confluent growths 
rather than multicentric carcinomas. 
(3) The possibility that the second neoplasm represents a metastasis should 
be excluded. The observation that the invasive carcinoma arises from an overlying 
epithelium that demonstrates a transition of carcinoma in situ to invasive carcinoma 
is helpful, and when the separate foci have significant differences in histology, the 
diagnosis of separate primary cancers is appropriate. 
Patients with no histologically proven second primary malignancy in the lung, 
are defined as patients with metastatic lung cancer. Patients with a radiologic 
progressive mass and with clinical deterioration, but without histological 
confirmation of a malignancy, are also defined as patients with metastatic lung 
cancer. In general these patients were in too bad a condition to allow histologic 
confirmation or curative surgery. 
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Patients with a radiographic lesion suspect for malignancy which did not show 
radiographic or clinical progression within a year, were not considered as patients 
with a pulmonary malignancy 
The incidence of a second primary malignancy or a pulmonary metastasis is 
calculated as a crude rate for all patients and as an actuarial incidence rate 
adjusted for the duration of follow-up by the Kaplan-Meier method [Kaplan and 
Meier, 1958, Peto et al , 1977] 
The survival of patients with a pulmonary malignancy was calculated by the 
Kaplan-Meier method; the survival curve of patients detected by the yearly chest 
radiography without symptoms and the survival curve of patients detected after 
symptoms are compared with the logrank-test [Kaplan and Meier, 1958, Cutler and 
Ederer, 1958] 
8.4 Results 
(a) Incidence 
a 
и 
с 
α) 
о 
Year 
Figure 8 1 · Actuarial incidence rate of metastatic or primary lung cancer following 
oral cancer (N=22/213), the figures indicate the number of patients at risk, dotted 
lines indicate 95% confidence limits 
During the follow-up period of 213 patients with squamous cell carcinoma of the 
oral cavity, 29 (13 6%) had a second primary malignancy Twenty-three patients 
(10.8%) had a localization in the upper aerodigestive tract, of which five (2 3%) 
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were localized in the lung. Of these five histologically proven second primary 
malignancies in the lung, two were adenocarcinomas and three were squamous 
cell carcinomas 
Another 17 patients had metastatic lung cancers, resulting in 22 patients 
(10 3%) with a pulmonary malignancy 
Figure 8 1 shows the actuarial incidence rate of pulmonary malignancies, both 
primary and metastatic 8 5% within one year following oral cancer and 13 0% 
within two years After more than two years following cancer of the oral cavity, no 
more primary lung cancers or lung metastases were seen in 100 patients at risk 
In 13 out of 22 patients (59%) with a pulmonary malignancy, the tumour was 
detected without symptoms by the yearly chest radiography Eleven patients had a 
lung malignancy within one year following treatment for oral cancer Only four of 
these 11 patients (36%) were detected at the beginning of that year without 
symptoms by the first chest radiography 
(b) Survival 
Figure 8 2· Survival rates of 
22 patients with a pulmonary 
malignancy, without symptoms 
(solid line, n=13) and with 
symptoms (broken line, n=9) at 
diagnosis 
Months 
The survival curve of 22 patients with a pulmonary malignancy following oral 
cancer in Figure 8 2 shows a meager one-year survival of 25% Figure 8 2 shows a 
significantly worse survival curve in nine patients with a pulmonary malignancy 
diagnosed after symptoms compared with 13 patients detected by yearly chest 
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radiography without symptoms (p=0.006). Median survivals are 2.0 months and 6.8 
months respectively. All patients detected with a pulmonary malignancy after 
symptoms died within 18 months. Four out of 13 patients (30%) with a pulmonary 
malignancy detected by yearly chest radiography without symptoms were still alive 
after 18 months follow-up. 
Only one out of five patients with a histologically confirmed primary lung 
cancer survived more than 18 months. In this specific patient, the lung tumour was 
detected synchronously with the oral cancer by a chest radiography. The patient 
died three years later of a local recurrence of the oral tumour. 
8.5 Discussion 
(a) Incidence 
Table 8.1 presents some incidence rates of second primary malignancies following 
cancer of the oral cavity as described in the literature; incidence rates range from 
7.1% to 26.8% . In our study the incidence rate is 13.6% . 
Corresponding with the literature referred in table 8.1, most of these second 
primary tumours (23/213 = 10.8%) are localized in the upper aerodigestive tract. 
Relatively few second primary malignancies were localized in the lung (5/213 = 
2.4%). This figure corresponds with the 3.0% incidence of lung cancer as found by 
Yellin et al. in 1986. The relatively low incidence of second primary malignancies in 
the lung may be partly due to the strictness of the criteria by Warren and Gates: In 
medical practice it may sometimes be extremely difficult or unethical to obtain 
representative histologic specimens from critically ill patients just to allow 
differentiation between metastatic and primary lung cancer. For this reason, some 
tumours defined as metastatic cancers may in fact have been primary lung 
malignancies [Adkins et al., 1968; Cahan, 1977; Lefor et al., 1986]. The distinction 
between metastatic and primary lung cancer can be of prognostic significance. 
However, in clinical practise it is frequently not feasible to make such a distinction 
properly. Therefore we evaluated the efficacy of the yearly chest radiography for 
both types of malignancies together. 
The 2 years actuarial incidence rate of pulmonary malignancies following 
carcinoma of the oral cavity rises up to 13%. We found no more pulmonary 
malignancies after two years follow-up. This finding suggests that the yearly chest 
radiography becomes superfluous after two years following a carcinoma of the oral 
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cavity. Our findings should be regarded with some reserve as figures for 
comparison are lacking in the literature: None of the articles reviewed used the 
actuarial or life-time estimate of the lung cancer incidence rate [Kaplan and Meier, 
1958; Cutler and Ederer, 1958; Peto et al., 1977]. The feature that lung cancer risk 
is only enhanced for a limited time following oral cancer might therefore have gone 
unnoticed in former studies. 
Most pulmonary malignancies (59%) have been detected by a yearly chest 
radiography in an asymptomatic stage. However, in the first year, only 36% of the 
lung malignancies were detected without symptoms by the first chest radiography. 
Apart from statistical chance, a biological and a technical explanation may be given 
for the low detection rate in the first year. The biological explanation is that relatively 
fast growing lung malignancies are preponderant in the first year compared to 
following years. The technical explanation is the lack of a former chest radiography 
in the first year for comparison with the first one; repeated sequential chest 
radiography may be essential for recognition of radiographic chances suspect for 
malignancy. If so, malignant pulmonary changes will be detected earlier without 
symptoms by more frequent chest radiography examinations in the first year 
following oral cancer. Comparative figures from the literature are not known to us. 
(b) Survival 
Cancer of the lung has a poor prognosis with 1-year survival rates ranging from 25 
to 35% [Fontana et al., 1984; Nou, 1984; Ries et al., 1983]. The value of a regular 
chest radiography for population screening for lung cancer has been discredited by 
the poor improvement, if any, in the prognosis of lung cancer [Bailar, 1984]. 
Although screening for lung cancer may be inefficient for the general population, a 
regular chest radiography may be more effective for patients with an enhanced risk 
in order to develop a pulmonary malignancy, either primary or metastatic. This 
study demonstrates a poor prognosis in patients with lung cancer following cancer 
of the oral cavity (1 year = 22%; 2 year = 15%). The survival rate of patients with a 
lung malignancy detected by the yearly chest radiography was significantly higher 
than of patients with symptoms, despite small population numbers and a small 
difference in median survival of only 4.5 months. However, it is not clear how far this 
higher survival rate in asymptomatic patients is biased by: 
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(1) The lead-time between asymptomatic detection by the yearly chest 
radiography and the time that a patient would present with symptoms (see 
appendix) and 
(2) the selection of relatively benign, slowly growing tumours in patients 
detected by a regular chest radiography compared to aggressive, fast growing 
tumours in patients with symptoms [Feinleib and Zelen, 1969] The exact benefit of 
regular chest radiography in the follow-up of cancer of the oral cavity can only be 
established by a randomized trial of early diagnostic manoeuvres [Sackett et al , 
1985] However, as without lead-time correction the differences in survival between 
symptomatic and asymptomatic patients is only a matter of months, the benefit of a 
regular chest radiography may in fact be small 
8.6 Conclusions 
Based on this study on the relevance of the chest radiography in the follow-up of 
213 patients with carcinoma of the oral cavity, three conclusions can be drawn 
(1) An increased occurence of lung cancer following oral cancer seems to be 
restricted to the first two years of clinical follow-up Hence, the application of yearly 
chest radiography may be limited to this short period 
(2) A prognostic benefit of chest radiography cannot be excluded, but the 
benefit will probably only be marginal To assess this benefit, a randomized trial 
would be necessary comparing yearly chest radiography with no chest 
radiography 
(3) More frequent chest radiography in the first year following treatment for 
oral carcinoma, may enhance the potency of a regular chest radiography to detect a 
pulmonary malignancy in an asymptomatic stage 
8.7 Appendix 
Lead-time bias is a well-known pitfall m a cancer screening program where an 
increased survival time after diagnosis does not necessarily mean that early 
diagnosis was helpful It might simply mean that the time of diagnosis has been 
advanced without necessarily meaning that the time of death has been delayed 
[Feinleib and Zelen, 1969] 
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Figure 8 3· Graph representing a hypothetical natural course of lung cancer from 
onset towards the time that cancer can be diagnosed by chest radiography, towards 
the time that a tumour gives rise to symptoms and eventually evolving towards the 
time of death from a fatal volume 
For example, figure 8 3 displays the hypothetical course of disease in a patient with 
lung cancer Let us presume that tumour growth is such that it will give rise to 
symptoms after three years and evolve into death after four years Survival time is 
said to be one year With chest radiography we might have diagnosed the tumour a 
year earlier in an asymptomatic stage The time between early detection and the 
time of onset of symptoms is called the lead-time Simply by advancing the time of 
diagnosis it seems as if we have prolonged survival time from 1 to 2 years In fact, 
we did not change the natural course of disease and the patient dies four years 
following onset of tumour growth Because of lead-time, the survival of patients 
diagnosed without symptoms seems better than the survival of patients detected 
with symptoms 
For instance, in Figure 8 2, if we presume an average lead-time of only four 
months, the survival curve of patients 'detected without symptoms' would shift about 
four months to the left and would converge with the curve of patients 'diagnosed 
after symptoms', and the previous observed difference between the two survival 
curves would disappear 
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9. Yearly chest radiography in the early detection 
of lung cancer following laryngeal cancer1 
9.1 Summary 
In a retrospective study of 556 patients (505 men, 51 women) with laryngeal cancer 
the incidence and prognosis of lung malignancies was studied in patients who 
were yearly examined by chest radiography. In 69 patients (12.4%) a lung 
malignancy was diagnosed of whom 28 patients with a histologically confirmed 
second primary malignancy. All 69 patients were men. The incidence of 
radiological assessed lung malignancies, both second primary and metastatic lung 
cancer, is higher and more prolonged following supraglottic carcinoma then 
following glottic carcinoma. In 47 patients (68%) without symptoms, the lung 
malignancy was detected by yearly chest radiography. The survival rate in patients 
with lung cancer detected by the yearly chest radiography was significantly higher 
than in patients diagnosed after symptoms (median survival = 10 and 5 months 
respectively). However, because of a lead-time between early radiologic diagnosis 
of lung cancer and the time a tumour would be diagnosed following symptoms, the 
observed survival benefit of yearly radiography is in fact much less or even nihil. 
9.2 Introduction 
In Western countries the incidence of laryngeal cancer is 114 in 1,000,000 in men 
and 6 in 1,000,000 in women [Waterhouse et al, 1982]. It predominantly is a 
disease of the sixth decade [Zagars and Morante, 1982]. 
Laryngeal cancer may give relatively early rise to symptoms, especially 
persistant hoarseness, and curative treatment can be relatively well attained both 
by radiotherapy and by surgery [Stalpers et al, 1987]. As early as 1932, Warren and 
Gates described an increased association between cancer in the head and neck 
region and second primary tumours [Warren and Gates, 1932]. Second primary 
tumours are predominantly seen in the lung, occuring in 2% to 12% of patients 
[Martin et al., 1979; Hordijk and De Jong, 1983]. This increased incidence of lung 
A.M. Engelen, LJ.A. Stalpers, J.J. Manni, J.H.J Ruijs, W.A.J, van Daal. 
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cancer following laryngeal cancer is probably due to cigarette-smoking as a 
common etiologic factor [Wynder et al , 1977] With improving results of the local 
treatment of laryngeal cancer, secondary tumours become a mam threat to the 
lifespan of patients Early detection and early treatment of second primary 
malignancies may eventually improve the overall prognosis of these patients 
[Hordijk and De Jong, 1983, De Vries et al , 1986] This is the rationale of regular 
chest radiography in the follow-up of patients with laryngeal cancer 
In this study we looked for (1 ) The incidence of second primary malignancies 
in the lung and lung metastasis in patients treated for laryngeal cancer and (2) the 
role of yearly chest radiography in the early detection of these lung malignancies 
9.3 Patients and Methods 
From January 1979 until January 1986, 590 patients with a squamous cell 
carcinoma of the larynx were admitted for treatment in the St Radboud University 
Hospital, Nijmegen, The Netherlands 
Figure 9 1 · Distribution by age 
and sex of 556 patients with 
squamous cell carcinoma of the 
larynx 
30 3Θ 40-49 50 59 60 69 70 79 80 89 
Age 
Eligible for this study were all patients admitted for primary treatment Excluded 
were 34 patients who came for treatment of a recurrency Eventually the medical 
records of 556 patients were reviewed for this study For estimation of the lung 
cancer incidence, follow-up closed in July 1986 The median observation duration 
was 37 months For estimation of the lung cancer survival rate, follow-up closed in 
July 1989, ensuring at least a follow-up of three years The mean follow-up was 52 
Frequency 
150 
100 
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months. The male:female ratio of the 556 patients was 9.9 (505 men, 51 women). 
The median age at diagnosis of the laryngeal tumour was 61 years (range: 32-96 
years). Figure 9.1 shows the distribution of sex and age. 
All tumours were staged according to the TNM-classification for tumours by 
site of the tumour (table 9.1). 
Table 9.1 · Distribution of 556 patients primarily treated for laryngeal 
cancer by tumour site and stage [AJC, 1978; UICC, 1978]. 
Site Stage: I II III IV All 
Supraglottic 35 42 58 106 241 
Glottic 173 62 58 23 309 
0 1 1 4 Subglottic 1 4 6 
Total 208 105 110 133 556 
Treatment consisted of radiotherapy in Ti and Tz carcinomas (70-74 Gy in daily 
fractions of 2.0 Gy in 6-8 weeks ). Surgical salvage was reserved for recurrent 
tumours. In more advanced stages, Тз and T4 primary surgery was performed with 
or without pre-operative radiotherapy (25.0 Gy in 5 daily fractions of 5.0 Gy in the 
week preceding operation) [Kazem et al., 1982]. Table 9.2 gives the follow-up 
protocol of patients with laryngeal cancer. 
The follow-up includes a yearly chest radiography consisting of an postero-
anterior and a lateral view. All chest radiograms were reviewed at least threefold 
before a definite report was given, both by a resident radiologist and a staff 
radiologist and finally by a radiologist and the prescribing oncologist. If a chest 
radiogram was suspected for malignancy, further radiologic examinations were 
performed. Depending on the feasibility of invasive diagnostics and on the 
curability of the patient, bronchoscopy and/or mediastinoscopy were performed. 
Surgery was performed in curable and operable lung cancer; radiotherapy and 
chemotherapy were reserved for palliative care. 
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Table 9.2 · Protocol for the follow-up of patients with laryngeal cancer 
Clinical examination 
1st year every 2nd month 
2nd year every 3rd month 
3rd year every 4th month 
4th year every half year 
>4 years annual 
II. Yearly chest radiography 
- Antero-posterior view 
- Lateral view 
III. Blood- and/or urine-analysis 
on indication 
Second primary lung cancer was defined by the three criteria of Warren and Gates 
as modified by Gluckman et al. in 1980 [Gluckman et al., 1980]: 
(1) The neoplasms must be clearly malignant as determined by histologic 
evaluation. 
(2) Each neoplasm must be geographically separate and distinct. The lesion 
should be separated by normal-appearing mucosa. If a second neoplasm is 
contiguous to the initial primary tumor or is separated by mucosa with intra 
epithelial neoplastic change, the two should be considered as confluent 
growths rather than multicentric carcinomas. 
(3) The possibility that the second neoplasm represents a metastasis should be 
excluded. The observation that the invasive carcinoma arises from an overlying 
epithelium demonstrating a transition of carcinoma in-situ to invasive 
carcinoma is helpful, and when the separate foci have significant differences in 
histology the diagnosis of separate primary cancers is appropriate. 
Patients with no histologically proven second primary in the lung are defined as 
patients with metastatic lung cancer. In this study patients with a radiologic 
progressive mass and clinical deterioration, but without histologic confirmation of a 
malignancy, are also defined as patients with metastatic lung cancer. In general 
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these patients were in too bad a condition to allow histologic confirmation or 
curative surgery 
Patients with a radiographic lesion suspect for a malignancy which did not 
show radiographic or clinical progression within a year, were identified as having 
no pulmonary malignancy 
The incidence of a second primary malignancy or a pulmonary metastasis 
was calculated as a crude rate of all patients and as an actuarial incidence rate 
corrected for the duration of follow-up [Cutler and Ederer, 1958, Peto et al, 1977] 
The survival of patients with a pulmonary malignancy was estimated by an 
actuarial method, the survival curve of patients detected by the yearly chest 
radiography without symptoms and the survival curve of patients detected after 
symptoms were compared with the logrank-test [Cutler and Ederer, 1958] 
Figure 9 2 · Incidence rate of lung 
cancer in the follow-up of patients 
with laryngeal carcinoma (patient 
numbers at risk are indicated) 
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9.4 Results 
In 69 of 556 patients (12 4%) a malignancy of the lung following laryngeal cancer 
was diagnosed Two patients with a histologically confirmed metastasis from breast 
cancer were not included in this number, all 69 patients were men In 28 patients 
(5 0%) the tumour was histologically confirmed as a second primary tumour, in 11 
patients (2 0%) the tumour was a histologically confirmed metastasis. In 30 patients 
(5 4%) no histological confirmation could be obtained for a progressive lung mass 
and were hence defined as having metastatic lung cancer Figure 9 2 shows the 
actuarial incidence rate for a lung malignancy, being 17% after 5 years and 
increasing to more than 20% after 7 years. 
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Figure 9 3 · Incidence rates 
of lung cancer following 
cancer of the glottic о г 
supraglottic larynx (patient 
numbers at risk are 
indicated) 
A lung malignancy was seen more frequently following supraglottic cancer (41/241 
= 17 0%) than following glottic cancer (28/309 = 9 1%) The difference was highly 
significant (p=0 001) Figure 9 3 shows the actuarial incidence rate of lung cancer, 
stratified by site of the laryngeal tumour The incidence rate of lung cancer following 
supraglottic cancer is 17% after 5 years rising up to 32% after 7 years The curve of 
the incidence rate following glottic cancer slopes down after two years follow-up 
(9%) up to 13% after five years. After five years, no more lung malignancies were 
seen in 67 patients with glottic cancer 
No Symptoms (N=47) 
All Patients (N=69) 
Symptoms (N=22) 
Figure 9 4 · Survival curves 
of patients with lung cancer 
following laryngeal cancer 
4
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Of 69 patients with a lung malignancy, 47 (68%) had no symptoms and were only 
detected by yearly chest radiography. The tumours in the other 22 patients (32%) 
were diagnosed after they had lead to symptoms between the yearly radiologic 
examinations. Figure 9.4 shows the survival curve of all 69 patients with a lung 
malignancy and the survival curves after stratification by mode of presentation. The 
survival of patients in whom the tumour was detected without symptoms is 
significantly better than of patients with symptoms (p<0.05), the median survival 
being 10 and 4 months respectively. 
Figure 9.5» Survival curves of 
patients with lung cancer 
stratified by mode of 
treatment 
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Figure 9.5 gives the survival curves after stratification by lung cancer treatment. 
Patients who had surgery did significantly better than patients who had 
radiotherapy or no treatment at all (p<0.05); the median survivals are 26, 11 and 3 
months respectively. 
9.5 Discussion and Conclusion 
INCIDENCE: As described in table 9.3, the incidence of lung cancer following 
laryngeal cancer and lung cancer has been reported to range from 1.1% to 11.7%. 
This wide range may be explained both by different length of follow-up periods and 
probably more important, by different criteria for diagnosis of a second primary 
malignancy [Cahan, 1977; Moertel, 1977]. 
e 
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To minimize the latter confusion, several authors stress the need of a histologic 
verification of the secondary lung tumour [Cahan, 1977, Moertel 1977, Gluckman et 
al , 1980] The requirement of histological confirmation of second primary 
malignancies may result in a selection of 'pure' second primaries but may result in 
an underestimation of the real incidence rate Moreover, overemphasis on the need 
for a histologically distinction between metastatic and primary lung cancer may 
distract from the clinical purpose of the yearly chest radiography, namely to detect 
a lung malignancy in a curable stage Therefore, we evaluated the role of yearly 
chest radiography for metastatic and primary lung cancer together Then we see 
that the risk of developing lung cancer following supraglottic carcinoma is higher 
than following glottic cancer This finding agrees with other studies by Wagenfeld et 
al (1980, 1981) 
Table 9 3 · Review of the literature on second primary 
malignancies following laryngeal cancer 
Author Period Patients Second primary malignancies 
All sites (%) Lung(%)* 
Sherman et a l , 1967 
Goff met et a l , 1973 
Brown, 197Θ 
Martin et a l , 1979 
Gluckman et al, 19Θ0 
Wagenfeld, 1980, 1981 
Hordijk et a l , 1983 
Rodriguez et al, 1984 
Miyahara et a l , 1985 
D e V n e s e t a l , 1986 
Present study, 1989 
1955-65 
1957-70 
1958-74 
1960-77 
1974-78 
1965-74 
1958-79 
1979-82 
1958-81 
1963-84 
1979-86 
187 
535 
1,600 
496 
189 
903 
691 
286 
1,389 
748 
556 
1 6 0 
4 1 
9 1 
179 
7 5 
20 5 
9 9 
1 3 9 
7 7 
7 4 
1 9 
1 1 
2 0 
6 8 
4 2 
11 7 
1 2 5 
1 7 
8 6 
5 0 
'excluding metastatic lung cancer 
Moreover we found that while an increased lung cancer risk persists for many years 
following supraglottic carcinoma, the incidence rate slopes down after 2 years 
following glottic carcinoma and becomes asymptotic after less than 5 years A 
similar pattern, although with lower incidence rates, was found if we confined the 
population to the 28 patients with a histologically confirmed second primary lung 
Following Laryngeal Cancer 107 
cancer (not presented here) These findings confirm the hypothesis of Wagenfeld et 
al that different mechanisms underlie the tumour development in patients with 
supraglottic and glottic carcinoma, despite common etiologic factors 
Second primary lung cancer following laryngeal cancer has been described 
as a feature predominantly seen in males [Sherman et al , 1967, Brown, 1978] We 
found no lung malignancy associated with laryngeal cancer at all in 51 women, 
while 7 cases (13%) were expected The finding could highly unlikely be attributed 
to chance alone (p=0 01) 
SURVIVAL The survival of patients with a lung malignancy following laryngeal 
cancer is poor [Sherman et al , 1967, Yellin et al , 1986] and similar to the lung 
cancer survival in the general population [Ries et al , 1983, Nou, 1984] 
The higher survival rate of patients detected by yearly chest radiography 
compared with patients diagnosed after symptoms suggests a benefit of yearly 
chest radiography However, median survivals differ only 6 months Considering a 
lead-time between early diagnosis of lung cancer and the time a tumour would be 
diagnosed following symptoms, the observed survival benefit of yearly chest 
radiography is in fact much less [Femleib and Zelen, 1969] If we would correct the 
survival of patients detected by chest radiography for only several months lead-
time, the survival curve would converge with the curve of patients diagnosed after 
symptoms and the earlier observed difference tends to disappear However, the fact 
that almost all patients diagnosed following symptoms have died within two years, 
while almost 20% of patients "without symptoms" show a long term survival, 
suggests a probably small benefit of yearly chest radiography 
The finding that yearly chest radiography hardly contributes to an improved 
survival of patients with lung cancer (and thus with laryngeal cancer) agrees with 
the disappointing results of population screening for lung cancer [Bailar, 1984, 
Fontanaetal , 1984] 
Although patients who had surgery for lung cancer show a better survival 
than those who had not, the benefit of surgery is probably spurious The policy in 
our clinic is to reserve surgery for curation Therefore, patients with a poor 
prognosis due to a poor general health or to large or multiple lung tumours are not 
eligible for surgery 
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Especially for patients with a prolonged enhanced risk of developing lung cancer 
we have to intensify the search for (a) better early detection methods (b) the 
underlying causes and (c) prevention of secondary cancers 
CONCLUSIONS 
(1) The incidence of lung cancer is both higher and more prolonged in the follow-
up of patients with supraglottic carcinoma than in patients with glottic 
carcinoma 
(2) An enhanced risk to develop lung cancer following laryngeal cancer is 
probably an exclusive feature in men 
(3) The survival of patients with lung cancer detected by yearly chest radiography 
is better than in patients diagnosed after symptoms The prognostic benefit of 
chest radiography could disappear after correction for lead-time 
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10. Markov Modelling m Clinical Trial Design 
Illustrated by a Trial to Assess the Value of Bronchoscopy in 
the Early Detection of Lung Cancer Following Laryngeal Cancer1 
10 1 Abstract 
This chapter studies the use of the Markov model in the design of a randomized 
clinical trial (RCT) to estimate the efficacy of a new medical treatment compared 
with the standard treatment The Markov model predicts a survival curve of patients 
for either treatment group, using time dependent probabilities derived from (a) 
disease related mortality rates taken from a retrospective study, (b) age-specific 
mortality rates and (c) assumptions about the benefit of the new treatment The 
Markov model can effectively be used to test the sensitivity of the efficacy of the new 
treatment for variation of the parameters used in the model 
The efficacy of the new treatment is expressed both as the improvement in 
survival predicted by the Markov model, and as the sample size of an RCT to detect 
the improvement The improvement itself is an indicator of the clinical importance of 
the new treatment, the sample size is an indicator of the feasibility of the trial 
Sample sizes are based on comparison of the survival curves predicted by the 
Markov model, rather than on comparison of single survival rates 
The method is illustrated by an RCT to assess the value of bronchoscopy in 
the early detection of lung cancer in patients with laryngeal cancer 
10 2 Introduction 
PRINCIPLES OF RANDOMIZED CLINICAL TRIALS 
A randomized clinical trial (RCT) is a clinical experiment to assess the efficacy of a 
new diagnostic or therapeutic treatment by randomization ι e by random 
assignment of either the new treatment or the old 'standard' treatment to 
consecutive patients The treatment groups of patients, -also denoted as treatment 
arms' or 'trial arms'-, are compared afterwards The treatment that, to a statistically 
significant extent, yields the best results, for instance the best survival rate is said to 
1
 L J A Stalpers, J H M Zwetsloot-Schonk, A L M Verbeek and W A J van Daal For publication m 
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be the superior treatment If the study yields no significant differences, the 
treatments are said to be equally effective The latter statement is only valid if the 
study is large enough not to miss a clinically important difference 
A major pitfall of an RCT concerns the discrepancy between the benefit of a 
treatment one wants to detect, the benefit one can expect and the subsequent 
sample size to detect it [Freiman et al , 1978, Haybittle 1988, Pocock SJ 1978] 
Therefore, in the designing phase of an RCT one should define which benefit is 
considered clinically important, estimate the potential benefit and estimate the 
feasibility of the trial considering the number of patients required and available to 
detect the benefit 
Two features may encumber the estimation of the efficacy of a new treatment 
by an RCT 
(a) Effect dilution It is generally unknown who amongst all treated patients will 
eventually profit from the new treatment For instance, adjuvant chemotherapy 
in breast cancer is aimed at elimination of subclinical tumour dissemination, 
so-called micrometastasis in women with locoregional tumourspread Since 
we do not know in advance who actually has micrometastasis, the effect of 
adjuvant chemotherapy has to be measured in all women with locoregional 
disease A potential benefit in a small number of patients may then become 
insignificant for the larger group of all treated patients 
(b) Effect timing It can be difficult to estimate how long we should observe our 
patients in order to detect the potential benefit This latter feature is 
encumbered by the fact that the prognosis of a patient changes In general the 
mortality risk from cancer decreases from the onset of treatment, but mortality 
from other causes increases 
THE MARKOV MODEL FOR SIMULATING RCT's 
The Markov model of prognosis [Beck & Pauker, 1983] can be used to simulate an 
RCT and to estimate the outcome of either arm The Markov model has some 
attractive features compared with a simple probability tree analysis (comparable to 
a decision tree analysis) Markov modelling can be used to represent decision 
problems in a dynamic way This is especially useful in structuring the course of a 
disease with time varying probabilities Hence, rather than estimating simple end-
points such as five-year survival rates, a Markov model can more accurately 
generate whole survival curves for comparison Furthermore, the Markov model is a 
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powerful tool to test the strength of conclusions by simulating the course of disease 
under various conditions Hence, it can effectively deal with several presumptions 
about the benefit of the new treatment compared with the standard treatment 
For a certain level of significance and power of study and for a given (or 
hypothesized) difference between the survival curves produced by the Markov 
model, the sample size of an RCT can be calculated 
EXAMPLE BRONCHOSCOPY IN PATIENTS WITH LARYNGEAL CANCER 
The use of a Markov model of prognosis in a clinical trial design is demonstrated by 
a European RCT investigating the efficacy of bronchoscopy for early detection of 
lung cancer in patients with cancer of the head and neck Pastorino et al , 1987] 
This trial is presented here for illustrative purposes only In the European trial a 
standard follow-up protocol which includes yearly chest-radiography is compared 
with a new protocol which includes frequent bronchoscopy to detect secondary 
lung cancer in a resectable stage It is assumed that by frequent bronchoscopy the 
mortality from lung cancer will be reduced which eventually results in a better 
survival in patients with laryngeal carcinoma The Markov model provides an 
estimate of the reduction of the mortality rate of patients diagnosed with laryngeal 
cancer due to bronchoscopy 
The probabilities used in the model are derived from (1) the incidence rate of 
lung cancer , (2) the disease-specific mortality rate from laryngeal cancer, (3) the 
mortality rate from secondary lung cancer These rates were estimated by data from 
an own retrospective study of patients with laryngeal cancer [Engelen et al , 1990] 
The model further includes (4) assumptions about the effect of bronchoscopy on the 
survival from lung cancer and (5) mortality rates from death of intercurrent diseases 
Assumptions about the benefit of bronchoscopy, expressed as reduced lung cancer 
mortality rates, are based on some population based studies drawn from the 
literature Mortality rates from intercurrent diseases are based on age-specific death 
rates for the Dutch population [CBS, 1987] 
AIM OF THE STUDY 
The aim of this study is to show the use of the Markov model to estimate the efficacy 
of a new treatment by an RCT The efficacy is expressed as the improvement in 
survival predicted by the Markov model, and as the sample size of an RCT to detect 
the improvement The sample size is expressed as the yearly number of patients 
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required for randomization The improvement itself is an indicator of the clinical 
importance of the new treatment, the sample size is an indicator of the feasibility of 
the trial The range of the inaccuracy of the model is explored in a sensitivity 
analysis on the parameters used in the model 
10.3. Data and Methods 
SOME FACTS AND FIGURES ON LARYNGEAL CANCER AND LUNG CANCER 
In Western countries laryngeal cancer is diagnosed in 114 per 1,000,000 in men 
and 6 per 1,000,000 in women per year [Waterhouse et al , 1982] It is 
predominantly a disease of the sixth decade [Zagars & Norante, 1982] Laryngeal 
carcinoma gives relatively early rise to complaints and cure can be relatively easily 
achieved both by radiotherapy and surgery [Stalpers et a l , 1987a, Stalpers et a l , 
1987b, Stalpersetal , 1988] 
A considerable number of patients cured from laryngeal cancer will develop 
lung cancer, probably because of smoking as a common etiological factor [Wynder 
et al , 1977] Lung cancer following laryngeal cancer is seen more frequently in 
male patients than in female ones and more frequently in patients with supraglottic 
cancer than with glottic cancer [Wagenfeld et al , 1980, Wagenfeld et al , 1981] 
Since the first study on second primary malignancies by Warren and Gates in 1932, 
increased occurrences of lung cancer following laryngeal carcinoma have 
frequently been described in the literature [Warren & Gates, 1932] The occurrence 
has been described to range from 2 0% to 12 0%, depending on the duration of 
follow-up in the different studies and the definition applied to differentiate a primary 
malignancy in the lung from a lung metastasis [Martin et al , 1979, Hordijk et al , 
1985, Cahan, 1977] 
The overall five-year survival rate of patients with lung cancer ranges from 
7% to 11% [Ries et al , 1983, Nou, 1984] Prognosis is related with histology and 
with disease stage For the prognostically favourable clinical stage I squamous cell 
carcinoma, the five-year survival may be 40% [AJC, 1979] Most patients die within 
two years, after a five-year survival a patient can be considered cured 
Regular lung-radiography is performed in the follow-up of patients with 
laryngeal cancer in most oncology centres Chest-radiography alone fails to detect 
lung cancer in an early stage in patients with cancer of the aerodigestive tract 
[Gluckman & Grissman, 1983] These findings agree with the disappointing 
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experiences with population screening for lung cancer [Bailar, 1984; Fontana et al., 
1984]. 
Bronchoscopy has been proposed to enhance the early detection of lung 
cancer. Bronchoscopy is an invasive diagnostic procedure which poses a 
substantial burden to the patient but which, in experienced hands, is said to be safe 
[Leipzig et al., 1985]. The test-characteristics of bronchoscopy are good when used 
to confirm radiographically suspect malignancies [Cortese et al., 1983; Mathisen et 
al., 1984]. However, it is not clear whether bronchoscopy will be useful in patients 
without manifest lung cancer [Leipzig et al., 1985]. 
RETROSPECTIVE STUDY: INCIDENCE RATES AND MORTALITY RATES 
We used data from an own retrospective study to obtain actuarial estimates for (1) 
the incidence rate of lung cancer, (2) the disease specific mortality rate from 
laryngeal cancer and (3) the mortality rate from secondary lung cancer [Cutler & 
Ederer, 1958; Engelen et al., 1990]. 
From January 1979 to January 1986, 556 patients with a newly diagnosed 
squamous cell carcinoma of the larynx have been treated and followed at the 
Nijmegen University Hospital, The Netherlands. The follow-up study closed in June 
1986, resulting in a minimum of 6 months and a maximum of 90 months follow-up 
(mean=36 months). Age ranged from 32 to 96 years with a mean age of 61 years. 
The male:female ratio was 10.5. Tumours were classified according to the TNM 
classification of tumours [AJC, 1978; UICC, 1978] and were localized in the glottic 
region in 317 patients (57%), in the supraglottic region in 234 patients (42%) and in 
the subglottic region in 5 patients (1%). 
In general, primary treatment consisted of radiotherapy (60-74 Gy in 5 
weeks) for T i and T2 glottic and for T2 supraglottic carcinomas. Surgery was 
performed as primary treatment in all other patients and as salvage treatment in 
patients with a loco-regional recurrence. Chemotherapy was reserved for palliative 
treatment. The follow-up protocol was similar to the standard protocol in the 
projected RCT, including regular physical examination of the head and neck and 
yearly radiography of the lungs. 
THE MARKOV MODEL 
A Markov model with time dependent transition probabilities was used to calculate 
the expected survival curve of patients with laryngeal cancer for each trial arm. The 
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Markov model includes annual estimates of the incidence rate of lung cancer 
following laryngeal cancer and death rates from laryngeal cancer, from secondary 
lung cancer with and without bronchoscopy and from intercurrent diseases In order 
to estimate the maximum possible benefit from bronchoscopy, it was assumed that 
all patients with lung cancer in the bronchoscopy group were detected in the most 
favourable clinical stage I The yearly required number of patients for randomization 
is calculated based on the expected reduction of the mortality rate after five years 
follow-up due to bronchoscopy 
Structure of the Markov Model 
Figure 10 1 gives the basic structure of the Markov model The model is structurally 
identical for the standard protocol as well as for the bronchoscopy protocol Of 
course, the transition probabilities are different for both arms 
Year = 0 
Year = 2 
Figure 10 1 · Basic structure of the Markov model with three states 
for the first two years following randomization 
Following randomization, all patients start in a state called "WELL" In the first year, 
a patient either dies of intercurrent disease or of laryngeal cancer ending in the 
state called "DEAD" or stays alive Some of these patients get lung cancer and 
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either die of lung cancer before the end of the year or survive These patients will 
start the next year in a state called "LUNG CANCER" The remaining patients stay 
well for the rest of the year, remaining in the state WELL again in the next year 
A patient starting with "LUNG CANCER" at year=1, may either die of laryngeal 
cancer, intercurrent disease or lung cancer or may survive As the risk of dying of 
lung cancer depends on the time elapsed since lung cancer was diagnosed, -and 
not on the time of randomization-, we defined separate lung cancer states for the 
first five years post lung cancer to enable modelling of a decreasing lung cancer 
mortality rate (not represented in figure 10 1) 
The events in the first four years following lung cancer are structurally 
identical However, the lung cancer mortality rate diminishes each year After five 
years following lung cancer detection, patients can be considered cured of lung 
cancer Therefore, we assumed that these patients are "WELL" five years after the 
diagnosis of lung cancer 
Summarizing, we framed the problem in a seven-state Markov model, including 
four separate lung cancer states 
1 WELL Alive, without lung cancer 
2-6 LUNG CANCER Alive, with lung cancer 
7 DEAD Dead, either of lung cancer, laryngeal 
cancer or of other causes 
The survival at any year following laryngeal cancer is the proportion of patients 
alive, both alive in the WELL state and alive in one of the LUNG CANCER states 
The mortality rate after Τ years follow-up is the proportion fatal Markov transitions 
(=deaths) of all transitions that could have ended fatally (=patient numbers at risk) 
Assignment of Probabilities 
The transition probabilities are not constant for all years With the years the risk of 
dying from laryngeal cancer, the risk of getting lung cancer and the risk of dying 
from lung cancer decreases, while the risk of dying from other "age-related" causes 
increases So the transition probabilities in our model are time-dependent To 
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estimate the transition probabilities we used data from the retrospective study and 
from the literature Table 10 1 gives a summary of the available data 
Table 10 1 · Summary of available data 
Variable 
(1) Five-year cumulative incidence of secondary 
lung cancer in patients with laryngeal cancer* 
• All patients 17% 
- female 0% 
-male 18% 
• Supraglottic 22% 
- male 24% 
• Glottic 13% 
-male 14% 
(2) Laryngeal cancer five-year survival rates, corrected for secondary 
lung cancer incidence and age-specific death rate (see text)* 
• All patients 87% 
-male 88% 
• Supraglottic 87% 
- male 88% 
• Glottic 88% 
- male 89% 
Five-year survival from lung cancer 
(3) · "Standard Protocor 2 1 % 
(4) · "Bronchoscopy Protocol" 40% * 
(5) Mean age at randomization = 61 years 
Based on the retrospective study [Engelen et al , 1990] 
# Based on the literature [AJC, 1979] 
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(1) Lung cancer incidence rate (LIR) 
In the retrospective study, 69 out of 556 patients with laryngeal cancer (12.4%) 
developed secondary lung cancer. After actuarial correction for the duration of 
follow-up, the cumulative incidence was 17% after five-year [Engelen et al., 1990].ln 
order to enable sensitivity analysis of the yearly incidence rate of lung cancer we 
approximated the incidence rate by a simple linear function: 
lung cancer incidence ratet = LIRt = a - b*t (1 ) 
where a denotes the initial incidence rate and b the regression coefficient, with the 
restriction that if LIR < 0 then LIR = 0. The cumulative incidence CI of secondary 
lung cancer at time i>1 is given in (2): 
Clj = Clo+ £ [LIRt · (1.0 - C I M ) 1 CIO = 0 (2) 
t=1 
Using least squares statistics, best curve fit to our data (correlation = 0.88) was 
obtained for: 
LIRt = 0.063 - 0.009-1 
Following stratification by primary site of the laryngeal tumour, the cumulative 
incidence is lower after glottic than after supraglottic cancer [Engelen et al., 1990]. 
The best fitting function for patients with glottic carcinoma was: 
LIRt = 0.0541 - 0.0089't 
and for patients with supraglottic carcinoma: 
LIRt = 0.0814-0.0104«t 
In the retrospective study, none of the 54 women developed lung cancer. Two 
women with verified lung metastasis from breast cancer were considered as not 
having lung cancer. Therefore we modelled the lung cancer incidences also for 
male patients only (see table 10.2). 
(2) Laryngeal cancer mortality rate 
The "cause-specific" mortality rate (CMR) of laryngeal cancer was calculated by 
correcting the crude mortality rate, observed in the 556 patients, for death of lung 
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cancer and for death of age and sex-related causes (ASR) The mean age of 
patients at diagnosis laryngeal cancer was 61 years. Correction for the ASR was 
performed by subtracting the age-specific mortality rate for the Dutch population 
aged 61 [CBS, 1987] at diagnosis laryngeal cancer from the crude mortality rate. 
We modelled the cause-specific mortality rate from laryngeal cancer by a simple 
linear function: 
CMRt = c-d.t (3) 
were с is the initial mortality rate. We made the restriction that CMRt ^ 0 than CMRt 
= 0. Best fit was obtained for с = 0 064 and d = 0.0108 (correlation = 0.99) 2 
(3) Lung cancer mortality rate 
Figure 10.2 shows the survival curve of 69 patients with lung cancer following 
laryngeal cancer. The five-year survival is 21%. Corresponding with the literature 
on lung cancer survival, the survival curve remains at the same level after five 
years. The survival curve could best be modelled if we presumed a decreasing 
exponential lung cancer mortality rate: 
lung cancer mortality rate = e _ x t (4) 
The survival (S) at any time=i following lung cancer can then be calculated with 
formula (5): 
S(l) = S(o)- ¿ [ β-λί χ S(t-i)] (ia1;S(0Fl) (5) 
t -1 
The λ cannot simply be calculated, but has to be approximated based on So). 
2
 The data on laryngeal cancer mortality in table 10 1 show an unexpected feature: The cause-
specific survival from supraglottic cancer, -ι e corrected for death from age and sex-related causes 
and lung cancer-, showed to be only marginally lower than the survival from glottic cancer. However, 
the overall survival in patients with supraglottic cancer is significant worse than in patients with glottic 
cancer, which agrees with the literature [Zagars & Morante, 19Θ3]. The disagreement between 
cause-specific and overall survivals could not be explained by a different distribution of age, sex or 
chance. It could be explained by the substantially higher incidence of (and subsequent death from) 
lung cancer in patients with supraglottic cancer. 
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Based on the five-year survival of 0 21 and using equation (4) a decreasing 
exponential mortality rate for patients with lung cancer following laryngeal cancer 
was approximated with λ = 0 58 in formula (5) The lung cancer mortality rate in the 
first year then will be e*0 5 8 x 1 = 0 56 and in the second year = e - 0 5 8 x 2 = 0 31 etc 
In order to estimate the optimal effect of bronchoscopy, we presumed that by 
bronchoscopy all patients with lung cancer have a squamous cell carcinoma 
detected in the most favourable clinical stage = I [AJC, 1978, 1979, UICC, 1986] 
Assuming a 40% five-year survival of these patients, λ is 0 84 The lung cancer 
mortality in the first year then will be е - 0 θ 4 χ 1 = 0 43 and in the second year e - 0 8 4 x 2 
= 019 etc 
We did not correct the lung cancer mortality rates for age-specific death rate 
or death of laryngeal cancer, as these mortality rates were negligible compared to 
the lung cancer mortality rate for the first five years To correct for state transitions 
during the year, we made half-time corrections of the transition probabilities (see 
appendix I, §10 6) 
Table 10 2 gives a summary of the baseline values for the probabilities used 
in the analysis 
Figure 10 2 Actuarial survival 
from lung cancer in 69 patients 
following laryngeal carcinoma 
(broken line, patient numbers at 
risk are indicated) and the curve 
based on eq (5) used in the 
Markov model (solid line) 
— 60 
0 + 
0 1 4 5 
Year 
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Table 10 2 · Summary of the baseline parameters used in the analysis 
Probability 
(1) Lung cancer incidence rate 
• All patients 
-male 
• Supraglottic 
-male 
• Glottic 
-male 
(2) Laryngeal cancer mortality rate 
• All patients 
-male 
• Supraglottic 
-male 
• Glottic 
-male 
Lung cancer mortality rate 
(3) · "Standard Protocol" 
(4) · "Bronchoscopy Protocol" 
(5) Death of 
intercurrent 
diseases 
Assumed time-
dependent model 
a - b*t per year 
a 
0 063 
0 0711 
0 0814 
0 0917 
0 0542 
0 0574 
b 
0 0090 
0 0103 
0 0104 
0 0120 
0 0089 
0 0094 
с - d»t per year 
с 
0 0635 
0 0629 
0 0655 
0 0765 
0 0604 
0 0624 
d 
0 0108 
0 0121 
0 0134 
0 0161 
0 0109 
00116 
β"
λ
* per year 
λ = 0 58 
λ = 0 84 
Increasing 
age-specific 
mortality rate 
Correlation with 
original data 
0 88 
0 94 
0 88 
0 88 
0 96 
0 96 
0 99 
0 95 
0 92 
0 97 
0 91 
0 94 
Age at 
randomization 
61 year 
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Validating the Markov Model 
Since mathematical modelling of all the transition probabilities might have lead to a 
deviation of the Markov model from the original data upon which it was based, we 
compared (1) the actuarial survival curve with (2) the survival curve as predicted by 
the Markov model for patients in the standard protocol As shown in figure 10 3 and 
table 10 3, the differences are marginal 
0 6 -
Actuanal 
Bronchoscopy 
· Standard 
Figure 10 3 The actuarial 
survival curve from laryngeal 
cancer (solid line) and the 
survival curves for the standard 
and the bronchoscopy protocol 
as predicted by the Markov 
model (broken lines) 
5 6 
Year 
CALCULATIONS OF REQUIRED PATIENT NUMBERS 
The calculation of the number of patients yearly required for randomization, is 
based on the expected differences in average mortality rates after five years 
recruitement and follow-up The numbers are calculated for a bi-armed randomized 
clinical trial comparing the standard protocol with the bronchoscopy protocol for a 
study with a two-tailed significance α = 0 05 and a one-tailed power 1-β = 0 90 
[Bulpitt, 1983] A significance of 0 05 means that there is only 5% chance that the 
trial will demonstrate a difference between the two protocols where there is in fact 
no difference A power of 0 90 means that there is a probability of 0 9 of 
demonstrating a benefit of bronchoscopy if there really is a benefit over the 
standard follow-up 
Halpenn et al (1968) described a method to calculate the required patient 
numbers in an RCT in order to detect the expected difference between two simple 
proportions with a certain significance and study power. 
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In follow-up studies such as most cancer clinical trials, one usually compares whole 
survival curves, rather than single endpoints such as the five-year survival rate. The 
survival curves produced by the Markov model can be treated as actuarial curves 
with one-year intervals. In analogy with the logrank test to compare survival curves 
[Mantel, 1966], we can define an average annual mortality rate for the duration of 
follow-up. Using the Markov probability distribution of states ptfAUVE.DEAD) for each 
year, we used an adjusted version of the Halperm method to calculate the annual 
number of patients for randomization based on the difference in average mortality 
rate for a certain duration of follow-up. The method is described in appendix il 
(§10.7). 
Table 10.3· Validation of the Markov model: Actuarial five-year survival and 
predicted five-year survival for patients with laryngeal carcinoma 
by sex and localization of the laryngeal tumour 
Patient group Standard protocol 
Actuarial 5-year Predicted 5-year 
survival (%) survival (%) 
All 68.5 67.74 
• male 68.0 68.32 
Supraglottic 66.4 66.53 
•male 65.4 64.16 
Glottic 71.32 70.79 
•male 71.33 70.41 
10.4 Results 
BASELINE ANALYSIS 
As shown in figure 10.3, a small improvement of the five-year survival of patients 
with laryngeal cancer thanks to regular bronchoscopy is predicted by the Markov 
model. The exact improvement 2.1% from 67.7% to 69.8%. After five years follow-
up, the average annual mortality rate was reduced from 8.21% to 7.72%. It can be 
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calculated that at least 9,550 patients are required for randomization every year to 
detect the predicted improvement (for calculation: See table 10.6 in Appendix II, 
p. 136). 
In the retrospective study we found that in patients with cancer of the glottic 
and supraglottic larynx after five years 13% and 22% respectively had developed 
lung cancer. The number of patients required for randomization is calculated for 
each patient group. As may be read from table 10.4, the predicted improvement in 
five-year survival ranges from 1.68% to 3.05%. The reduction in average annual 
mortality rate ranges from 0.40% to 0.75%. As we found no lung cancer in women 
in the retrospective study, no profit is to be expected from bronchoscopy for women. 
Table 10.4 · Baseline analysis: Predicted improvement in five-year survival rate, 
the reduction in average annual mortality rate after five years follow-
up and the patient numbers required in a bi-armed randomized 
clinical trial to detect this improvement (see text). 
Patient 
group 
All 
• male 
Supraglottic 
• male 
Glottic 
• male 
Predicted 
improvement 
in 5-year 
survival (%) 
2.08 
2.33 
2.81 
3.05 
1.68 
1.77 
Predicted 
mortality 
reduction (%) 
0.49 
0.55 
0.67 
0.75 
0.40 
0.43 
Number of 
patients 
required 
9550 
7509 
5356 
4715 
13013 
11496 
SENSITIVITY ANALYSIS 
The number of patients required in an RCT is based on the reduction in average 
annual mortality rate in a study with a follow-up of five years, a power of 0.90 and a 
significance of 0.05. These may be relatively stringent criteria. We therefore 
performed sensitivity analysis on (a) the power of the study trial and (b) the duration 
of the follow-up. 
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The retrospective study was based on a patient population from only one 
specific university hospital To account for variations in populations from the 
different hospitals involved in the multicentre trial, we performed sensitivity analysis 
on (c) lung cancer survival and (d) age at randomization 
(a) Power of the study 
Table 10 5 shows a sensitivity analysis on the power of the study for the number of 
patients required in the RCT For instance, if the study would have a power 0 80, -
which is said to be acceptable in many studies-, the number of patients required 
would be 6900 to detect a 0 5% mortality reduction from 8 21% to 7 71% per year 
Table 10 5 Required patient numbers in a bi-armed RCT by predicted reduction 
in the average mortality rate for various study powers 
Mortality 
reduction 
(%) 
01 
02 
04 
05 
06 
Power 
0 50 
86000 
21500 
5280 
3400 
2300 
0 60 
109000 
27000 
6710 
4300 
3000 
0 70 
137500 
34000 
8450 
5400 
3700 
0 80 
175500 
44000 
10780 
6900 
4700 
0 90 
234000 
58000 
14400 
9500 
6300 
(b) Duration of follow-up 
In the baseline analysis it was assumed that the study duration was five years, both 
for the follow-up and randomization However, the benefit of early detection of lung 
cancer may become more prominent if we would take a longer duration of follow-
up The Markov model easily allows us to predict survival improvements for shorter 
or longer follow-up periods Table 10 6 in appendix II (§10 7) shows the predicted 
survival improvement for a follow-up ranging from 0 to 20 years The mortality 
reduction increases up to 7 92% - 7 41% = 0 51% after 6 years follow-up After this 
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period, the mortality from age-specific diseases becomes larger than the mortality 
from lung cancer, and the reductions will gradually decrease (This finding agrees 
with the trivial knowledge about human existence that in the long run, everyone will 
die) From table 10 6 we can read that even for a follow-up of 10 years, at least 
2573 patients with laryngeal cancer are yearly required for randomization to detect 
the mortality reduction 
(c) Lung Cancer Survival 
In the retrospective study, the five-year survival of patients with lung cancer 
following laryngeal cancer was 21% If we presume worse five-year lung cancer 
survival rates in the standard protocol, more patients may profit from bronchoscopy 
Hence, the number of patients required in a randomized trial will be lower, 
providing of course that by bronchoscopy all patients with lung cancer will be found 
having a clinical stage I carcinoma with a 40% five-year survival 
Figure 10 4 shows the predicted survival improvement from laryngeal 
carcinoma for five-year lung cancer survival ranging from 0% to 25% From this 
figure we can read that in a study with a power of 90% the required patient numbers 
range from 2235 to 14980 
Figure 10 4 Sensitivity 
analysis of the required 
number of patients for various 
five-year survival rates from 
lung cancer in the standard 
protocol ranging from 0 to 
25% and for various study 
powers 
5 10 15 20 25 
5-Years lung cancer survival (%) 
For the baseline analysis it was assumed that, following bronchoscopy, all patients 
will be detected as clinical stage I, which is highly optimistic. In stage II, the five-year 
survival of lung cancer will drop to almost 20% [AJC, 1979] As far as we know, it is 
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not yet well established in what stages lung cancer is detected by bronchoscopy 
We therefore assume that the actual five-year survival ranges between 20% and 
40%, depending on the distribution of stages found in the bronchoscopy group For 
instance, if both stage I and stage II are equally represented, the five year survival 
of the bronchoscopy group wíl be the average = 30% Figure 10 5 gives the 
sensitivity analysis of the required patient numbers for various survival rates for 
lung cancer in the bronchoscopy group For a study power of 80% and a five-year 
survival of 30%, it can be read that 44070 patients are annually required 
Figure 10 5 'Sensitivity analysis 
of the required number of 
patients for various five-year 
survival rates from lung cancer 
in the bronchoscopy group 
ranging from 25 to 40% and for 
various study powers 
25 30 35 40 
5-Year lung cancer survival (%) 
(d) Age at Randomization 
The mean age of the retrospective study group was 61 years Because regular 
bronchoscopy is very inconvenient for older patients, they may be excluded from 
the study group Hence the mean age will be lower in an actual study group 
Figure 10 6 shows the predicted survival improvement and required number of 
patients for varying mean ages of the study population at randomization Since at a 
younger age mortality is less determined by age-related diseases and more by lung 
cancer mortality, a beneficial effect of bronchoscopy is higher at a younger age than 
at an older age This is expressed m a larger predicted improvement and 
correspondingly lower numbers required in a trial 
200OOO 
a 150000-
•£ 100000-
50000 
\ \ . . . 
\ \ 
\ 
Л 
\ 
4 \ 
\ \ 
\ v^^^ 
- ^ : 
Power - 0 BO 
- Power - 0 70 
^ 
Clinical Trial Design 129 
Figure 10 6 · Sensitivity analysis 
on the mean age at 
randomization ranging from 40 
to 80 years for various study 
powers 
10 5 Discussion 
This study describes the use of Markov modelling in the design of a randomized 
clinical trial to forecast the benefit of a new treatment in terms of survival 
improvement and to estimate the number of patients required to detect the benefit 
The Markov model is a powerful tool to predict patient prognosis with time 
dependent probabilities [Beck & Pauker, 1983, Ransohoff et al , 1983] As in any 
model, one of the greatest limitations for its application lies in the reliability of the 
data and the simplifications of the real world problem [Pauker & Kassirer, 1987] 
We used data from an own retrospective study to estimate probabilities This 
approach enables accurate modelling of time-dependent probabilities with 
actuarial data Rather than imposing a certain "biologically sound" model on our 
data, we preferred to modelling by "best fit" procedures This simple approach may 
conflict with some biological assumptions for which extra restrictions have to be 
made (such as that an incidence-rate may never become negative) Since an 
accumulation of simplifications may eventually lead to an increasing deviation from 
the "real world", we compared the survival curve predicted by the model with the 
actuarial survival curve of the original data-set Especially compared with a more 
simple "classical" probability tree using five years' results, the Markov model 
produces accurate estimates of the actuarial survival estimates It is evident, that 
external validation of the model is only possible by a check with another data-set 
The estimation of the highest benefit of the new treatment, -namely by 
reduction of the lung cancer mortality to the lowest realistic rate due to regular 
50 60 70 80 
Age at randomization 
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bronchoscopy-, was based on data taken from the literature, namely on the lung 
cancer survival rate in the prognostically most favourable clinical stage [AJC, 1979]. 
A sensitivity analysis was performed to analyse the efficacy of the new treatment 
under less and unrealistically more favourable conditions. 
Since the annually required number of patients is one of the most important 
factors determining the feasibility of an RCT, we used this number as an index for 
comparison. Rather than comparing single end-points such as the five-year survival 
rate, we compared the average mortality rates drawn from whole survival curves as 
predicted by the Markov model. The comparison of the average mortality rates is 
the essence of the logrank test as proposed by Mantel (1966). This approach does 
not only yield more powerfull and accurate information of survival, but can also be 
used to analyse the efficacy of the new treatment for varying durations of follow-up. 
The feasibility of an RCT does not merely depend on the number of patients 
required, but also on the availability of patients. In the European trial on which this 
study is based, it was suggested that within five years about 2,000 patients would 
be required for randomization [Pastorino et al., 1987]. Under the baseline 
assumptions given in table 10.3, this number will be insufficient to demonstrate a 
five-year survival improvement. Although the reduction in lung cancer mortality rate 
may be huge, the effect is so "diluted" by the whole group of patients with laryngeal 
cancer, that the eventual mortality rate is only marginally reduced due to 
bronchoscopy. To detect such small reductions as estimated by the Markov model 
with an acceptable power, it requires a long follow-up duration in a study with a 
(too) large sample size. A sensitivity analysis on the lung cancer survival rates or 
the average age at randomization shows only marginal variations in predicted 
improvements. 
A randomized clinical trial (RCT) is widely advocated to assess the value of a new 
diagnostic or therapeutic treatment [Grage et al., 1982]. The method described in 
this study may provide some necessary information in the design of an RCT. The 
decision whether or not to embark on an RCT depends on whether the participating 
institutes judge it worthwhile to detect a probably small benefit of a new treatment, 
to invest the effort to recruit the required number of patients and to invest the time to 
follow these patients for a sufficient length of time. 
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10.6 Appendix I: Half-time correction 
In a Markov model frequencies of transition states are calculated at the end of each 
cycle. Transitions may occur over the year. Patients may develop lung cancer in the 
first year and may die within that same year. To correct for this double transition in 
the same year, we assume that on the average the transition from WELL to LUNG 
CANCER occurs in the middle of the year and that a patient is a half year at risk of 
dying of lung cancer. For patients in the standard protocol, the risk of dying of lung 
cancer within the first year if lung cancer has occurred = 0.5e"Xx0'5.Then, with 
respect to the follow-up of lung cancer, the lung cancer mortality rate in the second 
year equals β_ λ χ 1·5. 
Consequently, the risk of dying of lung cancer in the i-th year following the 
year wherein lung cancer was detected = е"х('"0-5'. Correspondingly, the lung 
cancer survival curve as implemented in the Markov model will be an adjusted 
version of formula (5): 
ι 
S(i) = S(o.5) x (1.0 -0.5e-*°-5)-£ [ e-Mt-o.5) χ S(t-i)] (6) 
t=2 
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where S(o 5) = the initial proportion of patients developing lung cancer within the 
first year and i>1 
10 7 Appendix II Sample size 
A method to calculate the required number of patients in a bi-armed randomized 
trial is described by Halperin et al (1968) For a certain significance α and power 1-
β, the number N of patients in each trial arm is based on the difference between 
simple proportions p1 and p2 (e g the 5-year survival) in each trial arm 
м
 ( ZaV [2P(1 - P)] + ZßV [p1(1-p1) + p2(1-p2)] )2 
Ν
 = ' (й~Гр2]2 ( A 1 ) 
Ζ
α
 = Normal deviate for the two-tailed significance α of 0 05 = 1 96 
Ζρ = Normal deviate for the one-tailed 1-power β of 0 10 = 1 28 
p1 = Proportion in study arm 1 
p2 = Proportion in study arm 2 
P = 0 5(p1+p2) 
The Halperin method is a simple equation to give a rough estimate of the required 
numbers However, it disregards two important aspects of most cancer clinical trials 
(1) In follow-up studies one usually compares whole survival curves, rather than 
single proportions In general less patients are required to detect differences by 
comparing the survival curves than by single proportions In section 1 we give 
a method to calculate the required patient numbers for differences in survival 
curves predicted by the Markov model, starting with N patients in each arm 
(2) Although a clinical trial is usually analysed as a cohort study after a certain time 
of follow-up, the eventual number of patients at risk depends both on the 
number of patients for randomization each period (usually a year) and on the 
time during which new patients can be rendered into the study The longer the 
duration of randomization and follow-up, the less patients are required for 
randomization each period In section 2 we give a method to calculate the 
required number of new patients for randomization per period based on the 
Markov probability distribution after a certain period of randomization and 
follow-up 
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Section 1: Required numbers in a simple cohort study 
The Markov model, as described in this paper, predicts the actuarial survival curve 
of a simple cohort starting with N patients. Analogously to the logrank statistic 
commonly used for comparing actuarial survival curves [Mantel, 1966], we can 
calculate and compare the average mortality rates ρ of each survival curve for a 
follow-up of Τ years: 
where ηγ denotes the number of transitions (=deaths) and N j the number of 
potential transitions (=total number of patients at risk) during period T. Since more 
patients are at risk during the early years of follow-up than during later years, the 
mortality rates of those early years have a correspondingly greater weight in the 
calculation of the average mortality rate. The number of patients at risk for year t is: 
Nt = pt-i (ALIVE) · N (A.3) 
where pt-i(ALiVE) denotes the Markov probability of being ALIVE at time = t-1. For 
follow-up time T, the total number of patients at risk is: 
τ 
Ντ= £ pt-i(ALIVE) · Ν (A.4) 
t=-1 
The number of deaths nt in year = t is: 
nt = Pt(ALIVE^DEAD) · Νχ (A.5) 
where pt(ALiVE-DEAD) denotes the transition probability (= mortality risk) of year = t. 
The total number of deaths during period Τ is: 
nr = £ Pt(ALIVE-DEAD)· N (A.6a) 
t-1 
= PT(DEAD) · N (A. 6b) 
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where PT(DEAD) denotes the Markov probability of being dead after Τ years. 
Substituting equations (A.4) and (A.6) in equation (A.2) yields the average mortality 
rate ρ of a Markov survival curve: 
Ρ =NT T - у *
1
— ^ - tA.7) 
£ Pt-1 (ALIVE) 
t=1 
Substituting the average mortality rates p1 and p2 drawn from the Markov survival 
curves of trial arm 1 and 2 in equation (A.1) now yields М-р Substituting Νγ thus 
obtained from equation (A.1) in equation (A.4), yields the required number of 
patients N in each arm in a trial lasting Τ years: 
N = N T eg. (A.1) 
τ τ 
£ pt-1 (ALIVE) £ Pt-1 (ALIVE) 
t-1 t=1 
( ZgV [2P(1 -TT] + ZpV [pIQ-pp + р2(1-^2Л ) 2 
=
 J1
 j (Α. 8) 
(pi - ρ2) 2 ¿ Pt-1 (ALIVE) 
t-1 
Section 2: Yearly required numbers in an RCT 
In a randomized clinical trial new patients are yearly rendered into the study. Let us 
presume a trial with a follow-up of Τ years during which every year R new patients 
are rendered into each trial arm. In analogy to section 1, R is calculated based on 
the average mortality rates p1 and p2 for arm 1 and 2 respectively, as predicted by 
the Markov model. 
A trial in which every year new patients are entered during several years, can 
be seen as the cumulation of a cohort followed one year + another cohort followed 
two years + another followed three years etc.. Then, for a follow-up period of Τ 
years, the total number of patients at risk can be calculated in analogy to equation 
(A.4): 
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Τ 
Ντ = £ (T-t+1) · pt-1 (ALIVE) · R (A.9) 
t=1 
In analogy to equation (A.6b) the total number of death is: 
τ 
ПТ = Σ pr(DEAD)«R (Α. 10) 
t=1 
Substituting equations (A.9) and (A. 10) in equation (A.2), yields the average 
mortality rate of a Markov survival curve with new patients for randomization each 
year during Τ years of follow-up: 
τ 
^ PT(DEAD) 
ПТ t - 1 /A «IX 
Ρ =ñi =^ (A.11) 
Σ (T-t+1) pt-1 (ALIVE) 
t=1 
Substituting the average mortality rates p1 and p2 for the Markov survival curves of 
trial arm 1 and 2 in equation (A. 1 ) now yields Ντ- Substituting equation (A. 1 ) for N j 
in equation (A.9), yields the required number of patients R in each arm in a trial 
lasting Τ years: 
R = ^ 
Τ 
Σ (T-t+1) · pt-1 (ALIVE) 
Τ 
Σ 
t=1 
eq. 
(T-t+1) 
(A.1) 
• Pt-1 (ALIVE) 
t-1 
=
 ( ZgV [2P(1 - Pfl + ZpVTpÏÏ1-p1) + ρ2(1-ρ2)Ί )2 
(p1 - p2)2¿ (T-t+1) PMÍALIVE) 
t -1 
Table 10.6 gives an example of the calculation of the number of patients yearly 
required in a bi-armed RCT for various durations of follow-up. 
Table 10 6 · Calculation of required patient numbers per year in a bi-armed randomized controlled trial for various duration of follow-up 
Duration 
of follow 
up 
(Years) 
0 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
15 
20 
S T A N D A R D 
Probability 
distribution 
PtlALIVE. 
DEAD) 
(1 00,0 00) 
1912,088) 
(831, 169) 
( 765, 235) 
(715,285) 
( 677, 323) 
(651.349) 
( 627. 373) 
( 604, 396) 
(581,419) 
( 557, 443) 
(415,585) 
( 263, 737) 
Sum of 
probabilities 
dead 
Ipt(DEAD) 
0 088 
0 257 
0 492 
0 777 
1 100 
1 449 
1 822 
2 218 
2.637 
3 079 
5 707 
9 096 
Sum of 
probabilities 
atnsk 
1 0 
2 912 
5 654 
9 163 
13 386 
18 286 
23 837 
30 015 
36 797 
44 161 
88 802 
143 790 
Average 
mortality 
rate 
Pi 
0 0883 
0 0884 
0 0870 
0 0848 
0 0821 
0 0792 
0 0764 
0 0739 
0 0717 
0 0697 
0 0643 
0.0633 
B R O N C H O S C O P Y 
Probability 
distribution 
PtlALIVE. 
DEAD) 
(1 00.0 00) 
(914,086) 
(839.161) 
( 778, 222) 
( 732. 268) 
( 698 302) 
( 673. 327) 
(651.349) 
( 628. 372) 
( 604. 396) 
(579,421) 
(431..569) 
( 273, 727) 
Sum of 
probabilities 
dead 
Zpt(DEAD) 
0 086 
0 247 
0 469 
0 737 
1 039 
1 365 
1 715 
2 087 
2 4B3 
2 904 
5 438 
8 763 
Sum of 
probabilities 
atnsk 
1 0 
2914 
5 667 
9 197 
13 461 
18 422 
24 056 
30 347 
37 257 
44 772 
90 490 
146 963 
Average 
mortality 
rate 
P2 
0 0860 
0 0849 
0 0828 
0 0801 
0 0772 
0 0741 
0 0713 
0 0688 
0 0666 
0 0649 
0 0601 
0 0596 
Mortality 
rate 
reduction 
p1-p2 
0 0023 
0 0035 
0 0042 
0 0047 
0 0049 
0 0051 
0 0051 
0 0051 
0 0051 
0 0048 
0 0042 
0 0037 
Required 
numbers 
atnsk 
NT 
315741 
135639 
92467 
71901 
64099 
57127 
55207 
53482 
51956 
57198 
69424 
88448 
Yearly 
numbers 
required 
inarm 1 
R1 
315741 
46579 
16354 
7847 
4788 
3124 
2316 
1781 
1412 
1295 
782 
615 
Yearly 
numbers 
required 
in arm 2 
R2 
315741 
46547 
16316 
7818 
4762 
3101 
2294 
1762 
1395 
1278 
767 
602 
Yearly 
numbers 
required 
in an RCT 
RI +R2 
631482 
93126 
32670 
15665 
9550 
6225 
4610 
3543 
2807 
2573 
1549 
1217 
** = Z(T-t+1)pt.l(ALIVE) 
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Practical notes 
If Decision Maker 6 0™ [Pauker et a l , 1988] is used to analyse the Markov model 
the average mortality rate ρ can be calculated as follows 
1 Define DUAL bindings The bindings for each state ALIVE is 
mulNIT = DUAL(0,m CYCLE) 
mulNCR = DUAL(0 m CYCMAX-m CYCLE) 
and for the DEAD state 
mulNIT = DUAL(0,0) 
mulNCR = DUAL(1,0) 
2 Follow-up time Τ = m CYCMAX 
3 A Cost-Based C-Ε Analysis yields 
τ 
£ (T-t+1) · pt-1 (ALIVE) = COST 
t-1 
τ 
£ PT(DEAD) = EFF 
t=1 
ρ = AVG C/E 
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11. Utility Assessment by Time Tradeoffs: A Delusive Deal1 
11.1 Abstract 
Torrance's time tradeoff (TTO) technique has been promoted as a reliable and valid 
method to assess numerical values (utilities) for health-related quality of life issues. 
In a TTO-test the utility of a certain health state is complementary to the proportion 
that a subject is willing to tradeoff from the length of life in a worse health state. The 
TTO-technique is based on the major assumption that the proportion traded off is 
the same for any length of life in the worse state. 
The assumption of proportionality was tested in 56 medical students and 9 
physicians making tradeoffs between the quality of speech and the quantity of life in 
the choice between radiotherapy and surgery for cancer of the vocal cords. In order 
to live with a better quality of speech, subjects were generally willing to tradeoff a 
considerable bigger proportion of the length of life when faced with a long life 
expectancy than when faced with a short life expectancy. This study shows a 
severe violation of the proportionality assumption (p<0.01), giving rise to doubts 
about the validity of the TTO technique for the assessment of utilities. 
11.2 Introduction 
Since improvement of the quality of life forms an important goal of clinical and 
community health care, the assessment of numerical values (utilities) for health-
related quality of life issues has become a major topic both in clinical decision 
making and health care planning [Pauker, 1987; Torrance, 1987]. Torrance's time 
tradeoff technique has been promoted as a reliable and valid method to assess 
numerical values, so-called utilities, for health related quality of life issues. The 
utility of a certain health-state is the relative value of that health-state compared with 
other, better and worse, health states. In the time tradeoff technique, the utility of a 
certain health state is assessed by asking a subject how much length of life in this 
health state (s)he is willing to sacrifice in order to live in a better health state for less 
lifetime [Torrance, 1972]. 
L.J.A. Stalpers, Α. L.M.Verbeek and W.A.J. Van Oaal. Conditionally accepted for publication in the 
Journal of Clinical Epidemiology 
142 The Time Tradeoff Test 
On a utility scale ranging from 0 0 for death to 1 0 for the best outcome B, the TTO 
test states that the utility U(a) of a certain health-state A which is worse than health 
state B, is the proportion of the minimal amount of years Y(b) a subject is willing to 
live in the better state compared with the (larger) amount of years Y(a) in the worse 
state 
U(a, = ^ Π] 
It is customary not to ask for the minimal numbers of years Y(b) directly, but to 
assess the complement, namely maximum number of life years a subject is willing 
to tradeoff, from a certain length of life in the worse state A to get a better health 
state B. 
Y(b) = Y(a) - TRADEOFF (in years) {2} 
For example, if a person is willing to tradeoff 5 from 25 years in the worse state to 
live a (shorter) life in the best state, the utility of the better state equals (25-5)/25 = 
0.8. 
A major assumption of the TTO is that tradeoffs are proportional, i.e.the 
_,. Y(a) - TRADEOFF .
 it_ , , _ ^ t , r w proportion - ^ — ν l s the same for any length of life Y(a) in a worse state T(a) 
to be traded off [Weinstein and Fineberg, 1980]. For instance, if a subject is willing 
to tradeoff 5 from 25 years for a better health-state, proportionality requires that the 
subject is willing to tradeoff the same proportion (=0.2) from any length of life in the 
worse state, say, 2 years from 10 years or 1 year from 5 years. 
In a 1981 paper of McNeil et al., the TTO-techmque was used to calculate 
utilities for the quality of speech in the choice between radiotherapy and surgery for 
laryngeal cancer [McNeil et al., 1981]. Based on this paper, we used the time 
tradeoff technique in medical students and general physicians to test whether 
proportionality of tradeoffs holds for varying lengths of life. 
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11.3 Population and Methods 
(a) The Clinical Problem 
Cancer of the vocal cords can be treated both by surgery and by radiotherapy 
Survival rates following surgery are generally higher than following radiotherapy, 
although the differences may be small [Stalpers et al., 1987]. Successful 
radiotherapy generally results in a moderately hoarse but natural speech. 
Following surgical resection of the voice box, a patient has to learn an artificial 
speech. As the differences in survival rates (or the average lengths of life) between 
surgery and radiotherapy are only small, a definite choice between radiotherapy 
and surgery may depend on the value attached to quality of speech. 
(b) Population 
Two groups of 'medically experienced' subjects were asked to participate in an 
experiment to assess numerical values for the quality of speech in the choice 
between radiotherapy and surgery m cancer of the vocal cords The first group 
consisted of 56 students of the Faculty of Public Health, age ranging from 18-36 
years, mean=21 years, sex ratio male:female = 14:42. The second group consisted 
of 9 general physicians of the Nijmegen University Institute of General Physicians, 
age ranging from 39-52 years, mean=45 years, all male. 
(c) The Time Tradeoff Interview 
The interview began with a description of the goals and the hazards both of 
radiotherapy and of surgery for cancer of the vocal cords and a demonstration of a 
moderately hoarse 'natural speech' and of a so-called esophageal or 'artificial' 
speech. The subjects were asked to imagine they had cancer of the vocal cords 
themselves and that they had to make a choice between radiotherapy and surgery. 
It was suggested that the test was designed to help patients with cancer of the vocal 
cords to facilitate a treatment choice. 
The actual test consisted of six items. In each item the subject had to assess 
the maximum number of life years (s)he was willing to sacrifice from a given life 
expectancy with an artificial speech in order to live with a natural speech. See for 
instance the first item: 
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If you receive surgery you will have 25 life years with an artificial 
speech. How many of these life years are you willing to sacrifice to 
live with a natural speech following radiotherapy? 
In the six successive items the presumed length of life with an artificial speech was 
diminished from 25 to 20, 15, 10, 5 and 2 years. It was explicitly stated that it was 
also possible to tradeoff parts of a year or to express the tradeoff in months. 
The test was concluded with a short questionnaire on some personal 
characteristics (sex, age, marital state, education, profession) and two questions 
investigating the ability to imagine having cancer and the ability to deal with quality 
of life quantitatively. These questions could be answered on a five-point scale: (a) 
no difficulty, (b) slight problems, (c) moderate problems, (c) severe problems and 
(d) practically impossible. 
The TTO-test was repeated three weeks later for 15 medical students and 
three months later for 8 physicians. 
(d) Data Analysis 
Pearson's product-moment correlation coefficient г was used to calculate test-retest 
correlations. Linear regression statistics were used to test differences in the 
tradeoffs among the groups (sex, age, profession, marital state) and to test the 
proportionality assumption. Presuming a linear model of the utility U(a) of artificial 
speech on the length of life L, the condition of proportional tradeoffs holds if in the 
regression equation U(a) = с + ßL the coefficient ß=0 so that с is a constant. Chi-
square statistics were used to test differences in the answers of the two questions 
among the groups. 
11.4 Results 
On a utility scale ranging from 0.0 for death to 1.0 for a health state with a natural 
speech, figure 11.1 shows the utility of artificial speech as a function of the 
presumed length of life with artificial speech. 
The broken horizontal line gives the theoretically expected graph for strict 
proportional tradeoffs for any length of life between 0 and 25 years. The solid line 
interpolates the mean utility in the 64 subjects, showing a diminishing utility 
attached to artificial speech for increasing life-years (ß= -0.003). 
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Utility Of 1.0 
Artificial 
Speech 
τ г 
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Length of Life (Years) 
Figure 11.1· The utility of artificial speech as a function of the presumed length of 
life with this artificial speech. The broken line denotes the situation in which 
tradeoffs are proportional to length of life. The solid line denotes the mean utility 
values (+SD) in 56 medical students and 9 general physicians. 
Table 11.1 · The ability to imagine to have cancer of the vocal cords and the 
ability to deal with the quality of life quantitatively in 65 subjects. 
Ability to imagine 
having cancer of 
the vocal cords 
Ability to deal with 
quality of life 
quantitatively 
(a) No problems 3 (4.6%) 2 (3.0%) 
(b) Mild problems 5 (7.7%) 5 (7.7%) 
(c) Moderate 14 (21.5%) 10 (15 4%) 
(d) Severe problems 33 (50.8%) 38 (58.4%) 
(e) Practically impossible 10 (15.4%) 10 (15 4%) 
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The graph shows a significant deviation from the proportionality hypothesis (P = 
0 0035) No significant differences were seen between groups following 
stratification by sex, age, marital state or professional occupation (student vs 
physician), neither with respect to the average utilities nor to the extent that 
proportionality was violated In 23 retested subjects, the test-retest correlation 
coefficient r for the six items ranged from 0 63 to 0 85 with P-values < 0 05 
Table 11 1 summarizes the answers of the two questions about the ability to 
imagine having cancer of the vocal cords and the ability to deal with quality of life 
quantitatively A chi-square comparison did not demonstrate any significant 
differences for sex, age, marital state or profession, with respect to the two 
questions 
11.5 Discussion 
This study confirms the findings of earlier studies that the TTO-techmque produces 
relatively high test-retest reliability correlations (r= 0 63-0 85) [Torrance, 1987, 
Mohide et al , 1988, Churchill et al , 1987] However, as shown m table 111, almost 
all subjects had at least moderate problems dealing with quality of life quantitatively 
and imagining having cancer themselves The latter despite the medical 
background of the subjects In a wider sense, this observation may stress the 
limited value of non-patient judgements about quality of life issues for decision 
making both in clinical practise and in health-care politics 
This study could not identify differences in tradeoffs between the different 
groups, nor for sex. age, marital state or professional occupation The latter is most 
remarkable as the physician group was on the average 25 years older than the 
student group Both in the paper of McNeil and more recently in the paper of 
Mohide it is considered important to change the scale for years of future life 
according to the subject's age or life-expectancy [McNeil et al , 1981, Mohide et al , 
1988] This approach may enhance the feeling that the test resembles a subject's 
real life situation better However, our results suggest that such an approach is not 
necessary since we found no significant differences in tradeoffs among the young 
student group and the older physician group 
The most important observation of this study is that the proportionality 
assumption was violated (P<0 01) The subjects were willing to tradeoff a 
considerably bigger proportion of the length of life when faced with a long length of 
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life than when faced with a shorter length of life in order to live with a better quality 
of speech For example, if the length of life with artificial speech was 25 years, the 
average utility of artificial speech would be less than 0 8, but when faced with only 5 
years length of life, the same utility of artificial speech was almost 0 9 The 
observation that tradeoffs are not proportional can be hazardous if the TTO-utilities 
are used for real-life decision making Then it is important to realize that a decision 
may depend on the length of life used for tradeoff in a TTO-test, and not merely on 
the 'real' utility For instance, if the decision threshold for the utility of artificial 
speech is 0 85, -ι e everyone with a lower utility will be advised to receive 
radiotherapy, everyone with a higher utility will be advised to have surgery 
[Stalpers et al , 1986, Stalpers et al , 1988]-, relatively more patients will have 
radiotherapy if we use a TTO-test presuming a long length of life, and relatively 
more patients will undergo surgery if we use a test with a short length of life for 
tradeoff A potential bias might have been introduced by the fact that we did not 
present the tradeoff test items at random but, instead, by subsequential decreasing 
the length of life It is most likely that this bias leads to conservative or 'anchoring' 
results [Tversky & Kahneman, 1974], ι e , a subject tends to answer an item similarly 
to the previous item in order to seem consistent Then, however, it is the more 
striking that the tradeoffs are not proportional 
The most likely explanation for violation of the proportionality presumption is 
that not all life years have an equal value, ι e near years are valued relatively 
higher than distant life years This explanation may be so obvious that, as far as we 
know, it has never been tested before Therefore, in a tradeoff between quality and 
quantity of life, we have to assume an interaction of two separate utilities A utility of 
the quality of life and a utility of the length of life As long as we have no testable 
assumptions about how these two utilities interact, it will not be possible to separate 
them A probable solution for this problem may be found by using so-called conjoint 
measurement techniques [Luce & Tukey, 1964] In conjoint measurement three 
utility functions are made explicit One on the quality of life, one on the length of life 
and one on the combination Presuming that the utility function of the combination 
of the quality and length of life results from a simple additive effect of the two 
separate utility functions, a so-called additive conjoint measurement test was 
developed to infer the three utility functions from an individually assessed 
preference ranking on combinations of a quality and a quantity of life [Stalpers et 
a l , 1990] The early experiences with additive conjoint measurement, applied to the 
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treatment choice in laryngeal cancer, suggest that it may be a promising alternative 
for Torrance's TTO-technique [Stalpers et al., 1988]. Thus establishing tradeoffs by 
additive conjoint measurement, we hope to meet the appeal that Mohide recently 
made to other researchers 'to apply, and to help develop further, this promising 
approach" [Mohide et al., 1988]. 
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12. Utility assessment by additive conjoint measurement 
for clinical decision making1 
12 1 Summary 
Utility theory enables the subjective evaluation of health states and life-years of 
medical treatments Utility theory assumes (a) that loss in one attribute, e g life-
years, can be compensated by gam in another attribute, e g quality of life, (b) that 
both losses and gams may be quantified, expressed as utilities in an additive 
model, and (c) that the treatment with the highest subjective expected utility (EU) is 
preferred 
In additive conjoint measurement (ACM) tradeoffs between life-years and 
quality of life can be derived from an individual preference ranking on pairs each 
pair consisting of a combination of life-years and quality of life ACM is based on the 
principle that the utility UL,Q for such a combination is an additive effect of separate 
utilities for life-years UL and quality of life UQ 
U L . Q = U L + U Q 
The model holds if the preference ranking on pairs meets at least three conditions 
(a) transitivity, (b) independence of attributes, and (c) cancellation 
The preference ranking of combinations is assessed by having the patient 
make a series of choices in pairwise combinations Thus one can assess the extent 
of transitivity 
The method of measuring utilities will be illustrated by an example of a 
respondent who has to choose between radiotherapy and surgery for the treatment 
of laryngeal cancer Radiotherapy gives a better quality of voice but also a shorter 
life-expectation than surgery 
12.2 Introduction 
DECISION MAKING INVOLVING SURVIVAL AND QUALITY OF LIFE 
Survival rates, cure rates and life-years are among the major criteria by which 
treatments of patients with cancer are evaluated In recent years, some effective 
methods have been developed to combine age-specific and cause-specific 
1
 L J A Stalpers, A L M Verbeek, WA J van Daal For publication in the Journal of Clinical 
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mortality rates in predicting the prognosis in individual patients. These methods, 
such as the Markov model of medical prognosis, can generate an accurate 
description of the course of disease in individual patients and have effectively been 
applied to individual decision making [Beck & Pauker, 1983]. 
Few physicians with experience in oncology will cling to survival and cure 
rates as the only criteria in choosing between alternative cancer treatments. 
However, many physicians will hold to these rates as the main criteria of treatment 
success, since convenient and valid methods to measure quality of life for decision 
analytical purposes are still in an experimental phase. 
Most of the current methods for quality of life measurement in cancer 
treatment, such as the Karnofsky Performance Status Scale, are predominantly 
descriptive and do not provide norms for guiding clinical decision making 
[Karnofsky et al., 1948; Mor et al., 1984; De Haes & Van Knippenberg, 1985]. 
Norms for the quality of life may serve for comparison with other attributes 
such as survival rate, cure rate or life-expectancy. The quantitative assessment of 
qualitative properties on a common scale is denoted utility assessment. The utility 
approach to medical decision making is based on the utility theory as described by 
Von Neumann and Morgenstern (1953). This theory states that individuals should 
assign (or act as if they assign) a utility to each possible outcome and faced with a 
set of alternatives, choose the one that yields the highest mathematical utility 
expectation [Hershey and Baron, 1987]. Utilities can be inferred from choices in 
simple cases as assessed In a simple test. These utilities can be used in the 
analysis of complex clinical cases. Utility assessment is based on two "tradeoff" 
principles: 
(1). Compensation: A qualitative loss on one aspect of life can be compensated by 
a qualitative gain on another attribute. 
(2). Quantification: Losses and gains can be expressed quantitatively. 
The basic reference gamble and the time tradeoff technique have been used to 
asses utilities for clinical decision making [Pllskin et al., 1980; Torrance, 1987; 
McNeil et al., 1978; McNeil, 1981]. Practical and conceptual shortcomings of these 
methods actuate the search for alternative measurement techniques [Llwellyn-
Thomas et al., 1982; Stalpers et al., 1990b]. 
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In the present paper we describe additive conjoint measurement in the assessment 
of utilities both for the quality and for the quantity of life It is demonstrated how utili-
ties are assessed in individual patients choosing between radiotherapy and 
surgery for glottic cancer, and how these utilities are applied in a Markov model of 
medical prognosis in evaluating treatment choices 
CLINICAL PROBLEM GLOTTIC CANCER 
Patients with cancer of the vocal cords can be treated either by radiotherapy or by 
surgery Radiotherapy generally consists of a course of six weeks irradiation for 
which a patient has to come to the treatment centre daily Surgery consists of a 
resection of the involved vocal cord in patients with small tumours or complete 
resection of the voice box and surrounding structures in more advanced stages In 
terms of cure and survival, surgery gives better results than radiotherapy, especially 
m more advanced stages of the disease [Stalpers et al , 1987] In general the qual-
ity of speech is better after radiotherapy than after surgery [Dickens & Cassisi, 
1983] After successful radiotherapy, the quality of speech may range from a near 
normal speech to severe hoarseness, generally leaving a slightly 'cracking' voice 
After surgical resection of the voice box, the quality of speech is severely impaired, 
and a patient has to learn some form of artificial speech Most of these patients 
manage to learn a so-called oesophageal speech, whereby speech is produced by 
belching swallowed air Some patients do not manage to learn an oesophageal 
speech, and may find relief by a so-called electronic larynx This electronic device 
transforms the soundless articulation of the oral cavity to a somewhat metallic 
sounding speech A minority of patients stays mute and has to communicate by 
writing and gesturing 
In a choice between radiotherapy and surgery for cancer of the vocal cords, it 
may be obvious to consider both the quality of speech and the survival or life-years 
as valued by the individual patient [McNeil et a l , 1981] 
In the first part of this paper we describe the method of utility assessment based on 
additive conjoint measurement (§12 3) Next we will demonstrate the use of 
"additive" utilities in a decision analysis using a Markov model to simulate the 
course of disease in patients with glottic cancer (§12 4) 
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12 3 Additive Conjoint Measurement (ACM) 
Principles 
In additive conjoint measurement (ACM) tradeoffs between life-years and quality of 
life are derived from an individual preference ranking on pairs of alternatives Each 
pair consists of a combination of life-years (L) and quality of life (Q) It is assumed 
that the utility UL Q for such a combination is an additive effect of the separate utili­
ties for life-years UL and quality of life UQ [Luce & Tukey, 1964] 
UL,Q = UL + U Q (1) 
UL,Q . UL and UQ can be inferred from a preference ranking on pairs of L and Q if at 
least three conditions are satisfied 
(1 ) Transitivity of preferences If for any pairs A,B and C, you prefer pair A to B, and 
В to C, then you prefer A to С The opposite (or violation) of transitivity is called 
circularity For instance If you prefer pair A to В, В to С and, С to A, there is a 
cycle in the preference ranking on the three elements А,В and С In a 
preference ranking on the pairs A,B,C Z, both the number of cycles and the 
number of pairs in each cycle contribute to the severity of intransitivity 
[Bezembinder, 1981] 
(2) Independence of attributes The utility of one attribute is not determined by the 
utility of the co-attribute For instance Let q, r, s denote the levels on attribute 
Q and let I, m, η denote the levels on attribute L If you prefer the pair (q,l) to 
pair (r,l), you prefer q to r for any other level on L Similarly, if you prefer (q,l) to 
(q,m) then you prefer I to m for any level on Q 
(3) Double cancellation of preferences Let mute, oesophageal and normal denote 
three levels on quality of speech Q, and let 3, 6 and 9 years denote three levels 
on life-expectancy L Figure 12 1 gives the pairs of (Q,L) ordered in a 3x3 
matrix If you prefer the pair (n,6) to (о.З) (left panel) and the pair (o,9) to (m,6) 
(middle panel), then you prefer the pair (n,9) to (m,3) (right panel) If the 
condition of double cancellation is violated, there is no solution that yields 
additive utility functions from the preference ranking With q>3 and l>3 the 
number of levels in Q and L respectively, the condition of double cancellation 
goes for any 3x3 submatrix resulting from the original qxl matrix by picking 
three levels on Q and three levels on L 
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If: and if: then: 
L 
Q 
mute 
oesoph. 
normal 
(years) 
3 6 
m,3 m,6 
o,3 o,6 
n,3 n,6 
9 
m,9 
o,9 
n,9 
3 
m,3 
o,3 
n,3 
6 9 
m,6 m,9 
^ч 
o,6 0,9 
n,6 n,9 
3 
m,3 
o,3 
n,3 
6 
m,6 
\ 
n,6 
9 
m,9 
0,9 
n,9 
Figure 12.1 · 3x3 Matrix for the pairs of Q (mute, oesophageal speech and normal 
speech) and L (3, 6 and 9 years). 
Obtaining a preference ranking 
To obtain a preference ranking on pairs, we defined five different qualities and 
numbers of life-years. For the quality of speech: Normal speech (N), hoarseness 
(H), oesophageal speech (0), electronic-larynx speech (E) and muteness (M). For 
life-years: 3, 6, 9, 12 and 15 years. 
From five different qualities of speech and numbers of life-years, we can form 
25 pairs on Q and L. Figure 12.2 gives all 25 pairs in a 5x5 matrix (η χ m matrix). 
Q 3y 6y 9y 12y 15y 
Mute 
Electronic-larynx 
Oesophageal 
Hoarseness 
Normal 
M,3 
E,3 
0,3 
H,3 
N,3 
M,6 
E.6 
0,6 
H,6 
N,6 
M,9 
E,9 
0,9 
H,9 
N,9 
M,12 M,15 
E,12 E,15 
0,12 0,15 
H,12 H,15 
N,12 N,15 
Figure 12.2· 5x5 Matrix for the preference ranking on 
pairs of quality of speech and life-years. 
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For the different utilities of quality of speech UQ and life-years UL, we presume a 
strict preference ordering: 
U N > U H > U O > U E > U M (2a) 
and 
U15>U12>U9>U6>U3 (2b) 
Then, 3 years mute (M,3) is the least preferred pair (rank number 1) and 15 years 
normal speech (N,15) the most preferred (rank number 25). 
The preference ranking on pairs can be assessed by having the patient 
make a series of choices in pairwise combinations. For instance: 
Which do you prefer ? 
A. 9 Years with a normal speech or 
B. 12 Years with an oesophageal speech. 
For five qualities and numbers of life-years, there are ( 2 ) = 300 different pairwise 
comparisons. However, since in (2a) and (2b) we assumed strict preference orders 
of the utilities, there are 100 comparisons which will be a dilemma to the patient 
and are therefore non-trivial or 'hard' choices. In the ACM-test we ask to assess the 
preference on each of the 100 dilemmas1. The choices on all pairwise comparisons 
yield the ranknumber. If, for instance, one pair has been preferred 10 times over the 
other 24 pairs, the rank number of that pair is 10. If all rank numbers are different 
(from 0 to 24), the preference ranking is transitive. If the preference ranking further 
satisfies "independence" and "cancellation", there generally is a perfect additive 
solution to the preference ranking. Several algorithms are available to find 
representative utility functions UQ and UL assuming additivity. We used the 
For q and / levels on each either attribute Q and U the number of unique dilemmas is: 
q'l'(q-1)(l-1) ,3, 
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computer programme ORDMET3 to find these additive utilities for the quality of 
speech and for life-years [Roskam, 1987]. 
Example of ACM 
A 50-year old speech instructor, professionally involved with patients treated for 
laryngeal cancer, was asked to imagine having glottic cancer. To facilitate a choice 
between radiotherapy and surgery, we asked her to perform the ACM test. The test 
was performed three times with weekly intervals. Figure 12.3a gives the preference 
ranking ordered in a 5x5 matrix. The cell entries in the matrix represent the rank 
number of a pair of quality of speech (Q) and life-years (L) 
3y 6y 9y 12y 15y 
Mute 
Electronic larynx 
Oesophageal 
Hoarseness 
Normal 
0 
1 
2 
3 
5 
4 
6 
7 
9 
10 
8 
11 
12 
14 
18 
13 
16 
17 
19 
22 
15 
20 
21 
23 
24 
Figure 12.3a · Data matnx for the preference ranking on pairs of quality of speech 
and life-years as assessed by a 50-year old speech instructor ranking from 0 for the 
least preferred pair (3 years mute) to 24 for the most preferred (15 years normal 
speech). 
For this data matrix, ORDMET3 results in several possible utilities UQ, UL and UQ.L 
The average is given in figure 12.3b. The solution matrix represents a tight additive 
transformation of the data matrix 
• It is a transformation as the order of the data matrix is identical to the order of the 
solution matrix. For example: The utility of 12 years electronic-larynx speech 
being 1.04, ranks as number 16 between 0.0 for 3 years mute and 1.43 for 15 
years normal speech. 
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• It is additive, as the utility of the pair UL Q IS expressed as a simple addition of the 
mutual independent utilities U Q + UL For example The utility of 12 years 
electronic-larynx speech is 0 18 + 0 86 = 1 04 
• It is tighi as only marginal variations within the utilities UQ and UL preserve addi-
tivity For example, if we decrease the utility of hoarseness with only 0 02 points, 
the utility of 15 years hoarseness will equally dimmish from 1 30 to 1 28, and will 
hence become lower than the utility of 12 years normal speech being 1 29 Then, 
the original preference ranking is not preserved anymore in the solution matrix 
L 3yr 6yr 9yr 12yr 15yr 
UL 0 00 0 37 0 64 0 86 1 00 
Q UQ 
Mute 
Electronic-larynx 
Oesophageal 
Hoarseness 
Normal 
0 00 
0 18 
0 20 
0 30 
0 43 
0 00 
0 18 
0 20 
0 30 
0 43 
0 37 
0 55 
0 57 
0 67 
0 80 
0 64 
0 82 
0 84 
0 94 
1 07 
0 86 
1 04 
1 06 
1 16 
1 29 
1 00 
1 18 
1 20 
1 30 
1 43 
Figure 12 3b · Solution matrix for the additive utilities UQ and UL 
to the data from figure 12 3a 
Interpretation of additive utilities 
The additive utilities are close to and can, for practical purposes, be used as values 
on an interval scale [Roskam, 1968, ρ 17-18] The interval scales of the utilities L 
and Q have equal unities on a utility scale ranging from minus infinity to plus infinity 
For practical reasons only, figure 12 3b gives a solution matrix normalized between 
0 00 and 1 00 Since the scales are close to interval scales, only those 
transformations are allowed that preserve the ratios of intervals For instance, the 
ratio of the interval between the utilities of 15 and 12 life-years, ι e. 1 00 - 0 86 = 
0 14, to the interval between the utilities of oesophageal speech and hoarseness, 
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ι e 0 30 - 0 20 = 0 10, this ratio being 0 14/0 1 0 = 1 4 , has to be preserved under 
the transformation of the utility scales Based on these intervals, we can say that the 
difference between muteness and electronic-larynx, being 0 18, is nine times the 
difference between electronic-larynx speech and oesophageal speech, being 0 02 
In calculating the expected utility of a treatment, additive utilities can be best 
interpreted in terms of gaming points per year and gaming extra points for living 
with a better quality of speech than being mute during that period For instance 
Living 9 years will gam you 0 64 utilities Using an OESOPHAGEAL speech during 
this period instead of being MUTE, will give 0 20 extra points for the quality of 
speech, resulting m 0 64 + 0 20 = 0 84 utilities for the combination 
We based the test on 3-year intervals, using numbers of life-years of 3 and 
15 years as minimum and maximum respectively To allow extrapolation for more or 
less life-years, we approximated the utilities of life-years by a logantmic function 
UL = 0 63ln(L)-0 72 (4) 
As shown in figure 12 4, the data correlates well with the logantmic function (r 
0 99) 
Figure 12 4 · Additive utility 
function of life years UL for a 
speech instructor aged 50 
10 15 20 25 
Life expectancy (years) 
Now we can calculate the utility of any course of disease in patients with glottic 
cancer using the individually assessed utilities of quality of speech and quality of 
life 
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RADIOTHERAPY RECURRENCE DEATH 
HOARSE OESOPHAGEAL SPEECH 
1 
Figure 12 5 · One of many possible courses of disease for a patient with glottic 
cancer 
Figure 12 5 gives one of many possible courses of disease for a patient receiving 
radiotherapy for glottic cancer and remaining hoarse for the next two years Then 
she has a tumour recurrence, receives salvage laryngectomy and remains with an 
oesophageal speech until she dies three years later For the speech instructor, the 
utility of this specific course of disease is the sum of the utility of life-years 
UL=0 63ln(5)-0 72 = 0 29 
and the utility of the quality of speech 
UQ = | UH + 1 Uo = g x 0 30 + g χ 0 20 = 0 24 
resulting in the utility of the combination 
UQ,L = UL + UQ = 0 29 + 0 24 = 0 53 
If we see the outcome of a treatment (radiotherapy or surgery) as the outcome of a 
stochastic process, the Von Neuman-Morgenstern theory states that the expected 
utility of a treatment EU is the sum of products of the probability PQ І of a certain 
combinations (Q,L) and its utility UQti 
EU = 
 У l (PQ L · UQ.L) 
0^1 L=1 
(5) 
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A Markov model can be used to simulate all possible courses of disease, to calcu­
late its utilities and to determine the contribution of each course to the expected util­
ity of a treatment 
12 4 Decision Analysis: Treatment of Glottic Cancer 
In this paragraph we will demonstrate the use of "additive" utilities in a Markov 
decision tree analysis for the choice between radiotherapy and surgery for glottic 
carcinoma, considering both the time varying mortality risks for each patient and the 
utilities for the quality of speech and for life-years as individually assessed by addi­
tive conjoint measurement 
DATA TREATMENT RESULTS OF GLOTTIC CANCER 
Table 12 1 · Summary of a review of the literature on treatment results following 
radiotherapy and surgery for glottic carcinoma [Stalpers et al , 1987] 
Radiotherapy Surgery 
Mean* 
5-Year survival rates 
Ti 
T2 
тз 
T4 
79% 
68% 
48% 
45% 
Range 
73-86% 
46-78% 
36-67% 
25-75% 
5-Year disease-free survival rates 
T1 
T2 
тз 
T4 
72% 
63% 
30% 
27% 
72-73% 
37-72% 
26-38% 
25-33% 
Salvage rates following tumour recurrence 
T1 
T2 
T3 
T4 
72% 
5 1 % 
37% 
8% 
Mean 
80% 
66% 
75% 
54% 
95% 
64% 
79% 
54% 
65% 
27% 
26% 
0% 
Range 
76-81% 
59-72% 
59-79% 
50-67% 
NP 
59-81% 
NP 
NP 
Ν Ρ - not published in the literature * Mean - Mean of published reports 
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The Literature: In a review paper on treatment results of radiotherapy and surgery 
for glottic carcinoma, we described results in terms of 5-year survival, 5-year 
disease-free survival and salvage rate [Stalpers et al., 1987]. Table 12.1 lists the 
most relevant data by mode of treatment and by T-classification according to the 
TNM-classification of malignant tumours [UICC. 1978; AJC, 1978]. 
Although most investigators consider the quality of speech an important 
result of treatment of glottic carcinoma, only few studies report figures on treatment 
outcomes in terms of speech quality. Table 12.2 summarizes an overview of the 
literature over the past twenty years. 
Table 12.2 · Quality of speech following radiotherapy and surgery of glottic cancer 
as reported since 1968. 
Study 
Following radiotherapy: NORMAL HOARSE 
Stoicheff, 1975 101/227 = .445 126/227 =.555 
Karimetal., 1983 84/110= .764 26/110= .236 
Harwood and Rawlinson, 1983 .79-.93 
Following laryngectomy: 
OESOPHAGEAL ELECTRO MUTE 
King et al., 1968 37/88=426 20/88 = .227 31/88= .352 
De Bleuie and Damsté, .63-.84 .16 .05-.11 
1972 
Retrospective Study: Data from a retrospective study in 188 patients with T i -
T2N0M0 glottic carcinoma were used to model the instantaneous recurrence risk as 
a time-dependent probability. All patients were treated by primary radiotherapy 
between 1979-1987 at the Institute for Radiotherapy of the Nijmegen University 
Hospital, The Netherlands. Population characteristics including criteria and treat-
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ment methods are described elsewhere [Van den Ende et al., 1988]. Figure 12.6 
gives the actuarial disease-free survival curves stratified by T-classif¡cation. The 5-
year disease-free survival rates are 75% for Τι tumours and 56% for T2 tumours. 
Figure 12.7 gives the instantaneous recurrence risks per year. As shown, 
recurrence risks are highest in the first 2-3 years and become virtually zero after 4-6 
years following radiotherapy. 
ra 0 4 
0 2 
0 0 
T1N0M0 
T2N0M0 
7 8 
Year 
Figure 12.6 · Disease-free sur­
vival following radiotherapy in 
T1-T2N0M0 glottic carcinoma. 
о 
к. 
α. 
η 
Τ2Ν0Μ0 
Figure 12.7 · Annual tumour 
recurrence rate PREC per year 
following radiotherapy for 7V 
T2N0M0 glottic carcinoma. 
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The data of figure 12.7 were used to approximate the time-dependent model for the 
annual recurrence rate PREC· Best fits were obtained by a simple linear decreasing 
model on time: 
PREC = a - (b)(Year) per year (6) 
where a is the initial or 'zero-time' rate and b the linear regression coefficient. To 
avoid negative recurrence risk, we presumed that Prec = 0 for all Prec s 0. For Τι 
and Тг were found the best linear fits for: 
Ti : a = 0.096, b = 0.0134, Pearson's correlation = -0.68 
Тг : a = 0.39, b = 0.1, Pearson's correlation = -0.85. 
METHOD: STRUCTURE OF THE MARKOV MODEL 
A Markov model of prognosis with time-varying probabilities and time-varying utili­
ties was used to analyse the decision between radiotherapy and surgery for glottic 
carcinoma in the context of the patient's age, tumour-stage and value judgements 
(utilities) of the quality of speech and the quantity of life. 
We cast the problem in the framework of a Markov process to account for (1) 
decreasing tumour recurrence risks following radiotherapy, (2) increasing mortality 
rates for aging, (3) changes in the probability distribution of health states and (4) 
changing utilities attached to life years. 
To make the model tractable, a number of assumptions was made: 
1. Within each T-class, consecutive risks are mutually independent: A higher recur­
rence rate does not imply a lower or higher salvage rate. 
2. The tumour recurrence rate reaches and remains zero after five years. Hence 
PREC = a - (a/5)(Year) per year (6a) 
3. Following successful salvage treatment for a tumour recurrence, the risk of a 
second recurrence is assumed to be equal to the risk of a first recurrence. 
Figure 12.8 shows the decision tree representing the chance events in the first year 
following treatment for glottic carcinoma. 
The Markov model is based on six transition states, in decreasing order of 
preference: Life with NORMAL speech, HOARSE speech, OESOPHAGEAL speech, 
ELECTRONIC larynx speech, MUTE or DEAD. 
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tumour 
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normal 
speech 
NORMAL 
stay 
well 
hoarse 
speech 
HOARSE 
RADIOTHERAPY 
О 
о 
salvage 
oesophageal 
speech OESOPHAGEAL 
о 
electronic 
larynx 
recurrence 
0 
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mute 
MUTE 
death from 
other causes 
no salvage 
DEAD 
DEAD 
glottic 
cancer 
oesophageal 
speech 
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stay 
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<t 
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OESOPHAGEAL 
ELECTRONIC 
mute 
MUTE 
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speech 
о 
о 
salvage 
OESOPHAGEAL 
О 
electronic 
larynx 
SURGERY 
recurrence Ó 
ELECTRONIC 
mute 
MUTE 
death from 
other causes 
no salvage 
DEAD 
DEAD 
Figure 12.8 · Decision tree representing the chance events in the 
first year following primary treatment of glottic cancer. 
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Table 12 3 · Summary of the parameters used in the analysis, 
based on tables 1 and 2 (minimum and maximum 
values between brackets) 
Description Value 
(1) Recurrence rate pREC = a - (a/5)YEAR per year* 
Ti 
T2 
Тз 
T4 
(2) Salvage rate 
Ti 
T2 
Тз 
T4 
a Radiotherapy 
0 156(0 150-0 156) 
0 216(0 156-0 428) 
0 503(0 419-0 551) 
0 538 (0 470-0 563) 
Radiotherapy 
PSALV 
0 72 
0 51 
0 37 (±0 1) 
0 08 
(3) Probability of quality of speech 
Following radiotherapy 
Normal PNORMAL 
Hoarse PHOARSE 
Following surgery 
Oesophageal POESOPH 
Electronic PELECTRO 
Mute PMUTE 
(4) Death from 
other diseases 
a Suraery 
0 025 
0 209(0 102-0 244) 
0 114(0 209) 
0 281 
Suraerv 
PSSALV 
0 65 
0 27 
0 26 (±0 1) 
0 00 
0 55 
0 45 
0 70 
0 20 
0 10 
PASR Age specific mortality rate 
; for initial age = 50 year 
'providing that Prec = 0 for YEAR > 5 
Following radiotherapy, a patient may remain tumour free for the rest of the year in 
a state with a NORMAL speech or in a state with a HOARSE speech If there is a 
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tumour recurrence a patient may either be salvaged by laryngectomy, lesulting in 
life either with OESOPHAGEAL speech or ELECTRO-larynx speech or staying 
MUTE for the rest of life If a patient is not salvaged, death will follow soon (state 
DEAD) Patients who have been tumour-free the whole first year may undergo a 
similar stream of events in the next year, be it with different recurrence and mortality 
risks Patients salvaged from a recurrence may remain in one of the salvaged 
states, or may have a second recurrence in one of the following years Second 
recurrences are generally fatal within short time 
Following surgery, all patients will have some form of post-laryngectomy 
state (OESOPHAGEAL, ELECTRO or MUTE), both after primary treatment and after 
salvage treatment for a tumour recurrence 
In a Markov model, the probability distribution of states at the end of each 
year is the starting point for the chance events in the next year All transitions are 
unidirectional Transitions from a qualitatively inferior state to a superior state are 
not permitted As it is not likely that a patient's speech quality will deteriorate other 
than from tumour recurrence, we did not permit transitions from NORMAL to 
HOARSE, from OESOPHAGEAL to ELECTRO or MUTE or from ELECTRO to MUTE 
As there is no transition from the DEAD state and as all patients will eventually die, 
DEAD is called the Markov absorbing state The Markov model is structured like­
wise in the surgical arm, with the exception that the states NORMAL and HOARSE 
have been replaced by OESOPHAGEAL, ELECTRO and MUTE 
ASSIGNMENT OF PROBABILITIES 
The parameters used in this model are listed in table 12 3 
We modelled the instantaneous recurrence risk as a linear decreasing func­
tion of time, in accord with formula (6a) If we presume that the instantaneous 
recurrence rate (PREC) becomes zero five years following primary treatment, the 
instantaneous recurrence rate (PREC) and the initial recurrence rate (a) can be 
inferred reciprocally from the 5-year disease-free survival rates (DFS5) as given in 
table 12 1, using formula (6a) and (7) 
5 
DFS5= DFSo - I PREC Χ DFSYEAR-I (7) 
YEAR-1 
DFSo = 1 0 
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Figure 12.9 gives the 5-year disease-free survival rate DFS5 as a function of the 
initial recurrence rate a. 
The probability of dying from other diseases than glottic cancer Pasr is based on 
age- and sex-specific mortality rates of the Dutch population [CBS. 1987]. The 
baseline values of salvage rates (PSALV) are the mean values by tumour size as 
described in table 12.1, with a range of ±0.1 for sensitivity analysis. 
The baseline estimates for the distribution of quality of speech following radiother-
apy (PNORMAL and PHOARSE) and surgery (POESOPHAGEAL. PELECTRO and PMUTE) 
are mean estimates from table 12.2. 
Figure 12.9 · Five-year 
disease-free survival rate 
(DFSs) as a function of the 
initial rate a. 
00 02 04 06 08 10 
Initial recurrence rate a 
UTILITIES 
Treatment outcomes are expressed in terms of (1) life-expectancy and (2) expected 
utilities adjusted for quality of speech and life-years. For illustrative purposes we 
used the utilities assessed in the 50-year old speech instructor given in figure 12.3b 
and equation (4). 
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12.5 Results 
BASELINE ANALYSIS 
Table 12.5 summarizes life-expectancies and expected utilities predicted by the 
Markov model under the baseline assumptions provided. Considering a life-
expectancy of 31 years in women aged 50 in the Dutch population [CBS, 1987], the 
Markov prediction of the life-expectancy of a female patient with glottic carcinoma is 
reduced to 25.56 years following treatment by radiotherapy for a Τι tumour to 9.09 
years in a T4 tumour. 
Except for T2 tumours, the life-expectancy following surgery is higher. In 
terms of expected utilities, radiotherapy is preferred in Τι and T2 tumours, but not in 
T3 and T4 tumours. 
Table 12.5 · Baseline Analysis 
Ti 
T2 
T3 
T4 
Radiotherapy 
LE (year?) EU 
25.56 1.57 
22.54 1.41 
13.54 0.89 
9.09 0.63 
Surgery 
LE (years) EU 
27.01 
20.69 
23.92 
15.65 
1.52 
1.14 
1.32 
0.87 
LE = life-expectancy EU = expected utility 
SENSITIVITY ANALYSIS 
To examine how sensitive the results of the baseline analysis are for variation of the 
data from the literature, we performed sensitivity analysis on (1) the instantaneous 
recurrence risk, (2) the salvage rate, (3) and age at first treatment. As the quality of 
speech may be of less decisive importance in smaller tumours (T1.2). we merely 
present the analysis for T3 and T4 tumours (see comments). 
170 Additive Con|oint Measurement 
RECURRENCE RISK The instantaneous recurrence risk following surgery for T3 
glottic carcinoma is solely based on one paper, presenting a 79% 5-year disease-
free survival [Ennuyer and Bataim 1975] Considering that most papers on T2-
tumours give worse results following surgery, the 79% m T3 tumours probably is an 
exceptionally favourable result If for instance we would presume an equal 5-year 
disease-free surgical survival in T3 tumours as the average result in T2 tumours -
being 64% (see table 12 1)-, the expected utility following surgery would decrease 
from 1 32 to 1 14, the life-expectancy would decrease from 23 92 to 20 61 years 
Even under these circumstances favouring radiotherapy, surgery is to be preferred 
over radiotherapy for T3 glottic carcinoma Figure 12 10 gives the expected utility as 
a function of the 5-year disease-free survival following radiotherapy for T3 glottic 
carcinoma From this figure we can read that only if the 5-year disease-free survival 
following radiotherapy becomes higher than 35%, as described by Ennuyer and 
Bataim, radiotherapy is to be preferred 
Figure 12 10 · Expected 
utilities as a function of the 5-
year disease-free survival 
(DFS5) following radiotherapy 
for T3 glottic carcinoma The 
horizontal reference lines 
indicate expected utilities 
following surgery presuming a 
favourable disease-free sur-
vival (DFS5 = 79%) and a less 
favourable result (DFS5 = 
64%) 
SALVAGE RATES Salvage rates both depend on the size of the primary tumour 
and on the extent of the area involved in the tumour recurrence Although a recur-
rence following radiotherapy is generally more localized than following surgery, -as 
expressed by more favourable salvage rates for radiotherapy than for surgery-, a 
recurrence from a relatively large primary tumour would both decrease the salvage 
rate for radiotherapy and for surgery Hence, in a sensitivity analysis on salvage 
rate it is not very realistic to approach radiotherapy and surgery independently 
0 25 0 30 0 35 0 40 0 45 0 50 
5-Year Disease-free Survival 
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Figure 12.11 · Threshold 
analysis on expected utilities 
for varying salvage rates for a 
recurrence following 
radiotherapy (PSALV) and 
surgery (PSSALV)- The blank 
box indicates the area 
resulting from a sensitivity 
analysis for a variation of ± 
10% of the baseline salvage 
0 25 0 30 0 35 0 40 0 45 0 50 0 55 rates 
Psalv 
Therefore we performed a threshold analysis in which both the salvage rate for 
radiotherapy and surgery are varied. Figure 12.11 gives the threshold analysis on 
expected utilities for Тз glottic carcinoma presuming a 5-year disease-free surgical 
survival of 64%. From this figure we can read that for a baseline salvage rate of 
0.37 for radiotherapy, radiotherapy is only preferred in the unrealistic situation that 
the salvage rate for surgery would be less than 0.03 instead of 0.26. Surgery will 
still be preferred for a variation of ± 0.1 of the baseline salvage rates. A similar 
threshold analysis on expected utilities for salvage rates in T4 glottic carcinoma 
demonstrated a preference for surgery in all realistic salvage rates for radiotherapy 
(not shown here). 
AGE. The baseline value for age was 50 years. Most patients with glottic carcinoma 
are older, and as age is an important prognostic factor, we performed sensitivity 
analysis on age. Figure 12.12 shows the expected utilities following radiotherapy 
and surgery in T3 glottic carcinoma as a function of age. The analysis shows a 
preference for surgery for all ages, provided of course, that all other probabilities 
and utilities are fixed. A sensitivity analysis on age for the other T-classes did not 
alter the baseline conclusions (not shown here). 
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Figure 12.12 · Expected 
utilities following radiotherapy 
and surgery in T3 glottic 
carcinoma as a function of age. 
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12.6 Conclusions 
In this individual case, the analysis shows a benefit for surgery in T3 and T4 glottic 
tumours both in terms of life-expectancy and expected utility. The stability of the 
conclusion may depend on the representativeness both of the disease-free survival 
rates taken from the literature and the linear decreasing function we presumed for 
the instantaneous recurrence risk per year. Variation of the baseline probability of 
the salvage rate or age hardly influence treatment outcomes in terms of expected 
utility and do not change the baseline conclusions. 
12.7 Comments 
MODELLING ISSUES. The Markov model of prognosis, using time-dependent 
probabilities and time-dependent utilities, is a powerful mathematical tool to gen­
erate detailed and accurate assessments of life-expectancy and health status [Beck 
and Pauker, 1983]. To model the instantaneous tumour recurrence risk we used 
data from a retrospective study, choosing the model with the best fit, being a simple 
linear decreasing function of time. Elsewhere we demonstrated that 'best fit' 
modelling of time-dependent probabilities in a Markov process may generate 
accurate approximations of life-table estimates [Stalpers et al., 1990a]. A similar 
fitting procedure was used to approximate the utility function for life- years UL. A 
logaritmic function showed an excellent fit with the original data. 
1 β-
s 1 2 l 
Surgery (lavouraole) 
Surgery 
(unlav ) 
Radiotherapy 
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ADDITIVE UTILITIES. Additive conjoint measurement has some practical and con­
ceptual advantages over some other methods like the time-tradeoff test and the life 
standard gamble [Stalpers et al., 1988, 1990b]. The major advantage of conjoint 
measurement models is the possibility to assess utilities for the quality and quantity 
of life simultaneously in a so-called riskless context. Framing and anchoring, which 
are disturbing effects of other scaling methods can thus be bypassed [Tversky and 
Kahneman, 1974, 1981; Llewellyn-Thomas et al., 1982]. In this paper we demon­
strated a practical application of ACM in medical decision making, without dis­
cussing the reliability of the utility functions. The tightness of the additive solution in 
figure 12.3b does not allow us to perform a simple sensitivity analysis on the utility 
functions U L or UQ: A marginal variation of either utility function would disturb the 
transformation of the original preference ranking of figure 12.3a. However, figure 
12.3b represents only one possible additive transformation, -the so-called centroid 
solution-, among a group of solutions. We may choose any of these possible 
solutions and examine the effect on the results in a decision tree analysis. Since we 
defined five utility-levels on either attribute, of which we fixed the two worst levels 
on 0.0 (for 3 life-years and for mute), there are eight utility levels that can vary within 
the limited freedom implied by the original preference ranking. In other words: We 
defined two attributes with eight degrees of freedom. Since it is cumbersome to 
perform utility analysis on a prognostic factor with eight degrees of freedom, we did 
not perform a sensitivity analysis on the utility functions. 
CLINICAL ISSUES. In the Markov model we assumed that, -for all T-dasses-, the 
stream of events are alike, i.e. that surgery always consists of total laryngectomy. 
This may not be the case in small tumours, as in Τι and small Ta glottic tumours, 
where surgery may consist of so-called conservation surgery. Conservation surgery 
will generally give less impairment of speech as we presumed and may hence 
generate higher expected utilities than we presented. However, considering the 
small difference in life-expectancy between surgery and radiotherapy in Τι tumours 
and the even better predicted life-expectancy following radiotherapy in Тг tumours 
than after surgery, radiotherapy is to be preferred in Ti tumours and most Тг 
tumours [Dickens and Cassisi, 1983; Stalpers et al, 1988a]. 
The utility analysis is more applicable for patients with larger glottic tumours 
(large Тг and T3.4), where both the quality and the quantity of life are of decisive 
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importance in the choice between radiotherapy and surgery. For these cases we 
demonstrated how utilities assessed by additive conjoint measurement may 
optimize a choice of treatment by considering a patient's personal preference 
concerning life-years and the quality of speech. 
12.8 References 
1. American Joint Committee for Cancer Staging and End Result Reporting (AJC). Clinical staging 
systems for carcinomas of the larynx. AJC, Chicago 197B. 
2. Beck JR, Pauker SG. The Markov process in medical prognosis. Med Decís Making 3: 419-458, 
1983. 
3. Bezembinder TGG. Circularity and consistency in paired comparisons. Br J Math Stat Psychol 34: 
16-37, 1981. 
4. CBS - Dutch Center of Vital Statistics: Lrfetables, 1981-1985. Maandstat Bevolk 1: 59-60, 1987. 
5. De Haes JCJM, Van Knippenberg FCE. The quality of life of cancer patients: A review of the 
literature. Soc Sci Med 20:809-817, 1985. 
6. Dickens, WJ, Cassisi NJ. Treatment of early vocal cord carcinoma: A comparison of apples and 
apples. Laryngoscope 93: 216-219, 1983. 
7. Ende PLA van den, Stalpers UA, Teeuwes A, Broek Ρ van den, Daal WAJ van. Radiotherapy in 
early laryngeal cancer. Lecture before the 7th Annual Meeting of the European Society for 
Therapeutic Radiology and Oncology (ESTRO), The Hague, September 4-8, 1988. 
8. Ennuyer A, Bataini P. Laryngeal carcinomas. Laryngoscope 85: 1467-1476, 1975. 
9. Marwood AR, Rawlmson E.The quality of life of patients following treatment for laryngeal cancer. 
Int J Rad Oncol Biol Phys 9: 335-338, 1983. 
10. Hers hey JC, Baron J. Clinical reasoning and cognitive processes. Med Decís Making 7: 203-
211, 1987. 
11. Karnofsky DA, Abelmann WH, Graver LF, Burchenal JH. The use of the nitrogen mustard in the 
palliative treatment of carcinoma. Cancer'[: 634-656, 1948. 
12. Llewellyn-Thomas H, Sutherland HJ, Tlbshirani R, Ciampi A, Till JE, Boyd NF. The measurement 
of patient's values in medicine. Med Decís Making 2: 449-462,1982. 
13. Luce RD, Tukey JW, Simultaneous conjoint measurement: A new type of fundamental 
measurement. J Math Psychol 1: 1-27, 1964. 
14. Mor V, Laliberte L, Morris JN, Wiemann M. The Karnofsky Performance Status Scale: An 
examination of its reliability and validity in a research setting. Cancer 53: 2002-2007, 1984. 
Application in Clinical Decision Making 175 
15 Kanm ABMF, Snow GB, Siek HTH, Njo KH The quality of voice in patients irradiated for laryngeal 
carcinoma. Cancer 5 1 : 47-49, 19Θ3. 
16. King PS, Fowlks EW, Peirson GA. Rehabilitation and adaptation of laryngectomy patients Am J 
Physic Med 47· 192-203, 1968. 
17 McNeil BJ, Weichselbaum R, Pauker SG. Fallacy of the five-year survival in lung cancer /V Engl J 
Med 299. 1397-1401, 197Θ. 
18 McNeil BJ, Weichselbaum R, Pauker SG. Speech and survival. Tradeoffs between quality and 
quantity of life in laryngeal cancer. N Engl J Med 305. 982-987, 1981 
19. Pliskm JS, Donald SS, Weinstein MC. Utility functions for life years and health status. Operai Res 
28 206-224, 1980. 
2 1 . Roskam ЕЕ. Metric analysis of ordinal data in psychology. Thesis. VAM, Voorschoten, 1968. 
20. Roskam ЕЕ. ORDMET3 An improved algorithm to find the maximin solution to a system of linear 
(in)equalities. Internal report 87 MA 06, Nijmegen Institute for Cognition-research and 
Information-technology (NICI)/ Nijmegen, The Netherlands, 1987. 
21 Stalpers UA, Verbeek ALM, Daal WAJ van. Results of radiotherapy and surgery for glottic 
carcinoma Cancer Treatm Rev 14:131-141,1987. 
23. Stalpers UA, Bezembinder TGG, Van Daal WAJ. Additive conjoint measurement of utilities. The 
quality of speech and survival in patients with laryngeal cancer (abstract). Theoretical Surgery 3: 
49, 1988. 
22. Stalpers LJA, Verbeek ALM, Daal WAJ van Radiotherapy or surgery in T2N0M0 glottic 
carcinoma? A decision analytic approach Radiother Oncol. 14 209-217,1989 
24 Stalpers UA, Zwetsloot-Schonk JHM, Verbeek ALM, Daal WAJ van Markov modelling m clinical 
trial design. Submitted for publication to Med Decís Making, 1990a. 
25. Stalpers UA, Verbeek ALM, Van Daal WAJ. Utility assessment by time tradeoffs: A delusive deal. 
Submitted for publication to the Journal of Clinical Epidemiology, 1990b. 
26 Stoicheff ML. Voice following radiotherapy. Laryngoscope BS 608-618, 1975. 
27 Torrance GW. Utility approach to measuring health-related quality of life. J Chron Dis 40' 593-
600, 1987. 
28. Tversky A, Kahneman D. Judgement under uncertainty: Heuristics and biases. Science 185: 
1124-1131, 1974. 
29 Tversky A, Kahneman D. The framing of decisions and the psychology of choice. Science 211: 
453-458, 1981. 
30. International Union Against Cancer (UICC) UICC-TNM Classification of malignant tumours. UICC, 
Geneva 1978. 
176 Additive Conjoint Measurement 
31 . Von Neumann J, Morgenstern D. The theory of games and economic behavior. (3rd Ed). John 
Wiley, New York 1953. 
32. Weinstein MC, Fineberg HV (Eds). Clinical decision analysis Saunders, Philadelphia 1980. 
clinical decision making in oncology 
parte: 
appendices 

The Life Standard Gamble 177 
Appendix C. I : The Life Standard Gamble 
Life expectancy and operation risks 
Imagine that you have a serious disease for instance lung cancer, for which you 
can choose between surgery and radiotherapy. 
If you have surgery, there is a risk of dying during or shortly after the 
operation. If you survive the operation, you are considered to be cured and will live 
for another 25 years in good health. 
If you have radiotherapy, there is no risk of dying from the treatment itself. 
However, the disease will recur after a certain amount of years and you will 
eventually die from the disease. All these years you will live in good health. 
By the next three questions, we want to investigate the minimal amount of 
certain life-years you are willing to accept following radiotherapy to avoid the risk of 
dying during an operation. 
We only have three questions. Take your time and read them carefully: You will 
need the answer of the first question for the next questions. Please, do not hesitate 
and ask the interviewer to help you if necessary. 
Situation 1: 
If you have surgery you have: 
• 50% chance of dying during or shortly after the operation and 
• 50% chance to survive and live for 25 years in good health 
If you have radiotherapy you have: 
• 100% chance to live "X" years in good health 
Question 1 : Give the minimal amount of years "X" for which you would prefer 
radiotherapy to surgery: 
Give these "X" years here: (between 0 and 25 years) 
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Situation 2: 
If you have surgery you have: 
• 50% chance of dying during or shortly after the operation and 
• 50% chance to survive and live for 25 years in good health 
If you have radiotherapy you have: 
• 100% chance to live "Y" years in good health 
Question 2: Give the minimal amount of years "Y" for which you would prefer 
radiotherapy to surgery: 
Give these Ύ" years here: (between 0 and 25 years) 
Situation 3: 
If you have surgery you have: 
• 50% chance to survive and live "X" years in good health and 
• 50% chance to survive and live for 25 years in good health 
If you have radiotherapy you have: 
• 100% chance to live "Z" years in good health 
Question 3: Give the minimal amount of years "Z" for which you would prefer 
radiotherapy to surgery: 
Give these "Z" years here: (between "X" and 25 years) 
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Appendix C.2: The Time Tradeoff Test 
Information on treatment of cancer of the vocal cords 
Patients with cancer of the vocal cords can be treated either by surgery either by 
radiotherapy. Surgery involves removal of the larynx and subsequently a normal 
speech has become inpossible. Most of these patients manage to learn a so-called 
arificial or "esophageal" speech. This approach involves swallowing air and then 
forcing it through the throat. The result is some kind of 'belching' speech. Further, 
surgery leaves a small opening in the neck. This breathing hole must remain open 
throughout the patient's lifetime but may be covered by turtleneck sweaters, 
scarves, etc. As a result of this hole, patients are unable to participate in water 
sports, which perhaps could inadvertently lead to the entrance of water in the lungs 
through this hole. 
By radiotherapy, the voice can be preserved; therefore patients with small 
tumours will generally have radiotherapy. If a tumour is large, patients will have 
surgery, because in large tumours the survival after an operation is probably better 
than following radiotherapy. However, the differences are small. Therefore, it is 
questionable whether or not the better chances to survive outweigh the loss of 
normal speech. 
By the following test we want to elicit the value you attach to your voice. We 
therefore ask you to ¡mage having cancer of the vocal cords and having to choose 
between surgery and radiotherapy. 
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Question V 
If you receive surgery you will have 25 life years with an artificial speech How 
many of these life years are you willing to sacrifice to live with a natural speech 
following radiotherapy ? 
I will sacrifice year(s) 
Question 2: 
If you receive surgery you will have 2Q_ life years with an artificial speech. How 
many of these life years are you willing to sacrifice to live with a natural speech 
following radiotherapy ? 
I will sacrifice year(s). 
Question 3' 
If you receive surgery you will have 15 life years with an artificial speech. How 
many of these life years are you willing to sacrifice to live with a natural speech 
following radiotherapy ? 
I will sacrifice year(s). 
Question 4: 
If you receive surgery you will have 10 life years with an artificial speech How 
many of these life years are you willing to sacrifice to live with a natural speech 
following radiotherapy ? 
I will sacrifice year(s). 
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Question 5: 
If you receive surgery you will have 5 life years with an artificial speech. How many 
of these life years are you willing to sacrifice to live with a natural speech following 
radiotherapy ? 
I will sacrifice year(s). 
Personal Information 
1. Date of birth: 
2. Gender: male / female 
3. Marital state 
О not married, no spouse 
О not married, with spouse 
О married 
4. How many children do you have ? : 
5. Highest finished education: 
6. Profession: 
7. How difficult is it for you to imagine having 
cancer of the vocal cords yourself ? 
О No problems 
O Mild problems 
О Moderate 
О Severe Problems 
О Practically impossible 
8. How difficult is it for you to deal with quality 
of life (i.e. speech) in a quantitaive way ? 
О No problems 
O Mild problems 
О Moderate 
О Severe Problems 
О Practically impossible 
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Appendix C.3: The ACM test 
Which do you prefer ? 
A. 15 years mute 
or 
B. 12 years electronic larynx speech 
01 
Which do you prefer ? 
A. 15 years mute 
or 
B. 9 years electronic larynx speech 
02 
Which do you prefer ? 
A. 15 years mute 
or 
B. 6 years electronic larynx speech 
03 
Which do you prefer ? 
A. 15 years mute 
or 
B. 3 years electronic larynx speech 
04 
Which do you prefer ? 
A. 15 years mute 
or 
B. 12 years oesophageal speech 
05 
Which do you prefer ? 
A. 15 years mute 
or 
B. 9 years oesophageal speech 
06_ 
Which do you prefer ? 
A. 15 years mute 
or 
B. 6 years oesophageal speech 
07_ 
Which do you prefer ? 
A. 15 years mute 
or 
B. 3 years oesophageal speech 
08^ 
Which do you prefer ? 
A. 15 years mute 
or 
B. 12 years hoarseness 
0£ 
Which do you prefer ? 
A. 15 years mute 
or 
B. 9 years hoarseness 
10 
184 Appendix С.З 
Which do you prefer ? 
A. 15 years mute 
or 
B. 6 years hoarseness 
Which do you prefer ? 
A. 15 years mute 
or 
B. 3 years hoarseness 
12 
Which do you prefer ? 
A. 15 years mute 
or 
B. 12 years normal speech 
12 
Which do you prefer ? 
A. 15 years mute 
or 
B. 9 years normal speech 
V4 
Which do you prefer ? 
A. 15 years mute 
or 
B. 6 years normal speech 
15 
Which do you prefer ? 
A. 15 years mute 
or 
B. 3 years normal speech 
!§_ 
Which do you prefer ? 
A. 12 years mute 
or 
B. 9 years electronic larynx speech 
17_ 
Which do you prefer ? 
A. 12 years mute 
or 
B. 6 years electronic larynx speech 
і _ 
Which do you prefer ? 
A. 12 years mute 
or 
B. 3 years electronic larynx speech 
19_ 
Which do you prefer ? 
A. 12 years mute 
or 
B. 9 years oesophageal speech 
20 
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Which do you prefer ? 
A. 12 years mute 
or 
B. 6 years oesophageal speech 
2 ^ 
Which do you prefer ? 
A. 12 years mute 
or 
B. 3 years oesophageal speech 
22_ 
Which do you prefer ? 
A. 12 years mute 
or 
B. 9 years hoarseness 
23_ 
Which do you prefer ? 
A. 12 years mute 
or 
B. 6 years hoarseness 
2± 
Which do you prefer ? 
A. 12 years mute 
or 
B. 3 years hoarseness 
25 
Which do you prefer ? 
A. 12 years mute 
or 
B. 9 years normal speech 
26_ 
Which do you prefer ? 
A. 12 years mute 
or 
B. 6 years normal speech 
27_ 
Which do you prefer ? 
A. 12 years mute 
or 
B. 3 years normal speech 
28_ 
Which do you prefer ? 
A. 9 years mute 
or 
B. 6 years electronic larynx speech 
29_ 
Which do you prefer ? 
A. 9 years mute 
or 
B. 3 years electronic larynx speech 
30 
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Which do you prefer ? 
A. 9 years mute 
or 
B. 6 years oesophageal speech 
3 i 
Which do you prefer ? 
A. 9 years mute 
or 
B. 3 years oesophageal speech 
32_ 
Which do you prefer ? 
A. 9 years mute 
or 
B. 6 years hoarseness 
33 
Which do you prefer ? 
A. 9 years mute 
or 
B. 3 years hoarseness 
34 
Which do you prefer ? 
A. 9 years mute 
or 
B. 6 years normal speech 
35 
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Which do you prefer ? 
A. 9 years mute 
or 
B. 3 years normal speech 
36_ 
Which do you prefer ? 
A. 6 years mute 
or 
B. 3 years electronic larynx speech 
37_ 
Which do you prefer ? 
A. 6 years mute 
or 
B. 3 years oesophageal speech 
38_ 
Which do you prefer ? 
A. 6 years mute 
or 
B. 3 years hoarseness 
39_ 
Which do you prefer ? 
A. 6 years mute 
or 
B. 3 years normal speech 
40 
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Which do you prefer ? 
A. 15 years electronic larynx speech 
or 
B. 12 years oesophageal speech 
41 
Which do you prefer ? 
A. 15 years electronic larynx speech 
or 
B. 9 years oesophageal speech 
42 
Which do you prefer ? 
A. 15 years electronic larynx speech 
or 
B. 6 years oesophageal speech 
43 
Which do you prefer ? 
A. 15 years electronic larynx speech 
or 
B. 3 years oesophageal speech 
44 
Which do you prefer ? 
A. 15 years electronic larynx speech 
or 
B. 12 years hoarseness 
45 
Which do you prefer ? 
A. 15 years electronic larynx speech 
or 
B. 9 years hoarseness 
46 
Which do you prefer ? 
A. 15 years electronic larynx speech 
or 
B. 6 years hoarseness 
47 
Which do you prefer ? 
A. 15 years electronic larynx speech 
or 
B. 3 years hoarseness 
48 
Which do you prefer ? 
A. 15 years electronic larynx speech 
or 
B. 12 years normal speech 
49 
Which do you prefer ? 
A. 15 years electronic larynx speech 
or 
B. 9 years normal speech 
50 
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Which do you prefer ? 
A. 15 years electronic larynx speech 
or 
B. 6 years normal speech 
51 
Which do you prefer ? 
A. 15 years electronic larynx speech 
or 
B. 3 years normal speech 
52 
Which do you prefer ? 
A. 12 years electronic larynx speech 
or 
В 9 years oesophageal speech 
53 
Which do you prefer ? 
A. 12 years electronic larynx speech 
or 
B. 6 years oesophageal speech 
54 
Which do you prefer ? 
A. 12 years electronic larynx speech 
or 
B. 3 years oesophageal speech 
55 
Which do you prefer ? 
A. 12 years electronic larynx speech 
or 
B. 9 years hoarseness 
56 
Which do you prefer ? 
A. 12 years electronic larynx speech 
or 
B. 6 years hoarseness 
57 
Which do you prefer ? 
A. 12 years electronic larynx speech 
or 
B. 3 years hoarseness 
58 
Which do you prefer ? 
A. 12 years electronic larynx speech 
or 
B. 9 years normal speech 
59 
Which do you prefer ? 
A. 12 years electronic larynx speech 
or 
B. 6 years normal speech 
60 
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Which do you prefer ? 
A. 12 years electronic larynx speech 
or 
B. 3 years normal speech 
61 
Which do you prefer ? 
A. 9 years electronic larynx speech 
or 
B. 6 years oesophageal speech 
62 
Which do you prefer ? 
A. 9 years electronic larynx speech 
or 
B. 3 years oesophageal speech 
6 3 _ 
Which do you prefer ? 
A. 9 years electronic larynx speech 
or 
B. 6 years hoarseness 
6 4 _ 
Which do you prefer ? 
A. 9 years electronic larynx speech 
or 
B. 3 years hoarseness 
65 
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Which do you prefer ? 
A. 9 years electronic larynx speech 
or 
B. 6 years normal speech 
66_ 
Which do you prefer ? 
A. 9 years electronic larynx speech 
or 
B. 3 years normal speech 
67_ 
Which do you prefer ? 
A. 6 years electronic larynx speech 
or 
B. 3 years oesophageal speech 
6 _ 
Which do you prefer ? 
A. 6 years electronic larynx speech 
or 
B. 3 years hoarseness 
69_ 
Which do you prefer ? 
A. 6 years electronic larynx speech 
or 
B. 3 years normal speech 
70 
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Which do you prefer ? 
A. 15 years oesophageal speech 
or 
B. 12 years hoarseness 
7± 
Which do you prefer ? 
A. 15 years oesophageal speech 
or 
B. 9 years hoarseness 
72 
Which do you prefer ? 
A. 15 years oesophageal speech 
or 
B. 6 years hoarseness 
73 
Which do you prefer ? 
A. 15 years oesophageal speech 
or 
B. 3 years hoarseness 
74 
Which do you prefer ? 
A. 15 years oesophageal speech 
or 
B. 12 years normal speech 
75 
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Which do you prefer ? 
A. 15 years oesophageal speech 
or 
B. 9 years normal speech 
76 
Which do you prefer ? 
A. 15 years oesophageal speech 
or 
B. 6 years normal speech 
77 
Which do you prefer ? 
A. 15 years oesophageal speech 
or 
B. 3 years normal speech 
7Θ 
Which do you prefer ? 
A. 12 years oesophageal speech 
or 
B. 9 years hoarseness 
79 
Which do you prefer ? 
A. 12 years oesophageal speech 
or 
B. 6 years hoarseness 
о 
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Which do you prefer ? 
A. 12 years oesophageal speech 
or 
B. 3 years hoarseness 
8J_ 
Which do you prefer ? 
A. 12 years oesophageal speech 
or 
B. 9 years normal speech 
82_ 
Which do you prefer ? 
A. 12 years oesophageal speech 
or 
B. 6 years normal speech 
83. 
Which do you prefer ? 
A. 12 years oesophageal speech 
or 
B. 3 years normal speech 
в± 
Which do you prefer ? 
A. 9 years oesophageal speech 
or 
B. 6 years hoarseness 
Θ5 
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Which do you prefer ? 
A. 9 years oesophageal speech 
or 
B. 3 years hoarseness 
86_ 
Which do you prefer ? 
A. 9 years oesophageal speech 
or 
B. 6 years normal speech 
87_ 
Which do you prefer ? 
A. 9 years oesophageal speech 
or 
B. 3 years normal speech 
и 
Which do you prefer ? 
A. 6 years oesophageal speech 
or 
B. 3 years hoarseness 
89 
Which do you prefer ? 
A. 6 years oesophageal speech 
or 
B. 3 years normal speech 
90 
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Which do you prefer ? 
A 15 years hoarseness 
or 
B. 12 years normal speech 
91 
Which do you prefer ? 
A. 15 years hoarseness 
or 
B. 9 years normal speech 
92_ 
Which do you prefer ? 
A. 15 years hoarseness 
or 
B. 6 years normal speech 
92 
Which do you prefer ? 
A. 15 years hoarseness 
or 
B. 3 years normal speech 
94 
Which do you prefer ? 
A. 12 years hoarseness 
or 
B. 9 years normal speech 
95 
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Which do you prefer "> 
A. 12 years hoarseness 
or 
B. 6 years normal speech 
9 6 _ 
Which do you prefer ? 
A. 12 years hoarseness 
or 
B. 3 years normal speech 
9 7 _ 
Which do you prefer ? 
A. 9 years hoarseness 
or 
B. 6 years normal speech 
9 _ 
Which do you prefer ? 
A. 9 years hoarseness 
or 
B. 3 years normal speech 
99_ 
Which do you prefer ? 
A. 6 years hoarseness 
or 
B. 3 years normal speech 
100 
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Appendix С.4: The FORTRAN ACM-Programme 
PROGRAM ACM 
С A FORTRAN programme to assess the preference ranking of pairs of life expec-
C tancy and quality of life from pairwise comparisons The programme gener-
C ates the results of three observations, producing a fourth 'averaged' ranking for 
С which the violation of transitivity of the preference ranking is assessed 
С All variables are integers There are two attributes Year (Q) and quality of 
С speech (R) with M and N levels respectively Y is the first pair of a pairwise 
С comparison composed by a year-level (YQ) and a quality level (YR), X is the 
С second pair composed by XQ and XR 
CHARACTER*! IR(5), ANTW 
INTEGER*2 M,N,Y,X,YQ,YR,XQ,XR,Z 
С The number of levels on each attribute is limited to five 
DIMENSION MTX(25,25,6), NSOM(25), MSOM(25), ISOM(25) 
DIMENSION INDEX(25), MY(25), MX(25)1 NSOMRIJ(25), NRIJ(25) 
DIMENSION IQ(5), IX(25), NCUM(25), NPAAR(25) 
С First read the number of levels on each attribute 
PRINT '(' How many life expectancies are there (max 5) ^ ",$)' 
READ(5,·) M 
PRINT '(' How many life qualities are there (max 5) ? ",$)' 
READ(5,') N 
PRINT '(" There are", 12," life expectancies and",12,"life qualities"), M,N 
WRITE(6,') ' ' 
D0 5YQ=1,M 
PRINT '(" Give the value of life expectancy",l2," ",$)', YQ 
READÍS,*) IQ(YQ) 
5 CONTINUE 
WRITER,*) ' ' 
DO10YR=1,N 
PRINT '(" Give a name (1 capital) to life quality".l2," ",$)', YR 
READ(5,2005) IR(YR) 
10 CONTINUE 
WRITE(6,·) ' ' 
Z=0 
12 IOUT=6 
13 Z = Z + 1 
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IF (Ζ .EQ. 4) THEN 
С Calculate the cumulative result of three observations 
DO 14Y=1,M*N 
DO 14X=1,M*N 
ΜΤΧ(Υ,Χ.Ζ) = MTX(Y,X,1 ) + MTX(Y,X,2) + MTX(Y,X,3) 
14 CONTINUE 
GO TO 401 
ELSE IF (Z .EQ. 5) THEN 
С Calculate the cumulative result of three observations, 
С and transform them into a binary notation 
DO 15Y=1,M*N 
DO 15X=1,M*N 
ΜΤΧ(Υ,Χ,Ζ) = ΜΤΧ(Υ,Χ,Ζ-Ι) 
IF (ΜΤΧ(Υ,Χ,Ζ) .GT. DTHEN 
ΜΤΧ(Υ,Χ,Ζ) = 1 
ELSE 
ΜΤΧ(Υ,Χ,Ζ) = 0 
END IF 
15 CONTINUE 
GO TO 401 
ELSE IF (Z .EQ. 6) THEN 
STOP 
END IF 
WRITE(5,*) 'Results of replication no. ' ,Z 
С Is the paired comparison a dilemma or not ? KTEL is the counter of dilemmas 
KTEL=0 
DO200YQ=1,M 
DO200YR=1,N 
DO200XQ=1,M 
DO200XR=1,N 
Y = YR + N*(YQ-1) 
X = XR + N*(XQ-1) 
IF (YR .LT. XR) GO TO 20 
GO TO 25 
20 IF (YQ .GT. XQ) GO TO 125 
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MTXfY.X.ZH 
GO TO 200 
25 IF(YR.GT.XR)GOT0 35 
GO TO 45 
35 IF (YQ .LT. XQ) GO TO 200 
MTX(Y,X,Z) = 1 
GO TO 200 
45 IF (YQ .LE. XQ) ΜΤΧίΥ,Χ,Ζ) = 0 
IF (YQ .GT. XQ) ΜΤΧίΥ,Χ,Ζ) = 1 
GO TO 200 
С Read the binary value of the dilemma: 
125 KTEL = KTEL+1 
WRITE(6,3001)KTEL, IQÍYQ), IR(YR), IQ(XQ), IR(XR) 
3001 FORMAT(l3,' Give the value (1,0)ίο·.Ι2,Α2, ';*, I2,A1,' '$) 
READ(5,*) MTX(Y,X,Z) 
С Give the complementary binary value to the equivalent (trivial) dilemma 
MTXfX.Y.Z) = 1 - ΜΤΧίΥ,Χ,Ζ) 
200 CONTINUE 
MN = M*N 
С Titles to the results 
401 IF (Z .LT. 4) THEN 
WRITE(IOUT,2012) Ζ 
ELSE IF (Z .EQ. 4) THEN 
WRITE(IOUT,2009) ' Cumalative results' 
ELSE IF (Z .EQ. 5) THEN 
РІТЕООиТ.гООЭ) 'Cumulative results (binary)' 
END IF 
WRITEOOUT,*) 'Unsorted matrix of'.M,' life expectancies and',N,'life qualities' 
WRITE(IOUT,2010) (IQ((X-1+N)/N), IR(MOD(X-1,N)+1), X= 1,MN) 
WRITE(IOUT,2007) (' ', X = 1,MN+2) 
С Sum rows 
DO260Y=1,MN 
NSOM(Y) = 0 
D0 255X = 1
>
MN 
NSOM(Y) = NSOM(Y) + ΜΤΧ(Υ,Χ,Ζ) 
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255 CONTINUE 
260 CONTINUE 
С Write out the matrix by row 
DO280YQ=1,M 
D0 275YR=1,N 
DO 270X0=1,M 
D0 265XR=1,N 
Y = YR + N*(YQ-1) 
X = XR + N,(XQ-1) 
265 CONTINUE 
270 CONTINUE 
WRITE(IOUT,2001) IQ(YQ), IR(YR), (ΜΤΧ(Υ,Χ,Ζ), X= 1,MN), NSOM(Y) 
275 CONTINUE 
280 CONTINUE 
WRITE(IOUT,2007) (' ', X = 1,MN+2) 
С Sum columns and write the sum-score below the matrix 
D0 325X=1,MN 
MSOM(X) = 0 
DO320Y = 1,MN 
MSOM(X) = MSOM(X) + ΜΤΧ(Υ,Χ,Ζ) 
320 CONTINUE 
325 CONTINUE 
WRITE(IOUT,2002) '-', (MSOM(X)1 X = 1,MN), '--' 
WRITEdOUT,*) ' ' 
С Prepare matrix for sorting by marginal row and colum sum scores 
WRITE(IOUT,2009) 'Matrix sorted by marginal sum scores:' 
С Step 1 : Assignment of an index to each row and column 
DO330K=1,MN 
ISOM(K) = NSOM(K) 
330 CONTINUE 
DO350K=1,MN 
KL = ISOM(K) 
NKL = K 
DO340L=1,MN 
IF(KL .LE. ISOM(L)) GOTO 340 
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NKL = L 
KL = ISOM(L) 
340 CONTINUE 
INDEX(K) = NKL 
ISOM(NKL) = 9999 
350 CONTINUE 
С Step 2: Write the names of each pair sorted by column sum-score 
WRITE(IOUT,2010)(IQ((INDEX(J)-1+N)/N), 
1 IRÍMODdNDEXUM.NRD, J=1,MN) 
WRITE(IOUT,2007) (' ', X=1,MN+2) 
С Step 3: Sort the rows and columns marginal sum scores using a 
С row-index (INDEX(I)) and a column-index (INDEX(J)) 
DO 370 1=1,MN 
K=INDEX(I) 
KQ=(K-1+N)/N 
KR=MOD(K-1,NH-1 
WRITE(IOUT,2001) IQ(KQ), IR(KR), (MTX(K,INDEX(J),Z), J=1,MN), NSOM(K) 
370 CONTINUE 
WRITE(IOUT,2007) (' ', X=1,MN+2) 
WRITE(IOUT,2002) '-', (MSOM(INDEX(l))r I = 1,MN), '-' 
С Write the preference ranking 
WRITEdOUT,') ' • 
WRITE(IOUT,2009) 'Preference ranking of pairs:' 
WRITEdOUT^OOe) (IQ((INDEX(I)-1+N), IR(MOD(INDEX(l)-1,N>+1), 1=1,MN 
С Write the corresponding row sum score 
WRITE(IOUT,2008) (NSOM(INDEX(l)), I = Ι,ΜΝ) 
С Calculate and write the cumulative row sum score 
NCUM(INDEX(1)) = NSOM(INDEX(1)) 
DO510l=2,MN 
NCUM(INDEX(I)) = NCUM(INDEX(I-1)) + NSOM(INDEX(l)) 
510 CONTINUE 
WRITE(IOUT,2008) (NCUM(INDEX(I)), I = I.MN) 
С Calculate and write the corresponding pair-value 
DO520l = 1,MN 
NPAAR(l) = (l*(l-1))/2 
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520 CONTINUE 
WRITE(IOUT,2008) (NPAARO), I = 1,MN) 
С Write a N*M preference matrixof pairs of life expectancy and life quality 
WRITE(IOUT,2029) (IR(YR), YR = 1 ,N) 
WRITE(IOUT,2028) (' ', X=1,N+2) 
DO530YQ=1,M 
WRITE(IOUT,2030) IQ(YQ), (NSOM(I), l=((YQ*N)-N+1), YQ'N) 
530 CONTINUE 
WRITE(IOUT,2028) (' ', X=1,N+2) 
С Do you want the results to be filed ? 
IFdOUT.EQ. 9) GO TO 12 
WRITE(6,') · ' 
PRINT '(" Do you want these results to be filed ? ",$)' 
READ(5,2005) ANTW 
IF(ANTW.EQ. 'J') THEN 
IOUT = 9 
OPEN (UNIT=9, FILE^ACM.DAT', STATUS^UNKNOWN', 
1 CARRIAGECONTROL='FORTRAN') 
GO TO 401 
ELSE 
GOTO 13 
ENDIF 
2001 FORMATC ',I2,A1. <MN>(I4)1 I6) 
2002 FORMATC ', 1A3, <MN>(I4), 1A4) 
2005 FORMAT(A1) 
2006 FORMAT(<MN>(l3,A1)) 
2007 FORNMTC ' ,<MN+2>A4) 
2008 FORMAT(<MN>(l4)) 
2009 FORMAT('1',A50) 
2010 FORMATC '^MN^IS.AD) 
2012 FORMATd','Results of observation no.',l2) 
2028 FORMATC _'1<N+2>A3) 
2029 FORMATCO',' Γ,<Ν>Α3) 
2030 FORMATC МЗ," Γ,<Ν>Ι3) 
END 
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Samenvatting 
Dit proefschrift geeft de resultaten van een onderzoek naar de toepassing van 
klinische besliskunde ter rationalisering van behandelingskeuzen voor en van 
patiënten met kanker. 
Deel A geeft een inleiding tot de klinische besliskunde in de oncologie; deel В geeft 
een meer gedetailleerde beschrijving van klinische besliskunde bij patiënten met 
een larynxcarcinoom of een mondholtecarcinoom. 
Zoals wordt beschreven in hoofdstuk A. 1 wordt een formele beslissingsana-
lyse bij een patiënt met kanker vooral bemoeilijkt door (a) een gebrekkige kennis 
van relevante kansen en (b) de moeilijkheden bij het kwantificeren van de kwaliteit 
van het leven op waarderingsschalen uitgedrukt inutiliteiten. Een bijzonder 
probleem binnen de oncologische praktijk is (c) de tijdsafhankelijkheid van de 
kansen en de utiliteiten. 
In hoofdstuk A.2 wordt de beslisboom beschreven voor het structureren en 
evalueren van klinische keuzeproblemen, rekening houdend met de onzekerheid 
van de geschatte kansen en met meerdere met elkaar wedijverende uitkomsten, 
zoals de levensduur en de kwaliteit van het leven. In een gevoeligheids- of 
sensitiviteitsanalyse wordt de stabiliteit van een keuze nagegaan door het variëren 
van de uitgangswaarden in de beslisboom binnen de waargenomen spreiding van 
kansen. Middels een sensitiviteitsanalyse kan worden aangegeven wanneer er 
sprake is van een beslissingsprobleem en wanneer het van doorslaggevende 
betekenis is om andere factoren, -in het bijzonder de kwaliteit van het leven, 
uitgedrukt in utiliteiten -, nauwkeurig te bepalen. Op basis van een literatuurstudie, 
beschreven in hoofdstuk B.6, wordt in hoofdstuk B.7 een beslisboomanalyse 
beschreven voor de keuze tussen radiotherapie en chirurgie bij patiënten met een 
T2N0M0 glottisch carcinoom. 
In hoofdstuk A.3 wordt, gebaseerd op de door Beek e.a. in 1982 beschreven 
DEALE-methode, een eenvoudige methode beschreven om de levensverwachting, 
het gemiddelde sterfterisico per jaar en de vijf-jaars overleving te schatten op basis 
van een combinatie van leeftijdsspecifieke en ziektespecifieke sterftecijfers. 
Echter, noch de eenvoudige beslisboom, noch de DEALE lenen zich goed 
voor het structureren van het voor kanker typerende tijdsafhankelijke ziektebeloop. 
Het in hoofdstuk A.4 beschreven Markov model is een simpele methode om tijds-
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afhankelijke risico's en met de tijd variërende utiliteiten te modelleren en te evalu-
eren Gebruik makend van actuarieel beschreven mcidenties en sterftecijfers, zoals 
beschreven in hoofdstukken В 8 en В 9, wordt in hoofdstuk В 10 het Markov model 
gebruikt voor het schatten van de effectiviteit en de haalbaarheid van een geran­
domiseerde studie naar de waarde van bronchoscopie voor de vroege opsporing 
van longkanker bij patiënten met een larynxcarcmoom 
Subjectieve waardeoordelen van medische behandelingen, uitgedrukt als 
utiliteiten zijn tot nog toe slechts beperkt toepasbaar gebleken in de oncologische 
praktijk In hoofdstuk A 5 worden de resultaten beschreven van onderzoek met een 
drietal methoden om utiliteiten te meten 
De in hoofdstuk A 5 2 beschreven 'life standard gamble' is alleen al wegens 
de grote praktische moeilijkheden die proefpersonen ondervinden ongeschikt voor 
klinische toepassingen 
De in hoofdstuk A 5 3 beschreven 'time tradeoff technique' is niet valide 
omdat een belangrijke voorwaarde voor deze methode, -namelijk de proportionali-
teit van tradeoffs voor alle gegeven levensduren-, in hoge mate geschonden wordt 
door de meeste proefpersonen Hoofdstuk В 11 geeft de resultaten van de time 
tradeoff test bij een 65-tal medisch geschoolde proefpersonen 
Het in hoofdstuk A 5 4 beschreven additief conjunct meetmodel (ACM) voor 
het meten van utiliteiten komt tegemoet aan een aantal praktische en conceptuele 
bezwaren van de eerder beschreven methoden Gegeven een aantal modelvoor-
waarden kunnen utihteitsfuncties voor de kwaliteit van het leven en voor de levens­
duur worden afgeleid uit een individueel bepaalde voorkeursvolgorde van paren 
van kwaliteit en duur In hoofdstuk В 12 wordt beschreven hoe de middels de ACM-
methode bepaalde utiliteiten in combinatie met het Markov model gebruikt kunnen 
worden ter bepaling van de keuze tussen radiotherapie en chirurgie van het 
larynxcarcmoom, rekening houdend met de individuele omstandigheden en 
voorkeuren van de patient 
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Stellingen 
behorende bij het proefschrift 
'clinical decision making in oncology' 
1. De grondslagen van de klinische besliskunde en de daarop gebaseerde techieken 
bieden voldoende basis voor een verantwoorde besluitvorming bij de keuze van 
een behandeling door en voor een patiënt met kanker, rekening houdend met de 
individuele omstandigheden en persoonlijke voorkeuren van de patiënt. 
-dit proefschrift-
2. De "life standard gamble" en "Torrance's time tradeolTtechniek" zijn ongeschikt 
voor het bepalen van individuele afwegingen tussen de kwaliteit van het leven en 
de levensduur. 
-dit proefschrift-
3. Het jaarlijks röntgenologisch longonderzoek in de nacontrole van patiënten met 
een mondholtecarcinoom is niet zinvol na een ziektevrije periode van twee jaar. 
-dit proefschriñ-
4. Het levensreddende effect van regelmatige bronchoscopie in de nacontrole van 
patiënten met een larynxcarcinoom is niet aantoonbaar. 
-dit proefschrift-
5. De levensverwachting is een slechte maatstaf voor het succes van een 
behandeling als een patiënt toch niets meer van het leven verwacht. 
-dit proefschrift-
6. De slechtere prognose van patiënten met een supraglottisch larynxcarcinoom 
vergeleken met die van patiënten met een glottisch carcinoom kan vrijwel volledig 
worden toegeschreven aan de hogere sterfte aan een longmaligniteit na het 
supraglottisch carcinoom. 
-dit proefschrift-
7. Gezondheid kost. De goedkoopste patiënt is een dode patiënt. 
8. Een wetenschappelijke theorie is slechts een model dat wij opstellen om onze 
waarnemingen te beschrijven: het bestaat alleen in onze geest. Dus is het zinloos 
ons afte vragen: wat is echt ? Het komt er op aan welk model de meest bruikbare 
beschrijving oplevert. 
(Stephen Hawking, Hel Heelal 1988) 
9. Een gezond iemand heeft vele wensen, een zieke slechts één. 
(B.E. de Pauw, 22 januari 1987) 
10. Men mag stellen dat de vraag 'ben ik mijns broeders hoeder?' bevestigend 
beantwoord kan worden, maar dat daarbij wel aangetekend dient te worden dat 
mijn broeder beschouwd moet worden als een volwassen mens. 
(D.Th.G. Wagener, Ned Tijdschr Geneesk 1987; 132: 1984-1988) 
11. Prospectief onderzoek leidt tot bewijs, retrospectief onderzoek tot nadenken. 
12. Epidemiology: The art of destroying your conclusions. 
Nijmegen, 9 april 1991 Lukas Stalpers 
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